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“It's not how old you are, it's how you are old.” 
Jules Renard (Frans schrijver, 1864-1910) 
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The aging of the world population (“global graying”) creates many emergent challenges in 
different perspectives. Dermatologists and other providers of dermatological care are 
confronted with a growing number of -often frail- older adults. Frailty is defined as “a state of 
vulnerability to poor resolution of homoeostasis after a stressor event and is a consequence 
of cumulative decline in many physiological systems during a lifetime.”1 Consequently, minor 
stressor events can result in disproportionate health changes in frail older adults. Within this 
specific population skin problems are common, which may cause a high level of morbidity 
leading to a significant impact on quality of life.2-4 Factors that might contribute to the 
development of skin disorders often should be taken into consideration in older adults (e.g. 
immobility, incontinence, and comorbidities). Furthermore, general factors like a limited life 
expectancy or cognitive impairment deserve proper attention as well during medical 
decision making. Caregivers frequently face challenges and dilemma’s regarding these 
themes in daily clinical practice. In this introduction, the aging world population, skin aging 
and common dermatological disorders among older adults will be discussed. Special 
attention will be paid to skin cancer. Furthermore, an overview will be given on the 
organization of dermatologic care in older adults. 
 
 
1.1  Population aging 
 
Life expectancy increases worldwide due to factors like improving healthcare and a decline 
in the average number of children born per family (the latter is mainly the case in Western 
countries). According to calculations of the World Health Organisation the mean worldwide 
life expectancy (at birth) will increase by 15 years during this century, up to 83 years in 2100. 
In most Western countries the mean life expectancy is even expected to pass 90 years 
during this century. Consequently, the number of oldest-old persons in the world, defined 
as persons aged 80 years and over, is expected to increase rapidly from 125 million in 2015 
to approximately 1 billion in 2100. The greatest proportion of oldest-old persons lives in 
Europe (28% of all oldest-old persons in the world lives in Europe).5 Focusing on the 
Netherlands, the most recent predictions of Statistics Netherlands (Dutch: Centraal Bureau 
voor de Statistiek) state the number of persons aged 80 years and over keeps increasing to 
2053. Statistics Netherlands expects the number of oldest-old will triple in the period 2014-
2060, resulting in 2 million oldest-old people in the Netherlands in 2060, which is 11% of the 
total population. Current aging in the Netherlands seems both related to a decreasing 
mortality rate due to improving life style (e.g. less smoking) and medical development, as 
well as the currently aging baby-boom generation (the significant birth wave which was 
noted in the Netherlands after the Second World War between 1946-1955).6,7  
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1.2  Anatomy and functions of the skin 
 
To be able to understand the process of skin aging it is important to provide some basics 
regarding the anatomy and functioning of the skin first. The human skin (Latin: cutis) is 
composed of two major layers: the epidermis (outer layer) and the dermis. The epidermis 
could be further subdivided in several other layers (Latin: strata) and residents three major 
cell types (keratinocytes, melanocytes and Langerhans cells), of which keratinocytes 
represent the most numerous population. Figure 1 provides a schematic overview of the 
different anatomic structures of the skin  
 
 
Figure 1  Anatomy of the skin, modified from Burns et al.10 
 
 
 
 
The main function of the epidermis is a protective barrier function (e.g. prevention of water 
loss and invasion of pathogens). The dermis could be subdivided into the papillary and 
reticular region and consists of a mucopolysaccharide gel and fibroelastic network of 
collagen and elastin (extracellular matrix), which provides structural support to the skin. The 
dermis contains different cell types (e.g. fibroblasts, macrophages, and mast cells) as well as 
a vascular and nerve system providing circulation, nutrition and sensatory information. 
Furthermore, it also contains skin appendages as sweat glands, hair follicles, and sebaceous 
glands. Directly beneath the skin a layer of subcutaneous tissue is found (Latin: subcutis), 
which consists mostly of fat cells and has an important function in thermal isolation, 
attachment of the skin to deeper tissue layers and absorbing shocks.8,9 
|
General introduction, thesis aims and outline 15 
 
1.3  Skin aging 
 
Various changes occur in the skin with aging, influenced by several factors. Skin aging 
processes and related influencing factors are often classified in intrinsic and extrinsic skin 
aging.11-14 Many changes in the aging skin are influenced by both intrinsic and extrinsic 
factors and probably a lot of these influences and interactions are still unknown. Most of the 
changes in the aging skin relate (directly or indirectly) to common skin disorders in older 
adults, for instance a decrease in sebaceous gland function increasing the risk for xerosis 
and asteatotic dermatitis.11,13,14 In the next paragraphs a summary is given regarding the 
most important changes related to skin aging in more detail (please note these paragraphs 
are not exhaustive).  
 
1 . 3 . 1   I N T R I N S I C  S K I N  A G I N G  
Intrinsic skin aging is a process induced by physiological skin maturation and is also called 
chronological skin aging. Intrinsic skin aging results in a decrease and alteration of several 
functions of the skin and its different components (e.g. epidermal barrier function, immune 
function, and wound healing).11,13,14 An overview is given in Table 1. 
 
Epidermal changes 
With the intrinsic aging of the skin several changes occur within the epidermis. Both the 
number of epidermal cell layers and the turnover time of epidermal cells reduce, which for 
instance results in a diminished repair capacity of the skin after trauma.11,14 In addition, a 
recent meta-analysis showed increasing age is a strong predictor for loosening of the 
dermo-epidermal adhesion as well, which further increases the risk for skin trauma (e.g. 
blister formation and shear-type injuries).15 Furthermore, the endogenous emolliation of the 
skin diminishes with increasing age, which is thought to be a result of changes in both lipid 
synthesis and processing and seems closely related to changes in stratum corneum 
acidification.16 These changes result in a diminished epidermal barrier function, which 
increases the risk for several skin disorders (e.g. xerosis, pruritus and contact 
dermatitis).11,14,16 
 
Immunosenescence 
Aging of the immune system is typically called “immunosenescence”. Both changes in the 
innate and in the adaptive immune system are observed.11,14 Examples of these changes are 
a diminished number of antigen-presenting Langerhans cells in the epidermis and a 
decreasing production and function of B- and T-cells with advancing age.17,18 Consequently, 
both the incidences of infections and cancer of the skin are higher among older adults.11,14  
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Wound healing 
Several age-related changes in the skin and its components attribute to both an increased 
risk to develop skin ulcers and a delayed wound healing in the aged skin. Examples are 
structural changes like loss and changes in the extracellular matrix, altered vascular and 
inflammatory responses, a diminished fibroblast replication and changes in the sensatory 
function of the skin due to a decreasing amount of nerve endings within the dermis.19 
 
Other changes 
Various other skin changes occur with aging including, but not limited to, a reduced capacity 
to produce sweat, a decreased vitamin D synthesis, reduction in subcutaneous fat, and a 
decreased hair and nail growth.11,13 
 
1 . 3 . 2   E X T R I N S I C  S K I N  A G I N G  
Extrinsic aging is caused by environmental factors, of which exposure to ultraviolet radiation 
(UVR; photo-aging) is most important.11-13,20  
 
Photo-aging 
During a lifetime the human skin is frequently exposed to UVR, which strongly varies 
between persons due to factors like sun-protection behavior, the use of tanning devices, 
occupation, and geographical location. The skin is equipped with several protective 
mechanisms to reduce damage caused by UVR, which include epidermal thickening, 
formation and distribution of melanin pigment, DNA-repair mechanisms, and cell apoptosis. 
Photo-aging is defined as the skin changes caused by long-term UVR-exposure. Many of the 
skin changes due to intrinsic skin aging are accelerated due to photo-aging. UVR-exposure 
causes skin damage and photo-aging in several ways, ranging from direct DNA-alterations, 
to the generation of reactive oxygen specimens, stimulation of extracellular matrix 
breakdown, and induction of changes in signal transduction pathways, vascular structures 
and immunologic processes.12,20  
 
Other environmental and lifestyle influences 
Smoking is considered the most important exogenous skin aging factor, after UVR-exposure. 
Smoking accelerates several skin aging processes, e.g. the decrease of dermal collagen and 
elastin integrity, and microvascular changes. Also, smoking is an important risk factor for the 
development of squamous cell carcinoma (also discussed in section 1.5.2 “Squamous cell 
carcinoma”).21 Other factors potentially influencing extrinsic skin aging are air pollution and 
arsenic exposure.22,23  
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Table 1  An overview of the most important intrinsic skin changes with aging and their (potential) 
effects,a modified from Chang et al.11 and Jafferany et al.13 
 
Functions Changes 
Epidermal 
barrier 
function 
Loss of acidification of skin surface leading to decreased function 
of pH-dependent enzymes; results in decreased production of 
skin lipids and increased corneocyte retention 
Reduced aquaporin-3 gene expression, leading to decreased skin 
hydration 
Slower return to barrier homeostasis after perturbation (e.g. 
chemical irritant) 
Immune 
function 
Decreased numbers of antigen-presenting Langerhans cells on 
histology 
Cell-mediated immunity altered, including shift in balance of TH1 
and TH2 cells to favor TH2 predominance 
Skin integrity 
and wound 
healing 
Fibroblasts have increased doubling time 
Older fibroblasts have fewer remaining replicative cycles 
Altered levels of matrix metalloproteinases 
Fragmentation of extracellular matrix 
Flattening of dermal papillae, e.g. leading to an increased risk on 
skin injuries 
Vascular response to pressure abnormal in older skin, e.g. leading 
to an increased risk to develop pressure ulcers 
Decreased amount of nerve endings within the dermis, e.g. 
leading to an increased tendency on injuries and pressure ulcers 
DNA repair 
mechanisms 
Increased photocarcinogenesis / skin cancer risk 
Vitamin D 
production 
Decreased production, with previtamin D3 levels 2 to 3 times 
lower in older adults compared to younger populations 
Lipogenesis Decreased volume of subcutaneous fat, e.g. leading to an 
increased risk of hypothermia and less natural insulation 
Sweat 
production 
Reduced sweat production per sweat gland, e.g. leading to an 
increased risk of overheating and a reduced body odor 
 
a Table is not exhaustive.  
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1.4  Common skin disorders in older adults 
 
As discussed before several alterations in the aging skin increase skin vulnerability and the 
chance to develop a skin disorder. The most common skin disorders in both community-
dwelling as institutionalized older adults are summarized in Table 2 and briefly discussed in 
more detail. 
 
 
Table 2  Prevalences of the most common skin disorders in frail older adults 
 
Disorders Prevalence, median 
(range)a 
References 
Benign tumors 44% (1-99%) 24-29 
Xerosis 30% (5-95%)  24-28,30 
Fungal infections 17% (0-77%) 24-29 
Premalignant tumors 14% (0-74%) 24-28 
Dermatitis 9% (0-32%)  24-29  
Chronic ulcers (including pressure ulcers) 4% (1-10%)  24-29,31 
Malignant tumors 3% (0-13%) 24-28,32  
Other infections and infestations 1% (0-23%) 24-29 
 
a Mentioned prevalences are strongly dependent on several variables,  
e.g. clinical setting and definitions used. 
 
 
In addition, frailty-related factors like comorbidities (e.g. thyroid disease, renal insufficiency, 
and diabetes mellitus), polypharmacy, immobility (e.g. leading to chronic pressure on some 
parts of the skin), and incontinence, often contribute to the development of skin disorders in 
the population of older adults as well. Examples are shown in Table 3. 
 
1 . 4 . 1   S K I N  T U M O R S  
Various tumors could be present in the skin and incidence rates of most skin tumors rise 
with increasing age. Skin tumors may be benign, premalignant or malignant. Examples of 
common benign skin tumors are seborroic warts and cherry angioma.13 Treatment of 
benign skin tumors could be considered in case of complaints. Premalignant and malignant 
skin tumors are also very common among older adults and are discussed in more detail in 
section 1.5 (“Skin cancer and precursors”). 
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Table 3  Frailty-related factors and examples of (potential) skin-related consequences 
 
Factors Examples of (potential) skin-related consequences 
Comorbidities Diabetes causing an increased risk for fungal infections, chronic ulcers, 
and pruritus30,33-35 
Hypothyreoidism might result in a delayed wound healing, edema, xerosis, 
or nail- and hair changes11,35 
Chronic renal disease increasing the risk for pruritus and calciphylaxis34,35 
Polypharmacy Increasing the risk to develop drug-induced skin conditions like 
maculopapular drug eruptions, acute generalized exanthematous 
pustulosis (AGEP), drug rash with eosinophilia and systemic symptoms 
(DRESS)36 
Various medications could directly cause or attribute to the development 
of pruritus (e.g. calcium channel blockers, thiazides or opioids), by various 
mechanisms34,37 
Immobility Increases the risk to develop pressure ulcers11,19,38 
Venous hypertension and related skin conditions (including venous leg 
ulcers) are more common in patients with a limited mobility39 
Incontinence Increasing the risk for contact dermatitis (incontinence-associated 
dermatitis) and the development of pressure ulcers38,40 
Malnutrition A poor nutritional status increases the risk to develop pressure 
ulcers11,19,38 
Zinc deficiency might lead to several cutaneous manifestations, e.g. 
alopecia or peri-orifical dermatitis35 
 
 
1 . 4 . 2   X E R O S I S  A N D  D E R M A T I T I S  
As discussed in section 1.3.1 (“Intrinsic skin aging”) the aging skin becomes more prone to 
develop dryness (xerosis), which could ultimately result in asteatotic dermatitis. This is a 
form of dermatitis which is common among older adults and consists of itchy, red, scaling 
patches, mostly on the limbs. Frequent usage of water and soap increases the risk for 
xerosis and asteatotic dermatitis. Treatment consists of the regular application of 
moisturizers, diminishing the usage of water and soap, and in case of dermatitis a topical 
corticosteroid may be prescribed. Other forms of dermatitis (also called eczema) frequently 
diagnosed in older adults include (late-onset) atopic dermatitis, seborroic dermatitis, 
hypostatic dermatitis, (allergic or irritant) contact dermatitis, and nummular dermatitis.13,14 
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1 . 4 . 3   C H R O N I C  U L C E R S  
Chronic ulcers are common and incidence rates rise with increasing age. Several types of 
chronic ulcers can be distinguished, including pressure ulcers (decubitus), venous and 
arterial leg ulcers, diabetic ulcers etc. Two main types of ulcers among older adult patients 
often seen in dermatological practice, will be discussed below: pressure ulcers and venous 
leg ulcers.  
 
Pressure ulcers typically develop in areas with bony prominences exposed to chronic 
pressure. Important risk factors to develop pressure ulcers include immobility, loss of 
sensory functions in the skin, several comorbidities and a poor nutritional status (also 
described in section 1.3.1 “Intrinsic skin aging” and Table 3). Treatment mainly consists of 
avoidance of chronic pressure, while at the same time local wound/skin conditions, mobility, 
and nutritional status should be optimized. Surgical therapy may be necessary in some 
cases. Paramedics like a physical therapist, an ergotherapist, and/or a dietitian are included 
in a multidisciplinary treatment team on a regular basis.13,38 
 
Venous leg ulcers develop in the context of chronic venous disease, which is very common 
in older adults. Conservative management includes compression therapy and optimizing 
local wound/skin conditions. Ablative and surgical therapies of varicose veins or wound 
closure using surgical grafts could be an option in some cases.39 
 
1 . 4 . 4   S K I N  I N F E C T I O N S  A N D  I N F E S T A T I O N S  
Several skin infections are very prevalent among older adults. Fungal infections of skin and 
nails are most common, but bacterial (e.g. cellulitis), viral (e.g. herpes zoster), and parasitic 
infections are often seen as well. Older adults are thought to be especially prone to develop 
several skin infections due to immunosenescense (also described in section 1.3.1 “Intrinsic 
skin aging”), but also due to concomitant diseases like diabetes mellitus. Some common 
examples of skin infections and infestations are discussed below. 
 
Fungal infections represent the most common infections of skin and nails among older adult 
patients. Diagnosis is usually easily made during clinical examination and established by a 
potassium hydroxide preparation or culture. Treatment includes several topical and 
systemic antifungal agents, dependent on factors like the infection site, severity, and species 
causing the infection.13 
 
Herpes zoster, caused by re-activation of the varicella-zoster virus (which also causes 
chicken pox after primary infection), is regularly seen among older adult patients. A burning 
or stinging feeling of the skin and mild to more severe systemic complaints (fever, chills) 
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often precede the development of a vesicular erythematous eruption with a dermatomal 
distribution and local lymph node swelling. This skin condition is usually self-limiting within a 
few weeks, although in a significant number of patients (especially older adult patients) post-
herpetic neuralgia persists, which may result in a significant impact on quality of life. 
Treatment is therefore often recommended in an early stage using systemic antiviral 
therapy combined with pain medication and local protective and drying agents like zinc 
oxide ointment.13  
 
Scabies, which is an infestational skin disease, is frequently seen as well, especially in 
nursing home populations. Scabies is an infestation of the skin by the human itch mite 
(Sarcoptes scabiei var. hominis) and a typical clinical presentation includes severe itch and 
erythematous and scaling burrows, papules and papulovesicles on the wrists, interdigital 
spaces, buttocks, and genitalia. Scabies could spread from person to person after close and 
prolonged contact, which explains why outbreaks are seen in nursing homes on a regular 
basis.13 
 
 
1.5  Skin cancer and precursors 
 
Skin cancer and precursor lesions are very common among older adults, especially among 
the fair tanned. Skin cancer is the most common malignancy among Caucasians and its 
incidence is rising worldwide.41-46 Skin cancer is most often classified in two groups: 
melanoma skin cancer and nonmelanoma skin cancer (NMSC). NMSC includes cutaneous 
squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Precursor lesions are known 
for both melanoma and SCC, but not for BCC. Focusing on skin cancer numbers in the 
Netherlands over the period 1989-2005, BCC is the most common type of skin cancer (71%), 
followed by SCC (16%) and melanoma (11%).47 In addition, more rare types of skin cancer 
are sometimes included within the group of NMSC (constituting <2% of all skin malignancies; 
sometimes also called “orphan skin cancer”), e.g. cutaneous lymphomas, Merkel cell 
carcinoma, and various appendageal and soft tissue neoplasms.47  
 
In the following paragraphs the three main types of skin cancer and their precursors will be 
discussed in more detail. 
 
1 . 5 . 1   B A S A L  C E L L  C A R C I N O M A  ( B C C )  
As mentioned before, BCC is the most common type of skin cancer.48 In the Netherlands, 
age-standardized incidence rates increased fourfold in the period 1973-2009 (up to 165 and 
157 per 100 000 person-years in 2009, for men and woman respectively). Therefore it is 
|
22 Chapter 1 
 
currently estimated one out of five to six Dutch inhabitants will develop a BCC during their 
life. It should be noted incidence rates are believed to be even higher in daily practice, due 
to several mainly administrative reasons (e.g. most registries solely register the first BCC in a 
patient, although subsequent BCCs are very common).46 
 
Typically, a BCC is a slowly growing tumor with a relatively low-malignant potential in which 
metastases are very rare. However, local tissue destruction may be significant. It is believed 
that BCCs arise from stem cells within the hair bulb and/or infundibulum.49 In most BCCs a 
dysregulation of the “Hedgehog signaling pathway” is found, mostly due to mutations in 
PTCH1 or SMO, resulting in a dysregulation of cell growth and differentiation.50 
 
The most important risk factor to develop this tumor is UVR-exposure (especially childhood 
sunburn and both intermittent recreational and occupational sun exposure). Additional risk 
factors are: increasing age, male sex, previous skin cancer, a fair skin type (Fitzpatrick skin 
type I and II), genetic predisposition (e.g. basal cell nevus syndrome), immunosuppression, 
arsenic exposure, previous actinic keratosis and previous PUVA or radiation therapy.49,51,52 
 
Several subtypes can be distinguished and multiple classification systems are used in 
literature. One classification system, which is also used in the Dutch guideline for BCC, 
distinguishes four histopathological subtypes of BCC: (1) nodular, (2) superficial, (3) 
infiltrative, and (4) micronodular.53 It should be mentioned that a significant proportion (20-
74%) of BCC is reported to consist of multiple subtypes (mixed-type BCC).54-56 Most BCCs, 
especially nodular BCC (nBCC), are located in the head and neck area. However, the 
proportion of superficial BCC (sBCC; often located on the trunk) has been increasing during 
the last decades, probably due to changing sun exposure habits.53 
 
Various clinical features can be seen depending on the subtype, ranging from a pink or skin-
colored nodule with a pearly appearance and telangiectatic vessles in nBCC, to a scaling red 
plaque in sBCC. In case of doubt dermoscopy could be very useful in diagnosing BCC. 
Dermoscopy (or epiluminoscopy) is a form of hand-held skin surface microscopy, typically 
including a 10-14 times magnification lens and lightning system. A punch biopsy is often 
performed prior to treatment to confirm the diagnosis and to determine the 
histopathological subtype(s). Examples are shown in Figure 2. 
 
Several prognostic tumor-related factors are used to classify BCCs into high- and low-risk 
tumors. These factors are mainly based on the risk for recurrence after treatment and 
should be included in patient counseling and management decisions. High-risk factors 
known from literature include: aggressive histopathological subtype (infiltrative and/or 
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micronodular subtype), tumor localization within the face (especially the H-zone), tumor size, 
poorly defined lesions, recurrent tumors, perineural and/or vascular involvement.49,51,53 
 
 
Figure 2  Examples of basal cell carcinoma (from left to right: nodular, superficial, and infiltrative 
basal cell carcinoma) 
 
 
 
 
General treatment options for BCC comprise surgical excision (e.g. conventional excision or 
Mohs micrographic surgery), radiotherapy and local destructive therapies (e.g. cryotherapy, 
curettage with electrodesiccation, or laser therapy). In addition, sBCC can be treated 
topically by 5-fluorouracil cream or imiquimod cream, or by photodynamic therapy (using a 
topical photosensitizing cream, followed by illumination after a couple of hours incubation 
time).49,51,53 In locally advanced or metastatic BCC which cannot be treated by the earlier 
mentioned treatment modalities, systemic therapy by vismodegib and sonidegib may be an 
option.50  
 
Conflicting evidence can be found in current literature regarding the effect of various UVR-
protective measurements and prevention programs on the risk for development of 
subsequent (pre)malignant skin lesions. Nevertheless, protection against more skin damage 
induced by UVR-exposure is currently considered the most important preventive strategy by 
many experts.49,57 Sun protection includes the frequent and sufficient application of 
sunscreens, wearing sunprotective clothing (e.g. hats), and the discouragement of sun 
bathing and the usage of tanning devices. Follow-up examinations are scheduled based on 
several patient- and tumor characteristics (e.g. high or low-risk tumor, previous skin cancers, 
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and the ability to perform self-examinations). Usually, only patients who have had a high-risk 
BCC or multiple BCCs are scheduled for follow-up. 
 
1 . 5 . 2   C U T A N E O U S  S Q U A M O U S  C E L L  C A R C I N O M A  ( S C C )  A N D  P R E C U R S O R S  
SCC is the second most common form of skin cancer (after BCC) in most Caucasian 
populations.48 Actinic keratosis (AK) and Bowen’s disease (BD) are precursor lesions of SCC.  
 
Actinic keratosis (AK) 
AK is extremely common, especially in the fair-skinned, but population-based research is 
relatively scarce. Prevalence data from a prospective population-based cohort study in the 
Rotterdam area showed AK could be found after total-body examination in the majority of 
older adults (≥70 years).58 High strongly age-related prevalence rates were also found by 
other studies in Western countries.59,60 AK (or solar keratosis) is a premalignant skin lesion, 
which is histopathologically characterized by intraepidermal atypical keratinocytes. Not 
surprisingly, risk factors for AK are highly comparable with the risk factors for BD and SCC 
(discussed in section 1.5.2 “Cutaneous squamous cell carcinoma”).61,62 
 
Clinically, AK typically present as superficial, keratotic, scaly, skin-colored, pink or white-
yellow papules on sun-exposed skin (mostly in the head and neck area and on the dorsal 
hands). Multiple lesions are common. The diagnosis is typically made based on clinical 
examination. To rule out invasive growth (SCC), a punch biopsy should be performed in case 
of doubt (e.g. a painful lesion). An example is shown in Figure 3. 
 
Although a relationship between AK and the development of SCC is generally accepted 
based on clinical, histopathological and genetic similarities, data regarding the exact 
progression rates are scarce. Most studies report a yearly progression rate per lesion of 
<1%. On the other hand, spontaneous regression of AK has also been reported (regression 
rates up to 63% of individual lesions). However, since multiple lesions (field cancerization) 
are often seen and it is not possible to predict which AK will transform into SCC, treatment is 
generally recommended.61,62 Treatment options for AK include cryotherapy, photodynamic 
therapy, topical treatments (5-fluorouracil cream, imiquimod cream or ingenol mebutate 
gel), curettage, and laser therapy. Treatment choices are influenced by several factors, like 
the number of lesions, the body side distribution, and patient compliance.61,62 
 
Bowen’s disease (BD) 
Incidence rates of BD are scarce and outdated (15-174 per 100 000 person-years; most 
studies >20 years old).63 BD (or squamous cell carcinoma in situ) is histologically 
characterized by dysplasia throughout the entire (full-thickness) epidermis. Clinically, BD is 
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typically presenting as an hyperkeratotic, well-demarcated, erythematous papule or plaque 
(Figure 3), but several clinical variants are described (e.g. pigmented BD). In case of doubt a 
punch biopsy can confirm the diagnosis. Previous studies suggested a risk of progression 
from BD to SCC ranging from 3-5%. Treatment options include topical treatment with 5-
fluorouracil cream, photodynamic therapy, local destructive therapies (e.g. cryotherapy or 
curettage with electrodesiccation), or surgical excision. In case none of these therapies are 
possible, radiotherapy may be an option.63,64 
 
 
Figure 3  Examples of actinic keratosis (left) and Bowen’s disease (right) 
 
 
 
 
Cutaneous squamous cell carcinoma (SCC) 
The incidence of SCC has been rising over the past decades and is also strongly related to 
increasing age.41,43,45,47,48 In the Netherlands, age-standardized incidence rates increased 
from 22 up to 35 per 100 000 person-years in the period 1989-2008. As in BCC, this is 
probably an underestimation, mostly due to administrative reasons.65  
 
SCC arises from keratinocytes in the epidermis and related appendages. Risk factors of SCC 
include: UVR-exposure (especially cumulative chronic sun exposure), chronic 
immunosuppression, increasing age, male sex, fair skin type (Fitzpatrick skin type I and II), 
previous skin cancer or precursor lesions, smoking, chronic inflammatory processes (e.g. 
lichen sclerosus), chronic wounds and burn scars, genetic predisposition (e.g. epidermolysis 
bullosa and oculo-cutaneous albinism), arsenic exposure, and previous PUVA or radiation 
therapy.52,66,67 Some subtypes of human papillomavirus and Merkel cell polyomavirus are 
thought to contribute in the development of (a subset) of SCC as well, especially in chronic 
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immunosuppressed patients.68 However, more research is needed to improve our 
understanding of a potential causative role.68,69  
 
The clinical presentation of SCC usually consists of an indurated tumor with a keratinizing or 
crusted surface. Ulceration is common, especially in larger and/or less differentiated tumors. 
Examples are shown in Figure 4. SCC is growing faster and more aggressive as compared to 
BCC. Furthermore, SCC has a potential to metastasize, mostly to regional lymph nodes 
(±85%), although distant metastases are possible. Most studies report a 5-year metastatic 
risk ranging from 1-4% for low-risk SCC to a risk up to 10% in high-risk SCC, and even higher 
in specific subgroups of patients. Several factors are known to increase the risk for 
development of metastasis, of which the following are most commonly included in clinical 
practice guidelines: (1) SCC arising from the lip or ear, (2) SCC with a diameter ≥2 cm, (3) SCC 
with ≥ 4 mm depth growth, (4) undifferentiated or poorly differentiated tumors, (5) 
perineural or vasoinvasive tumor growth, (6) SCC in chronic immunosuppressed 
patients.66,67,70,71 
 
Although clinically often suspected, a definite diagnosis is made by histopathological 
examination (after biopsy or excision), which includes the examination of the above-
mentioned prognostic variables. To detect metastasis lymph node palpation should be 
performed, which is often complemented by ultrasound examination and ultrasound-
guided aspiration (in case one or more suspicious lymph nodes are detected) in high-risk 
lesions.66,67 
 
 
Figure 4  Examples of squamous cell carcinoma 
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In most cases SCC is treated by surgical excision, which allows histopathological control of 
the excision margins. Other treatment options which can be used in some cases are 
radiotherapy, cryosurgery or curettage with electrodesiccation.66,67 As discussed in BCC, also 
in SCC and its precursor lesions adequate UVR-protection is considered an essential 
preventive measure.66 More convincing evidence is available in favor of UVR-protection as 
preventive measurement in the development of SCC as compared to BCC and melanoma.57 
Follow-up examinations are usually scheduled for five years after a SCC, influenced by both 
patient and tumor characteristics (e.g. previous skin cancer, tumor stage, possibility to 
perform self-examination). 
 
1 . 5 . 3   C U T A N E O U S  M E L A N O M A  A N D  P R E C U R S O R S  
The cutaneous melanoma is a malignant tumor arising from melanocytic cells in the skin. 
Although less frequent, melanoma can also arise from melanocytic cells in other organs 
(eye, meninges and various mucosae). In the further context of this thesis, extracutaneous 
melanoma are not included and only cutaneous melanoma are mentioned by the word 
melanoma.  The most common precursor lesion of melanoma (melanoma in situ) is lentigo 
maligna, which is relatively common among older adults in chronically sun-exposed body 
sites. 
 
Next to BCC and SCC, the incidence of melanoma is also increasing worldwide in 
Caucasians.72,73 Multiple studies have shown the rise of incidence rates of melanoma is most 
pronounced among older adults.73 Reported incidence rates range from <10 per 100 000 in 
some European populations to 50-60 per 100 000 in some Australian studies.74 The most 
important exogenous risk factor for melanoma is UVR-exposure, especially sun burns. Other 
risk factors include: a total number of naevi >100, multiple (>5) atypical naevi, fair skin type, 
red or blond hair color, ephelides, blue eyes, large congenital naevi, actinically damaged skin, 
a history of NMSC, and genetic susceptibility (e.g. CDKN2A mutation).52,72,74 
 
Four subtypes are used to classify melanoma: superficial spreading melanoma, nodular 
melanoma, lentigo maligna melanoma and acral lentiginous melanoma.74 In older adults, the 
proportion of superficial spreading melanoma decreases and the proportion of the other 
forms seem to increase. Cutaneous melanoma in older adults are most commonly located 
in the head and neck region.75 Melanoma have the potential to metastasize and cause 
death. Melanoma account for 90% of all deaths due to skin cancer and mortality rates 
related to melanoma are higher in older adults compared to younger populations, especially 
in males. Other prognostic factors of melanoma include: vertical tumor thickness (Breslow’s 
depth; increasing thickness is related to a poorer prognosis), ulceration (related to poorer 
prognosis), the presence of dermal mitosis (related to poorer prognosis), level of invasion 
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(Clark’s level; increasing invasion is related to a poorer prognosis), and tumor location on the 
trunk or head and neck region (poorer prognosis compared to the limbs).73,74 The poor 
prognosis of melanoma among older adults compared to younger patient groups is thought 
to be mainly caused by a late diagnosis and treatment. Examples of possible explanations 
for this delay are a lower awareness of skin cancer and the differences in subtype 
distribution among older adults.73 
 
In case of a suspicion of a melanoma clinical examination is often complemented with 
dermoscopy. The ultimate diagnosis is made by histopathological examination after 
diagnostic excision. Excisional biopsy is preferred over incisional (punch) biopsy, due to the 
risk of sampling error and difficulties with establishing the Breslow’s depth. Another 
hypothethical risk of incisional (punch) biopsy might be the induction of tumor spread, 
although evidence from current literature appears to be insufficient to support this 
statement.74,76 The current guidelines recommend to use the staging system of the 
American Joint Committee on Cancer (AJCC) to classify melanoma.72,77 After diagnostic 
excision, a sentinel-node biopsy is typically considered in melanoma stage IB or higher 
(melanoma with vertical tumor thickness >1 mm or ≤1 mm with ulceration and/or the 
presence of dermal mitosis). A sentinel-node biopsy includes histopathological examination 
of the first regional draining lymph node(s). This procedure mainly provides prognostic 
information, since the impact on prognosis is currently still controversial and a main topic of 
discussion in current literature.72,74,78 Further staging in metastatic melanoma is usually 
performed, but seems out of the scope of this section. 
 
Next, treatment consists of a therapeutical re-excision. An excision margin is chosen based 
on the Breslow’s depth: 1 cm margin in tumors with a Breslow’s depth <2 mm, 2 cm margin 
in tumors with a Breslow’s depth ≥2 mm. Melanoma in situ is generally treated with an 
excision margin of 5 mm. Radiotherapy might be considered in inoperable cutaneous 
melanoma. In case of metastatic melanoma surgical excision (including lymph nodes 
dissection), radiotherapy and/or systemic therapy is usually performed.72,74 
 
As discussed in BCC and SCC (including precursor lesions), also in melanoma adequate UVR-
protection is considered an essential preventive measure.74 Furthermore, patients are 
usually instructed how to perform self-examinations of the skin. Follow-up examinations are 
scheduled based on tumor stage and other patient characteristics like the ability to perform 
a self-examination and the presence of risk factors related to the development of 
subsequent skin tumors. 
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Figure 5  Examples of melanoma (left: superficial spreading melanoma, right: nodular melanoma) 
 
 
 
 
1 . 5 . 4   S K I N  C A N C E R  C A R E  I N  F R A I L  O L D E R  A D U L T S   
Skin cancer care in frail older adults can be challenging in daily practice. Several patient- and 
tumor characteristics should be taken in consideration, including factors like prognostic 
tumor characteristics, a limited life expectancy, comorbidities, the impact on quality of life, 
and the treatment burden for a patient.  
 
On the one hand, as described before, some highly prevalent skin cancer types (especially 
the low-risk NMSC) are slowly growing, rarely metastasize, and could stay asymptomatic for 
months. While on the other hand, the risk for local tissue destruction and related morbidity 
leading to a worse quality of life and even death in some cases, should not be 
underestimated. Furthermore, treatment in an early phase may be easily performed and 
result in a low patient burden, while the opposite may be increasingly seen with a longer 
delay. Balancing management decisions and the risk for under- and overtreatment is 
therefore essential, but not always easily performed. 
 
 
1.6  Organisation of general long-term care in frail older 
adults in the Netherlands 
 
Most older adults in the Netherlands live within their own houses (community-dwelling). 
Based on the extent and complexity of the care needed, an older adult may move to a 
permanent healthcare facility, which could be stratified into residential homes (“old people’s 
homes”) and nursing homes.79 The number of residential homes in the Netherlands has 
decreased over the past couple of years, since governmental policy stimulates older adults 
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to keep living in their own homes longer.80 Community-dwelling older adults and older 
adults living in residential homes are usually in need of some assistance in their activities of 
daily living and may be supported with basic (home) nursing, domestic and social services, 
an alarm service and provision of meals. These older adults usually receive primary medical 
healthcare by a general practitioner.79,80  
 
Older adults living in nursing homes are in a need of more extensive and complex 
healthcare. Nursing home inhabitants usually are more frail and dependent compared to 
inhabitants of residential homes, and typically need help with most of their activities of daily 
living. In nursing homes primary medical healthcare is provided by an elderly care physician 
(previously called “nursing home physician” (NHP)), usually complemented by a 
multidisciplinary team of health-care professionals (e.g. physiotherapists, dietitians, and 
psychologists).79,80  
 
 
1.7  Organisation of dermatologic care in the Netherlands 
 
In the Netherlands dermatologic care is organized in three layers of care: primary, 
secondary, and tertiary medical care.  
 
1 . 7 . 1   P R I M A R Y  D E R M A T O L O G I C  C A R E   
The first layer of dermatologic care (primary medical care) is provided by primary care 
physicians. Primary care physicians include general practitioners and elderly care physicians, 
depending on the living situation of an older adult, as discussed before. These primary care 
physicians are often referred to as “gatekeepers” of medical specialist care (secondary and 
tertiary care), since patients need a referral from a primary care physician before they can 
visit a dermatologist.80 Skin diseases account for a significant part (12.7%) of the conditions 
seen by Dutch general practitioners.81  
 
1 . 7 . 2   S E C O N D A R Y  A N D  T E R T I A R Y  D E R M A T O L O G I C  C A R E  
In general, the second and third layer of dermatologic care (secondary and tertiary care) are 
provided by dermatologists working within general hospitals (or private practices) and 
university hospitals, respectively.80 University hospitals combine the provision of healthcare 
services with research and education. Although these hospitals do provide general 
dermatologic care, their main function is to provide top clinical and multidisciplinary 
dermatologic care services and expertise. This last resort function for referrals from 
dermatologists in general hospitals typically qualifies them as tertiary institutions.82  
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1 . 7 . 3   “ A N D E R H A L V E L I J N S Z O R G ”  
During the last couple of years more and more attention has been paid to a new initiative 
called “anderhalvelijnszorg”. In the context of dermatologic care, this concept may imply a 
dermatologist providing healthcare in a primary care practice. Such provision of secondary 
care in a primary care setting is assumed to be less expensive and a qualitatively equivalent 
method of healthcare provision compared to secondary (hospital-based) dermatologic care 
in some cases. 
 
1 . 7 . 4   T E L E D E R M A T O L O G Y  
Teledermatology is a form of e-health, in which a dermatologist is digitally consulted by 
another healthcare provider. This form of consultation mostly encompasses the use of a 
standardized questionnaire combined with photographs of a skin disorder, which are send 
through a secured internet connection. This type of teledermatology is often designated as 
“store-and-forward” (S&F) teledermatology. In the Netherlands, teledermatology has been 
increasingly used since the late nineties, especially by general practitioners.83 Multiple 
studies showed that teledermatology is a highly efficient, cost-effective and easy-to-use 
consultation method.84 
 
Moreover, previous research showed the use of S&F-teledermatology could prevent up to 
68% of the referrals from general practitioners to dermatologists, which might result in a 
cost reduction of 18%.85 Most studies indicated that the diagnostic accuracy and users 
satisfaction of S&F-teledermatology was acceptable in general, although face-to-face 
consultation was shown to have a superior accuracy. This accuracy may be limited by 
several aspects, including the type of skin condition. Several important logistical, legal and 
financial framework conditions are important to effectuate optimal implementation of 
teledermatological consultation. Potential (dis)advantages of S&F-teledermatology are 
summarized in Table 4.83,84 
 
In addition, another form of teledermatology is real-time teledermatology (by video 
connection). This type of teledermatology includes live interaction between the users by 
means of a secured internet video connection. Real-time teledermatology may be able to 
overcome some of the limitations of S&F-teledermatology. For example, this type of 
teledermatology might improve diagnostic accuracy due to possibility to observe a skin 
lesion from different angles. Furthermore, it might be easier to obtain more information 
regarding the skin disease or patient’s context with real-time teledermatology, since it is 
possible to ask additional questions and non-verbal communication can be observed.  A 
potential logistical limitation of real-time teledermatology is that all users have to be 
available on the moment of consultation.83  
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Table 4  Potential (dis)advantages of store-and-forward teledermatology, modified from Lubeek et 
al.83 
 
Potential advantages 
Accessibility improvement of access to dermatologic care, which might be 
especially valuable in patients with physical and/or cognitive 
impairments limiting the possibility to visit a hospital 
Efficiency increased efficiency of dermatologic care, for instance because 
adequate treatment may be started earlier 
Prevention of 
unnecessary referrals 
prevention of unnecessary referrals to a dermatology outpatient 
clinic 
Cost reduction by minimizing diagnostic and treatment delay and the prevention 
of unnecessary referrals, total healthcare costs may be reduced  
Education providing an educational value, by facilitating the exchange of 
knowledge and experiences between users  
Patient satisfaction a comparable patient satisfaction was demonstrated in 
teledermatology compared to dermatology outpatient clinic visits  
Potential disadvantages 
Diagnostic accuracy a lower diagnostic accuracy, especially in case of a solitary 
(pigmented) lesion  
Financial investment e.g. purchase of the needed soft- and hardware, including a 
photocamera  
Time investment  the time needed to prepare arrangements, to learn how to use 
teledermatology, and to learn how to make sufficient photographs 
Dependency the internet connection and soft- and hardware has to work 
properly 
Limited information 
regarding the skin 
condition  
the lack of live face-to-face interaction limits the possibility to 
obtain additional information regarding the skin condition, for 
instance by asking additional questions, by palpation of a skin 
lesion or by observing non-verbal communication 
Limited information 
regarding  the context 
of a patient 
limits the possibility to “look beyond” the skin problem and gain 
information regarding the clinical and psychosocial context of a 
patient (e.g. general prognosis, comorbidities, cognitive 
impairment), needed to optimize a patient-specific management 
approach in some situations 
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1.8  Thesis aims and outline 
 
Skin diseases are prevalent among older adults and healthcare providers are expected to 
be increasingly confronted with skin diseases in this population in the future, since the 
world population is aging rapidly. Skin diseases may have a significant impact on health-
related quality of life. Little is known about the current need for, provision of, and quality of 
dermatologic care in the frailest older adult population (nursing home patients). One of the 
most common skin conditions dermatologists (and other healthcare providers) are 
confronted with in older adults is skin cancer and precursor lesions. Healthcare providers 
are regularly confronted with management dilemma’s in this patient population in daily 
practice.  
 
The aims of this thesis are: 
I. To study the current need for, provision of, and quality of general dermatologic care 
among nursing home patients (Part A of this thesis) 
II. To study current skin cancer care among older adults and to provide guidance in medical-
decision making in skin cancer among older adults (Part B of this thesis) 
 
Taking the above-mentioned aims into account, the following research questions were 
addressed (corresponding parts and chapters given between parentheses): 
 
I .  D E R M A T O L O G I C  C A R E  I N  I N S T I T U T I O N A L I Z E D  O L D E R  A D U L T S  ( P A R T  A )  
 
(1) What is the current need for and provision of dermatologic nursing home care 
according to nursing home physicians in the Netherlands? (Chapter 2) 
 
(2) What is the current role of Dutch dermatologists in dermatologic care provision in 
nursing homes? (Chapter 3) 
 
(3) What are the reasons and barriers for dermatologist consultations in nursing 
homes? (Chapter 3) 
 
(4) How could we improve dermatologic care for nursing home patients? (Chapters 2 
and 4) 
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I I .  S K I N  C A N C E R  C A R E  I N  F R A I L  O L D E R  A D U L T S  ( P A R T  B )  
 
(1) What is the current and potential future role of nursing home physicians in the 
diagnosis and treatment of (pre)malignant skin lesions among nursing home 
patients? (Chapter 5) 
 
(2) What is the influence of high age and comorbidities in medical decision making 
and guideline-adherence by dermatologists in older adults in daily clinical practice? 
(Chapter 6) 
 
(3) What is currently known about the epidemiology and clinicopathological features 
of BCC in the oldest-old to guide healthcare providers and policy makers? 
(Chapter 7) 
 
(4) Which items are considered important in medical decision making in frail older 
adults with NMSC and should be integrated in NMSC clinical practice guidelines? 
(Chapter 8) 
 
(5) What is the extent of integration of these items in current NMSC clinical practice 
guidelines worldwide? (Chapter 8) 
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Abstract  
 
Objectives 
To assess the need for and provision of dermatologic care among Dutch nursing home 
patients and to obtain recommendations for improvement. 
 
Design 
Cross-sectional nationwide survey. 
 
Setting  
All 173 nursing home organizations in the Netherlands. 
 
Participants 
Physicians working in nursing homes. 
 
Measurements 
Web-based questionnaire concerning the burden of skin diseases in nursing home patients, 
diagnostic procedures and therapy, collaboration with dermatologists, physicians’ level of 
education, and suggestions for improvement. 
 
Results  
A total of 126 (72.8%) nursing home organizations, with 1133 associated physicians 
participated in our study and received the questionnaire. A total of 347 physicians (30.6%) 
completed the questionnaire. Almost all respondents (99.4%) were recently confronted with 
skin diseases, mostly (pressure) ulcers, eczema, and fungal infections. Diagnostic and 
treatment options were limited due to a lack of availability and experience of the physicians. 
More live consultation of dermatologists was suggested as being important to improve 
dermatologic care. Other suggestions were better education, more usage of telemedicine 
applications, and better availability of diagnostic and/or treatment procedures like 
cryotherapy. 
 
Conclusion 
Physicians in nursing homes are frequently confronted with skin diseases. Several changes 
in organization of care and education are expected to improve dermatologic care in nursing 
home patients.  
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Introduction  
 
With the rapidly aging of the world population, the number of older adults in need of long-
term care is steadily increasing.1-3 Although considerable differences between countries with 
regard to the organization of long-term care for older adults exist, all countries seem to 
share the primary goal to deliver the most appropriate care to this frail population.4,5 In the 
Netherlands, older adults with multimorbidity and complex health problems generally live in 
nursing homes. Specially trained elderly care physicians (officially recognized as a medical 
discipline within the Netherlands since 1990) provide the medical care in these nursing 
homes.6,7 
 
Skin diseases form a major health problem among institutionalized older adults8-10 and 
could have a significant impact on quality of life.11-13 The most common skin problems in 
institutionalized older adults are xerosis and eczema, fungal infections, (pressure) ulcers, 
and both benign as malignant skin tumors.10,14-17 In all of these diseases both intrinsic (i.e. 
physiological skin maturation, resulting in a decrease or alteration of several functions) as 
extrinsic aging of the skin (e.g. photo-aging) often play an important role.10 Furthermore, 
common geriatric problems including incontinence and an impaired mobility could be 
important etiologic factors in skin diseases among institutionalized older adults.10,18,19 
 
Despite of the prevalence and the impact on quality of life, little is known about the need for 
and provision of dermatologic care in institutionalized older adults. The aim of this study 
was to assess the need for and provision of dermatologic care according to physicians in 
nursing homes. Furthermore, recommendations for improvement were obtained. 
 
 
Methods 
 
Q U E S T I O N N A I R E  D E S I G N  
A 49-item web-based questionnaire was developed and pretested in several 
multidisciplinary brainstorming sessions attended by multiple elderly care physicians and 
dermatologists (n=24).  
 
The main sections in the final questionnaire contained questions about the need for and 
provision of dermatologic care among nursing home patients, diagnostic procedures and 
therapy, collaboration between primary and secondary care providers, level of medical 
education, and suggestions for improvement. The diagnostic section included 
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dermatoscopy and punch biopsy as frequently used diagnostic procedures in dermatologic 
diseases. Because other frequently used diagnostics (i.e. laboratory tests and cultures) are 
widely available, these were not included in the questionnaire. The question types mostly 
used were 5-point Likert scales and multiple choice questions (examples are shown in 
Figure 1).  
 
 
Figure 1  Examples of questions used in the questionnaire  
 
How often were you confronted with a skin condition in your patients during the last three 
months? 
 
  Never 
  1-3 times 
  4-6 times 
  7-9 times 
  10 times or more 
 
 
Did you ever attend continuing medical education on a dermatology-related subject? 
 
  Yes 
  No 
 
 
 
S T U D Y  P O P U L A T I O N  A N D  Q U E S T I O N N A I R E  A D M I N I S T R A T I O N  
Data were collected between October 2013 and April 2014. All nursing home organizations 
within the Netherlands (n=173) were approached by telephone to give information about 
our study. When interested, the link to the web-based questionnaire was sent to a contact 
person (mainly a medical director), who further distributed the questionnaire to all 
physicians working in the organization. At least 2 attempts were made to contact an 
organization. All physicians working in nursing homes who were willing to participate were 
included (i.e. elderly care physicians, elderly care residents, and junior doctors). 
Approximately 4 weeks later a reminder was sent.  
 
S T A T I S T I C A L  A N A L Y S E S  
For numerical data, we calculated means and standard deviations (SD). Categorical data 
were expressed as numbers and percentages. We tested for selection bias due to non-
response, comparing the age and gender of the respondents with the target population. 
Reference data about the target population were available only for elderly care physicians 
and elderly care residents because of limited availability of national registries.20 In subgroup 
|
Current dermatologic care in Dutch nursing homes 47 
 
analyses, we stratified the respondents based on years of experience (<10 years or ≥10 
years). To examine the statistical significance of differences in responses, we used two-
sample t-tests for numerical variables and χ2 or Fisher’s exact tests for categorical variables. 
Differences were considered to be statistically significant when P was less than 0.05. We 
used a complete case approach for analyses. Data analyses were performed using the 
Statistical Package for Social Sciences (SPSS) for Windows, version 20.0 (IBM Corporation, 
Armonk, New York, United States). 
 
 
Results 
 
A total of 173 nursing home organizations were contacted, of which 126 (72.8%) were 
interested in participating. A total of 1133 physicians received the link to the web-based 
questionnaire, of which 362 (32.0%) completed the questionnaire. After exclusion of 15 non-
physician respondents, 347 questionnaires (30.6%) were eligible for inclusion. Age and 
gender of the respondents showed no statistically significant differences compared with the 
target population, indicating representativeness regarding these characteristics (data not 
shown). Table 1 provides an overview of the respondent characteristics. 
 
N E E D  F O R  A N D  P R O V I S I O N  O F  D E R M A T O L O G I C A L  C A R E  I N  N U R S I N G  H O M E S  
Of the participants, 99.4% (n=345) were confronted with a dermatologic problem in 1 or 
more patients during the past 3 months, of which 62.5% (n=217) 10 times or more. Skin 
diseases most respondents were confronted with during the past 3 months were (pressure) 
ulcers (94.2%), eczema (88.2%), fungal infections (87.0%), pruritus sine materia (78.4%), 
bacterial infections (61.7%), and cutaneous (pre)malignancies (59.4%). A complete overview 
is shown in Figure 2. 
 
D I A G N O S T I C  P R O C E D U R E S  
Only few respondents had the possibility to perform dermatoscopic examination (6.1%) or 
punch biopsy (32.0%) within their organization. Furthermore, an even smaller number 
actually ever performed these diagnostic procedures and only a limited proportion of 
respondents had the possibility to ask a colleague to perform them. Subgroup analyses 
showed no significant differences based on years of experience. More detailed data are 
shown in Table 2. Finally, a considerable proportion of the responding physicians 
considered themselves completely incompetent to perform these diagnostic procedures 
(64.0% and 50.4%, respectively). A complete overview of the self-assessed competence is 
presented in Table 3. 
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Table 1  Responder characteristics of this cross-sectional nationwide survey among physicians in 
Dutch nursing homes to evaluate current dermatologic care (n=347) 
 
Characteristics Values 
Age, mean (SD), y 43.9 (11.5) 
Male gender, n (%) 105 (30.3) 
Physician subgroup, n (%)  
Specialist 244 (70.3) 
Resident 34 (9.8) 
Junior doctor 59 (17.0) 
Other 10 (2.9) 
Experience in elderly care, mean (SD), y 11.8 (9.5) 
Number of patients, mean (SD) 58.4 (25.8) 
 
Abbreviations: SD, standard deviation; y, years.  
 
 
Figure 2  Percentage of respondents confronted with different skin diseases in nursing home 
patients during the last 3 months  
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Other 
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Viral infections 
Psoriasis 
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Bacterial infections 
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Fungal infections 
Eczema 
(Pressure) ulcers 
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Table 2  Availability and performance of diagnostic procedures and treatment in skin diseases by 
physicians in Dutch nursing homes  
 
 Available, 
% 
Ever performed/prescribed, % Possibility to ask 
colleague, % <10 YoE ≥10 YoE P-value 
Diagnostics 
Dermatoscopy 6.1 4.5 3.7 0.697 9.8 
Punch biopsy 32.0 14.4 16.4 0.607 33.1 
Non-pharmacological treatments 
Incision 91.6 70.2 83.4 0.004* 81.0 
Excision 70.6 31.8 42.7 0.04* 57.9 
Curettage 40.6 18.0 20.5 0.559 32.6 
Cryotherapy 38.3 23.2 27.3 0.390 38.3 
Pharmacological treatments 
Topical: 
Antibacterials NA 91.6 95.8 0.107 NA 
Antifungals NA 100.0 99.5 0.366 NA 
Capsaicin NA 18.1 36.3 <0.001* NA 
Calcineurine 
inhibitors 
NA 15.5 21.6 0.150 NA 
Corticosteroids NA 99.4 99.5 0.885 NA 
Emollients NA 96.8 95.8 0.633 NA 
Fluorouracil NA 38.4 65.6 <0.001* NA 
Imiquimod NA 12.3 16.3 0.287 NA 
Vitamin D 
analogues 
NA 40.0 45.3 0.326 NA 
Systemic: 
Antibiotics NA 94.2 98.9 0.012* NA 
Antifungals NA 65.2 84.2 <0.001* NA 
Antiviral NA 58.7 85.8 <0.001* NA 
Prednisolone NA 83.9 95.8 <0.001* NA 
 
Abbrevations: NA, not applicable; YoE, years of experience in elderly care. * p<0.05. 
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Table 3  Self-assessed competence of physicians in Dutch nursing homes to perform several 
diagnostic and therapeutic procedures  
 
 Level of competence, % 
Procedure Completely 
incompetent 
Somewhat 
competent 
Averagely 
competent 
Above 
averagely 
competent 
Completely 
competent 
Dermatoscopy 64.0 18.4 10.3 5.8 0.6 
Punch biopsy 50.4 15.3 13.5 17.0 2.6 
Incision 6.9 6.9 20.5 53.3 11.8 
Excision 22.8 19.0 23.6 29.4 4.0 
Curettage 46.4 17.3 16.4 14.7 3.7 
Cryotherapy 25.4 15.9 20.5 30.5 6.9 
 
Values may not add up due to rounding. 
 
 
N O N - P H A R M A C O L O G I C A L  T R E A T M E N T   
Non-pharmacological treatment options mostly available were incision (91.6%), excision 
(70.6%), curettage (40.6%), and cryotherapy (38.3%). Again, a smaller subset of respondents 
actually ever performed these treatment options themselves (76.1%, 37.2%, 18.7%, and 
25.1%, respectively). Respondents with 10 years or more of experience were more likely to 
perform incision (59.5% vs. 40.5%, p=0.004) and excision (42.7% vs. 31.8%, p=0.04) than 
respondents with fewer than 10 years of experience.  
 
A complete overview of data considering non-pharmacological treatment, including the 
possibility to ask a colleague and the self-assessed level of competence, is shown in Table 2 
and 3, respectively. 
 
P H A R M A C O L O G I C A L  T R E A T M E N T   
Topical treatments ever prescribed by the vast majority of respondents were corticosteroids 
(99.4%), antifungals (99.7%), emollients (96.3%), and antibacterials (93.9%). Subsequently, 
emollients, antifungals, and corticosteroids were also prescribed most frequently during the 
past 3 months (at least once a week by 85.3%, 72.0%, and 56.3% of the respondents, 
respectively). More experienced physicians were more likely to have ever prescribed 
capsaicin (36.3% vs. 18.1%, p<0.001) and 5-fluorouracil cream (65.6% vs. 38.4%, p<0.001) 
than physicians with fewer than 10 years of experience. Table 2 presents a complete 
overview of data, including systemic treatments. 
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C O L L A B O R A T I O N  W I T H  D E R M A T O L O G I S T S  
 
Outpatient visits of nursing home patients 
Most of the responding physicians (88.5%) indicated 1 or more of their patients visited a 
dermatology outpatient clinic during the past year. The most often reported reasons for 
these visits were cutaneous (pre)malignancies (80.1%), followed by (pressure) ulcers (25.7%), 
bullous diseases (19.9%), and eczema (15.6%). Figure 3 provides a complete overview of the 
reasons for dermatology outpatient clinic visits.  
 
 
Figure 3  Percentage of respondents confronted with different skin diseases as a reason for 
dermatologist consultation and outpatient visits of nursing home patients during the past year 
 
 
 
 
Several suggestions for improvements with respect to the outpatient clinic visits were made 
(n=117). Taking into account a patients general health status during medical decision-
making more often was the most frequently made suggestion (33.3%), followed by more 
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communication between a dermatologist and the referring physician during the medical 
decision-making process (25.6%), better and/or more complete referral reply letters from 
dermatologists (23.9%) and to take into account the (logistical) limitations of a nursing home 
more often (4.3%). 
 
Consultation of a dermatologist  
More than three-quarters of the respondents (79.3%) consulted a dermatologist regarding 1 
or more of their nursing home patients during the past year, of which 41.5% at least once 
every quarter of a year. The type of communication used by most of the respondents was a 
telephone conversation (76.4%), followed by telemedicine applications (31.6%), face-to-face 
consultation in a nursing home (31.3%), or e-mail (21.5%). The skin diseases most commonly 
named as a reason for these consultations are shown in Figure 3. More experienced 
physicians were more likely to have consulted a dermatologist during the past year 
compared with less experienced physicians (84.7% vs. 72.9%, p=0.007).  
 
Management recommendations by dermatologists 
The subsequent question focused on the amount of which several important patient-related 
factors (quality of life, multimorbidity, cognitive impairment, and (limited) life expectancy) are 
taken into account by dermatologists making medical management decisions in nursing 
home patients. Scores ranged from 1 to 5 (higher scores indicate taking the factor more into 
account). Data are shown in Figure 4. Quality of life received the highest score (mean (SD), 
3.38 (1.07)), followed by multimorbidity (3.27 (1.00)), (limited) life expectancy (3.13 (1.07)), 
and cognitive impairment (2.97 (1.09)). All differences between the four patient-related 
factors were statistically significant with p≤0.008. 
 
D E R M A T O L O G Y  ( C O N T I N U I N G  M E D I C A L )  E D U C A T I O N  
 
Basic training 
Almost all respondents received basic training in dermatology during an undergraduate 
medical school course (95.7%) and/or clinical rotation (94.5%), irrespective of years of 
experience. Only a small minority received additional training during an elective 
dermatology course or clinical rotation (4.6% and 5.2%, respectively). Less experienced 
physicians were more likely to have attended an elective clinical rotation in dermatology 
compared to more experienced respondents (9.0% vs. 2.1%, p=0.004). The proportion of 
respondents who received an elective dermatology course during medical school was not 
influenced by years of experience. 
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Continuing medical education 
Almost two-thirds of the participants (64.0%) had ever attended continuing medical 
education on a dermatology-related subject, of which  (geriatric) dermatology in general was 
the most mentioned subject, followed by (pressure) ulcers (41.8%) and cutaneous 
(pre)malignancies (30.3%). More experienced physicians were more likely to have followed 
continuing medical education than less experienced physicians (85.8% vs. 37.4%, p<0.001).  
 
 
Figure 4  The amount of which several patient-related factors are taken into account by 
dermatologists making medical management decisions in nursing home patients, according to 
physicians from Dutch nursing homes 
 
 
 
a Scores ranged from 1 (“not”) to 5 (“very much”), so higher scores indicated taking a factor more into account; b 
Number of physicians. 
 
 
Demand for more education and suggested improvements of education  
More continuing medical education was requested by 72.0% (n=250) of the responding 
physicians and 534 specific subjects were proposed. Suggested subjects could be divided in 
specific (groups of) dermatologic diseases (77.2%), (geriatric) dermatology in general (14.6%), 
and diagnostic/therapeutic skills (8.2%). Cutaneous (pre)malignancies were by far the most 
frequently (37.1%) mentioned subject among the specific (groups of) dermatologic diseases 
(Figure 5).  
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       1          2          3         4         5a (not) (very much) 
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Next, the participants were asked in which way(s) education could be further improved. A 
total of 207 suggestions were made and the most common suggestion was more (specific) 
training focused on dermatology in older adults (42.5%), followed by more educational 
outreach visits (i.e. bed-side teaching) (23.7%), more online modules / e-learning (9.2%), the 
possibility to accompany a dermatologist in daily practice at an outpatient clinic (7.7%), more 
attention to dermatologic diseases in elderly care residency programs (4.9%) and 
subspecialty training of elderly care physicians with special interest in dermatology (2.4%).  
 
S U G G E S T I O N S  F O R  G E N E R A L  I M P R O V E M E N T  O F  D E R M A T O L O G I C  C A R E  A M O N G  
N U R S I N G  H O M E  P A T I E N T S  
Most respondents (79.5%) reported suggestions to improve dermatologic care among 
nursing home patients in general. Of all suggestions (n=505), making more and better use of 
telemedicine applications (21.6%) and more consultation of dermatologists or dermatology 
nurses in nursing homes (21.4%) were most frequently suggested. Other suggestions were 
better availability of diagnostic and/or treatment procedures in nursing homes (15.8%), 
better clinical skills training (15.0%) and more knowledge about skin diseases in older adults 
(11.5%). 
 
 
Figure 5  Specific skin diseases requested as topics for continuing education, in % 
 
  
37.1 
14.1 12.9 
8.0 
6.1 
5.3 
4.6 
2.4 
1.5 
8.0 
Cutaneous 
(pre)malignancies 
Eczema 
(Pressure) ulcers 
Pruritus sine materia 
Bullous diseases 
Psoriasis 
Fungal infections 
Bacterial infections 
Viral infections 
Other 
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Discussion 
 
Skin diseases are common among institutionalized older adults and could have a significant 
impact on quality of life.8-13 Our study is the first to examine the need for and provision of 
dermatologic care among institutionalized older adults from the perspective of physicians in 
nursing homes. Almost all respondents (99.4%) were confronted with skin diseases in their 
patients on a regular basis and have experience with the most common pharmacological 
treatment options. However, diagnostic procedures and non-pharmacological treatment 
options are less commonly applied. Possible explanations shown in the present study are a 
lack of training and a lack of availability.  
 
In this study (pressure) ulcers, eczema, and fungal infections were the most common skin 
diseases responding physicians were confronted with in institutionalized older adults. 
Nevertheless, cutaneous (pre)malignancies were the most frequently recorded reason to 
consult a dermatologist. Although the incidence of skin cancer is rising worldwide,21,22 
previous studies have shown a relative low incidence of skin cancer compared to other skin 
diseases among institutionalized older adults.14-17 However, these studies were mainly 
conducted in non-Caucasian populations and some might be outdated. Limitations in 
experience with skin cancer and the earlier mentioned limited availability of diagnostic and 
treatment options could be other explanations for this frequent dermatologist consultation 
in skin cancer. Future research is needed to study this in more detail. 
 
More and better usage of telemedicine applications was the most frequently made 
suggestions to improve current dermatologic care among nursing home patients. Previous 
studies showed telemedicine could improve nursing home care, might replace outpatient 
clinic visits and is generally accepted by patients, families, and caregivers.23-29 Interestingly, 
most respondents in the present study (76.4%) used a telephone to consult a dermatologist, 
while telemedicine applications were used by relatively few respondents (31.6%). A possible 
explanation for this discrepancy could be a limited availability of telemedicine applications 
or a limited familiarity with telemedicine applications.  
 
Although most participants in our present study received basic dermatology training, more 
and better training was requested by most of the respondents, especially educational 
outreach visits. More nursing home visits by dermatologists could be an option to partially 
meet these requests.  Furthermore, more and better education could possibly result in 
lowering the threshold for a physician to obtain more experience in daily clinical practice 
and to improve the necessary (logistical) conditions (like the purchase of certain medical 
equipment). 
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To take into account a patient’s general health status during medical decision making seems 
to be a suggestion to improve care of particular interest for dermatologists. Next to the 
earlier mentioned effects, a better and more intense collaboration between physicians in 
nursing homes and dermatologists could probably improve this item as well. Moreover, 
enough information about the patient’s general health status, (end-of-life) treatment 
limitations, and the logistical (im)possibilities in a referral letter or consultation request to 
the dermatologist from the physician in a nursing home seems to be essential to create the 
required awareness among dermatologists for this item. 
 
L I M I T A T I O N S  
There are several limitations in the present study. Non-physicians were not included in our 
study, because our questionnaire mostly focused on physician-specific items like 
prescription patterns and medical education. However, we acknowledge the increasing role 
of nurse practitioners and physician assistants in daily (dermatologic) care in nursing homes. 
Moreover, despite of our multidisciplinary brainstorming sessions and pretesting of the 
questionnaire, possible misinterpretation of some questions and the self-assessing 
character of the questionnaire might have influenced the results. 
 
 
Conclusion 
 
In conclusion, physicians working in nursing homes are frequently confronted with skin 
diseases in their patients and consultation of a dermatologist is requested on a regular 
basis. Better diagnostic and treatment facilities in nursing homes, better education, more 
usage of telemedicine, and more nursing home visits by dermatologists were designated as 
most important suggestions to improve dermatologic care in nursing homes. 
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Abstract  
 
Background  
Dermatologists are expected to be increasingly confronted with institutionalized older adult 
patients, due to the rapidly aging world population.  
 
Objectives  
To determine the proportion of dermatologists visiting patients in nursing homes, together 
with the reasons for consultation, barriers to perform these visits and diagnostic and 
treatment patterns.  
 
Materials and methods 
A web-based questionnaire regarding dermatologic care in nursing home patients was 
developed by a multidisciplinary group of dermatologists, residents and elderly care 
physicians. A cover letter containing a link to the final questionnaire was sent by e-mail to all 
661 dermatologists and dermatology residents in the Netherlands.  
 
Results 
A total of 130 eligible questionnaires were returned (19.7%). Most respondents (79.2%) ever 
had contact with an elderly care physician concerning a nursing home patient. However, 
only 30.0% of the respondents ever visited a patient within a nursing home. The most 
common reasons for nursing home visits were cutaneous (pre)malignancies (51.4%), 
eczema/dermatitis (25.7%) and (pressure) ulcers (8.6%). The most important barriers 
mentioned to perform nursing home visits were a lack of time and indistinct and/or 
inadequate financial compensation. Diagnostic and treatment patterns often differed from 
the outpatient clinic due to various patient-related and logistic factors. 
 
Conclusion 
Dermatologists are frequently confronted with nursing home patients but only a minority 
visits patients within nursing homes. Lack of time and/or financial compensation seem 
important barriers. 
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Introduction  
 
People aged 80 years and older (oldest-old) is the fastest growing age group worldwide and 
it is expected this age group will increase approximately sevenfold in the period 2013-2100, 
to 830 million people in 2100.1 A considerable number of oldest-old people are in need of a 
permanent healthcare institution and the future demand for these institutions is expected 
to increase.2-5 Although long-term older adult care differs around the globe, the concept of 
institutionalization of older adults in need of the highest level of care appears to be 
universal.3-6 Within the Netherlands permanent healthcare institutions are classified into 
residential homes and nursing homes, depending on the type and extent of (medical) care 
needed. Older adults in need of the most complex care often live within nursing homes, 
where medical care is mainly provided by specially trained elderly care physicians.7 
 
Skin problems form a significant part of care needed within permanent healthcare 
institutions.8-11 The older adult skin is vulnerable to many skin problems due to both intrinsic 
and extrinsic aging. Intrinsic skin aging is caused by a physiological maturation of the skin, 
resulting in a decrease and alteration of several functions like immunosenescence, 
epidermal barrier function, and wound healing. Extrinsic aging is caused by environmental 
factors, of which exposure to ultraviolet radiation (photo-aging) is the most important.12,13 
Furthermore, frailty – defined as an increased risk of poor health outcomes due to 
vulnerability caused by a cumulative decline in multiple physiologic systems – but also more 
specific factors like immobility, multimorbidity, and cognitive impairment could affect the 
optimal detection and care of skin problems, especially in institutionalized older adults.14-17 
The most prevalent skin diseases affecting institutionalized older adults are xerosis, fungal 
infections, (pressure) ulcers, dermatitis, and skin tumors (both benign and malignant).17-20  
Skin problems may have a significant effect on quality of life in (institutionalized) older 
adults.21-23 Consequently, consultation of a dermatologist in this vulnerable group of 
patients often seems desirable in daily practice. However, attending a dermatology clinic 
may not be feasible due to the various frailty-related factors mentioned before. In this 
situation a dermatologist visiting an institutionalized patient could be a solution.  
 
Dermatologic care in the Netherlands can be distinguished in both primary, secondary, and 
tertiary care. Primary dermatologic care is mainly delivered by general practitioners or the 
previously mentioned elderly care physicians in the case of a nursing home patient. In 
contrast, both secondary and tertiary dermatologic care are delivered by dermatologists, 
within a general hospital (or medical specialist clinic) and academic hospital, respectively. 
Secondary and tertiary care is only available for a patient after referral of a primary care 
physician, to prevent unnecessary usage of medical specialist care.24 Within the current 
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healthcare regulations dermatologists may visit patients outside of a hospital or clinic (for 
instance within a nursing home), although these regulations lack further specifications for 
this type of care and no nationwide arrangements are currently made to cover all nursing 
homes within the Netherlanders. Therefore, in case attendance of a nursing home patient 
to a dermatology clinic is not feasible, patients are dependent on primary dermatologic care, 
which could only be supplemented by secondary or tertiary dermatologic care if 
arrangements are made with one or more local dermatologists. Data regarding these visits 
of dermatologists to patients outside a hospital or clinic is currently missing in the literature. 
 
This study aimed to determine the current proportion of dermatologists visiting 
institutionalized patients in nursing homes in the Netherlands, including reasons for 
consultation and barriers to perform these visits. Furthermore, diagnostic and treatment 
patterns were studied. 
 
 
Methods 
 
D E V E L O P M E N T  A N D  C O M P O S I T I O N  O F  T H E  Q U E S T I O N N A I R E  
The present, exploratory, cross-sectional, nationwide survey was performed using an 
anonymous web-based questionnaire intended for all dermatologists and dermatology 
residents within the Netherlands. We developed a 49-item questionnaire containing 
sections concerning the main outcomes: respondent characteristics, dermatologist 
consultation in nursing homes, diagnosis and treatment of skin diseases in nursing home 
patients, implementation of dermatologic care, decision-making in geriatric dermatology, 
and level of medical training. The questionnaire contained multiple choice questions, 5-point 
Likert scale questions (ranging from never to always), and open-ended questions. 
Concerning decision-making in geriatric dermatology, respondents were asked to score the 
amount of attention paid to four different items (quality of life, multimorbidity, cognitive 
impairment, and limited life expectancy) by themselves and by dermatologists in general, 
which are related to medical decision-making in older adult patients (in all clinical settings). 
The initial draft was extensively discussed and pretested in several multidisciplinary 
brainstorming sessions with multiple dermatologists, dermatology residents, and elderly 
care physicians. 
 
S T U D Y  P O P U L A T I O N  A N D  D I S T R I B U T I O N  O F  T H E  Q U E S T I O N N A I R E  
In March 2014 all dermatologists and dermatology residents within the Netherlands were 
approached by e-mail by the Dutch Society of Dermatology and Venereology, which 
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contained a cover letter and a link to the web-based questionnaire. A reminder e-mail was 
sent six weeks later.  
 
S T A T I S T I C S  
Continuous data were expressed as mean and standard deviation (SD) and categorical data 
were expressed as number and percentage. The age, gender, and physician subgroup 
(dermatologist or dermatology resident) of the respondent population were compared to 
the target population to test for selection bias due to non-response. Subgroup analyses 
were performed to determine the influence of the main respondent characteristics (age: 
<40 or ≥40 years; physician subgroup; and years of experience: <10 or ≥10 years) and 
whether a respondent visited nursing homes (yes or no) on some of the main outcomes: 
(willingness to perform) nursing home visits and level of medical training. A paired two-
sample T-test was used to compare general with self-assessment scores, while an 
independent two-sample T-test was used to compare other continuous data. Categorical 
data were compared using a Chi-squared test (or Fisher’s exact test in case any of the cells 
had an expected count of less than 5). We used a complete case approach and a p-value of 
<0.05 was considered statistically significant. All analyses were conducted using Statistical 
Package for Social Sciences (SPSS) for Windows, version 20.0 (IBM Corporation, Armonk, 
New York, United States). 
 
 
Results 
 
R E S P O N D E N T  P R O F I L E  
Of the 661 dermatologists and dermatology residents who were invited by e-mail, 131 
(19.8%) returned the questionnaire. No duplicate questionnaires were received. One 
questionnaire was excluded from further analysis because all answers with exception of the 
respondent characteristics were missing, resulting in 130 (19.7%) eligible questionnaires.  
 
A comparison of age, gender, and physician subgroup between the respondent population 
and the target population showed no significant differences (data not shown), indicating an 
appropriate representativeness regarding these characteristics. Table 1 provides an 
overview of the baseline characteristics for respondents, separately specified for 
dermatologists and dermatology residents. The questionnaire was completed by 95 
dermatologists (73.1%) and 35 dermatology residents (26.9%). The mean age (SD) of the 
respondents was 43.7 (11.0) years and a minority of the respondents (42.3%) was male. 
Dermatology residents were younger (mean (SD), 31.9 (3.1) years vs. 47.9 (9.6) years, 
p<0.001) and less often male (17.1% vs. 51.6%, p<0.001) compared to dermatologists. 
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Table 1  Baseline characteristics for respondents in our nationwide survey on dermatologic care 
in nursing homes 
 
Characteristics Total (n=130) Dermatologists 
(n=95) 
Dermatology 
residents (n=35) 
Age, mean (SD), y 43.7 (11.0) 47.9 (9.6)* 31.9 (3.1)* 
Male gender, n (%) 55 (42.3) 49 (51.6)* 6 (17.1)* 
YoE, mean (SD)   NA 14.8 (10.5) NA 
Year of training, n (%) NA NA 1: 4 (11.4) 
2: 7 (20.0) 
3: 7 (20.0) 
4: 7 (20.0) 
5: 10 (28.6) 
 
Abbreviations: NA, not applicable; SD, standard deviation; y, years; YoE, years of experience. * p<0.001. 
 
 
C O N S U L T A T I O N  I N  N U R S I N G  H O M E  P A T I E N T S   
 
Long-distance consultation 
The majority of the respondents (79.2%) indicated they had contact with an elderly care 
physician to discuss 1 or more patients at some point in the past (correspondence by letter 
excluded), also shown in Table 2. Dermatologists were more likely to be contacted by an 
elderly care physicians compared to residents (87.4% vs. 57.1% respectively, p<0.001). No 
statistically significant differences in age or years of experience were observed. Regarding 
the methods of communication, most of those surveyed reported a telephone conversation 
(89.3%). Dermatologists more often used teledermatology applications or e-mail compared 
to dermatology residents (data shown in Table 2). For more than half of the participants 
(55.3%) these contacts took place at least 4 times a year. Most of the respondents (88.3%) 
indicated that it is sometimes or often possible to provide proper advice without live 
examination, but 7.8% rarely or never does this (3.9% were missing). An overwhelming 
majority (92.2%) of respondents which were contacted by an elderly care physician in the 
past indicated there had been patients for whom they believed it would have been better 
when they were consulted earlier: 15.5% even reported this often happened. 
 
Nursing home visits 
A total of 39 respondents (30.0%) reported that they had visited 1 or more patient(s) in a 
nursing home at some point in the past. None of the dermatology residents visited a 
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nursing home patient before. Dermatologists who visit nursing homes were more likely to 
be older (89.7% ≥40 years old vs. 67.9% ≥40 years old, p=0.013) and more experienced 
(82.1% ≥10 years of experience vs. 59.2% ≥10 years of experience, p=0.021) than those who 
never visited a nursing home. Of the dermatologists who had visited 1 or more patients 
within a nursing home in the past year, over half (54.3%) did so at least 4 times a year. For 
an overview of all data regarding consultation and nursing home visits, shown in Table 2.  
 
Over two thirds of the participants (68.5%) are willing to visit patients on location within a 
nursing home (for the first time or more often when already performed a visit in the past). 
Interestingly, respondents who are willing to perform (more) visits were more likely to be 
younger (81.8% vs. 58.1%, for respondents aged <40 years old vs. ≥40 years old, p=0.004), 
to have less years of experience (77.8% vs. 55.7%, for respondents with <10 years of 
experience vs. ≥10 years of experience, p=0.049) and to be a resident (88.6% vs. 61.1%, for 
dermatology residents versus dermatologists, p=0.003). There was no difference in 
willingness between respondents who visited nursing homes in the past and those who did 
not. Among the respondents not willing to perform nursing home visits, most mentioned a 
lack of time to perform visits (80.5%) and indistinct and/or inadequate financial 
compensation (34.1%) as reasons. Of the dermatologists who visited patients in a nursing 
home during the past year, 51.4% reported (suspected) cutaneous (pre)malignancies as the 
most common reason for consultation, followed by eczema/dermatitis (25.7%). Figure 1 
provides a complete overview of these data. 
 
 
Figure 1  An overview of skin diseases reported as most common reasons for nursing home visits 
by dermatologists, in % 
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Table 2  Consultation and nursing home visits of dermatologists and dermatology residents 
 
Total activities Total number of 
respondents (n=130) 
Dermatologists (n=95) Dermatology 
residents (n=35) 
P-value 
Had contact with an elderly care physician, n (%)a 103 (79.2) 83 (87.4) 20 (57.1) <0.001* 
Visited a patient in a nursing home, n (%)a 39 (30.0) 39 (41.1) 0 (0) <0.001* 
Willing to visit nursing homes (more often), n (%) 89 (68.5) 58 (61.1) 31 (88.6) 0.003* 
Consultations Number of respondents  
(n=103) 
Dermatologists (n=83) Dermatology 
residents (n=20) 
P-value 
Proportion of the respondents using different methods of communication, n (%)b: 
Telephone 92 (89.3) 72 (86.7) 20 (100) 0.085 
Teledermatology applications 38 (36.9) 38 (45.8) 0 (0) <0.001* 
E-mail 33 (32.0) 31 (37.3) 2 (10.0) 0.019* 
Other 9 (8.7) 9 (10.8) 0 (0) 0.123 
Frequency of contact with elderly care  physician in the last year, n (%):   
0 times 3 (2.9) 3 (3.6) 0 (0) <0.001* 
1-3 times 43 (41.7) 25 (30.1) 18 (90.0)  
4-6 times 23 (22.3) 23 (27.7) 0 (0)  
7-9 times 11 (10.7) 9 (10.8) 2 (10.0)  
10 times or more 23 (22.3) 23 (27.7) 0 (0)  
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Table 2  Consultation and nursing home visits of dermatologists and dermatology residents (continued) 
 
Nursing home visits Number of respondents 
(n=39) 
Dermatologists (n=39) Dermatology 
residents (n=0) 
P-value 
Frequency of nursing home  visits in the last year, n (%): 
0 times 4 (10.3) 4 (10.3) NA NA 
1-3 times 16 (41.0) 16 (41.0) 
4-6 times 8 (20.5) 8 (20.5) 
7-9 times 5 (12.8) 5 (12.8) 
10 times or more 6 (15.4) 6 (15.4) 
Number of nursing home locations visited in the last year, n (%): 
1 18 (51.4) 18 (51.4) NA NA 
2 9 (25.7) 9 (25.7) 
3 or more 7 (20.0) 7 (20.0) 
Type of nursing home visits in the last year, n (%): 
Planned/standardized visits 18 (51.4) 18 (51.4) NA NA 
Ad hoc visits 16 (45.7) 16 (45.7) 
Both 1 (2.9) 1 (2.9) 
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Table 2  Consultation and nursing home visits of dermatologists and dermatology residents (continued) 
 
Nursing home visits Number of respondents 
(n=39) 
Dermatologists (n=39) Dermatology 
residents (n=0) 
P-value 
Present during nursing home visits in the last year, n (%): 
Elderly care physician 30 (85.7) 30 (85.7) NA NA 
Nursing staff 32 (91.4) 32 (91.4) 
Dermatology nurse 5 (14.3) 5 (14.3) 
 
NA, not applicable. Values may not add up due to missing values and rounding. a At some point in the past; b Contact by letter excluded; * p<0.05.  
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D I A G N O S I S  A N D  T R E A T M E N T  W I T H I N  N U R S I N G  H O M E S  
 
Diagnostic procedures 
The majority of the dermatologists visiting nursing homes (82.9%) performed diagnostic 
procedures within a nursing home, of which punch biopsy (65.7%) and dermatoscopic 
assessment (62.9%) are the most common procedures used, followed by the collection of 
tissue samples to detect pathogenic micro-organisms (45.7%), and (ordering) blood tests 
(40.0%). 
 
Among the respondents visiting nursing homes, 91.4% confirmed that there were 
differences between the diagnostic procedures performed within a nursing home compared 
to the outpatient clinic. More specifically, a less frequent usage of diagnostic procedures 
within nursing homes was most often mentioned (81.3%), followed by no performance of 
diagnostic procedures in nursing homes at all (12.5%). The remaining 6.2% reported to use 
other diagnostic procedures within nursing homes. The most common reasons for these 
diagnostic differences were: a limited life expectancy of the patient (68.8%), excessive 
burden for the patient (62.5%), unavailability of diagnostic procedures (53.1%), physical 
impairment of the patient (40.6%), requested by the patient or relatives (40.6%), cognitive 
impairment of the patient (34.4%), requested by the elderly care physician involved (28.1%), 
and a lack of supporting staff (21.9%). 
 
Dermatological treatment 
Non-pharmacological treatment in a nursing home was performed by 80.0% of the 
respondents visiting nursing homes, of which cryotherapy (68.6%) was most commonly 
applied, followed by shave excision or curettage (40.0%), surgical excision (22.9%), 
mechanical debridement (22.9%), UVB phototherapy (8.6%), and electrodesiccation (5.7%).  
 
All dermatologists indicated their treatment decision sometimes differed within a nursing 
home compared to the outpatient clinic. Almost half of the participants reported to perform 
less treatment or no treatment at all (43.8%), followed by use of other treatment options 
(28.1%). The most common reasons for the treatment differences mentioned were: 
requested by the patient or relatives (65.7%), excessive burden for the patient (60.0%), a 
limited life expectancy of the patient (54.3%), physical impairment of the patient (51.4%), 
unavailability (40.0%), requested by the elderly care physician involved (37.1%), cognitive 
impairment of the patient (28.6%), a lack of supporting staff (22.9%), and an expected 
increased risk to develop complications (22.9%). 
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Implementation of dermatologic care 
The recommendations given by the dermatologists visiting nursing homes were often 
(45.7%) or always (45.7%) properly followed according to most of the respondents, while 
one respondent (2.9%) indicated given recommendations were only sometimes properly 
followed and two respondents (5.7%) did not know. The reasons suggested for the incorrect 
implementation of recommendations by most respondents were non-compliance and/or 
misunderstanding of the nursing staff (70.6%), the elderly care physician (38.3%), or the 
patient (11.8%). Furthermore, 29.4% of the respondents indicated a delayed delivery or no 
delivery of medication as a reason. 
 
D E C I S I O N - M A K I N G  I N  G E R I A T R I C  D E R M A T O L O G Y  
Regarding the items on decision-making in geriatric dermatology, almost all of the 
respondents (96.9%) gave themselves a high score (4 or 5 out of 5) on “taking quality of life 
into account”, resulting in a mean score (SD) of 4.4 (0.6). All other items were scored 
significantly lower (3.7-4.0, p≤0.001). When dermatologists were scored in general, they 
received significantly lower scores on all items compared to the self-assessment (p≤0.001). 
The scores for dermatologists in general were significantly lower given by dermatology 
residents compared to dermatologists on “taking quality of life into account” (mean (SD), 
3.47 (0.75) vs. 3.93 (0.76), p=0.003) and “taking comorbidities into account” (mean, (SD), 3.41 
(0.74) vs. 3.71 (0.67), p=0.003). All of the items scored by the respondents are summarized 
in Table 3.  
 
 
Table 3  Scoring of items taken into account by respondents during medical decision-making (5-
point scale, higher scores suggest items are taken more into account) 
 
Items Self-assessment 
scores 
Scores for 
dermatologists 
in general 
Difference  
(95% CI) 
Quality of life, mean (SD) 4.4 (0.6) 3.8 (0.8) 0.6 (0.50.7)* 
Multimorbidity, mean (SD) 4.0 (0.7) 3.6 (0.7) 0.4 (0.3-0.5)* 
Cognitive impairment, mean (SD) 3.7 (0.9) 3.5 (0.7) 0.2 (0.1-0.4)* 
(Limited) life expectancy, mean (SD) 4.0 (0.9) 3.5 (0.8) 0.5 (0.4-0.6)* 
 
Abbreviations: 95% CI, 95% confidence interval; SD, standard deviation. * p≤0.001. 
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L E V E L  O F  T R A I N I N G  
A minority of the participants received training in geriatrics during medical school (44.6%). 
Furthermore, 41.5% of the participants received training during the medical internship years 
and only 28.5% received training during continuing medical education activities. 
Nevertheless, the majority of the respondents (83.8%) considered themselves sufficiently 
trained to provide an adequate level of dermatologic care in nursing home patients. 
Dermatology residents were less likely to consider themselves sufficiently trained compared 
to dermatologists (65.7% vs. 90.5%, p<0.001), while no statistically significant influences of 
age and years of experience were observed. Furthermore, respondents who visited nursing 
homes in the past more often considered themselves sufficiently trained compared to those 
who did not (100% vs. 78.0%, p=0.002).  
 
The main subjects of which a lack of training and/or knowledge was reported were geriatric 
medicine in general (22.6%), polypharmacy (22.6%), multimorbidity (19.4%), and skin cancer 
care in older adult patients (9.7%). Furthermore, half of the respondents (50.8%) would like 
to receive more training in geriatrics. 
 
 
Discussion  
 
To the best of our knowledge the present study is the first to examine the nationwide need 
for and provision of dermatologic care in institutionalized older adults. Our study shows a 
high demand for dermatological care among frail institutionalized older adults. In 
accordance with these present results, previous studies also showed a considerable 
demand for consultation within permanent healthcare institutions by different medical 
specialists. Furthermore, the availability of a consultant service by medical specialists could 
improve medical care in nursing homes.25-26 
 
The most common skin diseases affecting institutionalized older adults generally 
correspond with the most common reasons for consultations in nursing homes by 
dermatologists found in our study. However, we found a strikingly high portion of cutaneous 
(pre)malignancies as a reason for consultation.17-20 Possible explanations for this finding 
could be the ongoing rise of incidence of skin cancer worldwide,27-28 a lack of knowledge 
and/or experience in diagnosing and treating cutaneous (pre)malignancies among elderly 
care physicians, and/or inadequate logistical possibilities for the latter. Considering the 
potential morbidity and mortality of cutaneous (pre)malignancies, timely diagnosis and 
treatment is considered important. Therefore, future research should focus more 
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extensively on skin cancer care in institutionalized older adults, including the role and 
training of elderly care physicians and/or specialized nurses.  
 
Another important finding in our study was that the majority of dermatologists and 
dermatology residents is willing to visit institutionalized patients when indicated. However, at 
present only a minority actually performs visits to nursing homes. Lack of time and financial 
compensation were stated as major explanatory factors for this mismatch. Potential other 
factors which could possibly influence the mentioned willingness to visit institutionalized 
patients are a lack of an adequate infrastructure (both technically as personally) and a lack 
of a proper and uniform documentation system. More attention for these aspects by 
healthcare policymakers seems to be important in order to optimize care and meet the 
expected increase in frail older adults living in permanent healthcare institutions, in which 
an outpatient visit to a dermatology clinic often may not be feasible.  
 
Finally, this study shows that several diagnostic and treatment procedures are less 
frequently used within nursing homes as compared to outpatient clinics. This can be 
explained by multiple factors, as indicated by the respondents in this study. First, patient-
related factors, such as an excessive burden for the patient or a limited life expectancy of 
institutionalized older adults, could make a dermatologist less prone to perform (extensive) 
diagnostic or treatment procedures. In addition, several logistic factors, such as 
unavailability of procedures and a lack of supporting staff, are also mentioned as reasons 
for the less frequently usage of diagnostic and treatment procedures. The latter could be an 
important limitation to deliver the optimal dermatological care within this population.  
 
In conclusion, this nationwide survey showed few dermatologists visit institutionalized 
patients within a nursing home when an outpatient appointment is not feasible, despite the 
frequent confrontation with this frail group of older adults and a considerable willingness to 
perform these visits. Several, mainly logistic factors were stated as limitations in 
dermatologic care.  
 
L I M I T A T I O N S  
A limitation of this study is the relatively low response rate, resulting in possible selection 
bias. This could for instance have led to a potential overestimation of the proportion of 
dermatologists visiting nursing homes. Nevertheless, it is reassuring we found no significant 
differences in baseline characteristics between respondents and the target population. In 
addition, despite of our thorough multidisciplinary questionnaire development process, the 
partial self-assessing character of some questions and the possibility of misinterpretation 
could have influenced the results. 
|
Dermatologic care of institutionalized older adults: the role of dermatologists 75 
 
 
A C K N O W L E D G E M E N T S  
We would like to thank the dermatologists, dermatology residents, and elderly care 
physicians who participated in the brainstorming sessions during the questionnaire 
development process. Furthermore, we are grateful to all respondents in our study. 
  
|
76 Chapter 3 
 
 
References 
 
1. United Nations, Department of Economic and Social Affairs, Population Division. World population 
prospects: the 2012 revision. New York, United States: United Nations, 2013. Available from: 
https://esa.un.org/unpd/wpp/publications/Files/WPP2012_HIGHLIGHTS.pdf. Accessed November 8, 
2014.  
2. United States Department of Health and Human Services, Administration on Aging and Community 
Living. A profile of older Americans: 2013. Washington, United States: Administration for Community 
living, 2013. Available from: http://www.aoa.gov/Aging_Statistics/Profile/2013/ docs/2013_Profile.pdf. 
Accessed November 8, 2014.  
3. Bettio F, Verashchagina A, Mairhuber I, et al. Long-term care for the elderly: provisions and providers in 
33 European countries. Rome, Italy: European Commission, 2012. Available from: 
http://ec.europa.eu/justice/gender-equality/files/elderly_care_en.pdf. Accessed May 4, 2014.  
4. Garssen JH, Harmsen C. Ouderen wonen steeds langer zelfstandig. The Hague, the Netherlands: 
Statistics Netherlands, 2011. Available from: https://www.cbs.nl/nl-nl/nieuws/2011/28/ouderen-wonen-
steeds-langer-zelfstandig. Accessed November 8, 2014. Dutch.   
5. Congress of the United States, Congressional Budget Office. Rising demand for long-term services and 
supports for elderly people. Washington, United States: Congressional Budget Office, 2013. Available 
from: http://www.cbo.gov/publication/44363. Accessed May 4, 2014.  
6. Ribbe MW, Ljunggren G, Steel K, et al. Nursing homes in 10 nations: a comparison between countries 
and settings. Age Ageing. 1997;26 Suppl 2:3-12. 
7. Schols JM, Crebolder HF, van Weel C. Nursing home and nursing home physician: the Dutch 
experience. J Am Med Dir Assoc. 2004; 5(3): 207-12. 
8. Kottner J, Rahn Y, Blume-Peytavi U, Lahmann N. Skin care practice in German nursing homes: a 
German-wide cross-sectional study. J Dtsch Dermatol Ges. 2013; 11(4): 329-36. 
9. Meesterberends E, Halfens RJ, Spreeuwenberg MD, et al. Do patients in Dutch nursing homes have 
more pressure ulcers than patients in German nursing homes? A prospective multicenter cohort study. 
J Am Med Dir Assoc. 2013; 14(8): 605-10. 
10. Norman RA. Geriatric dermatology. Dermatol Ther. 2003; 16(3): 260-8. 
11. Beauregard S, Gilchrest BA. A survey of skin problems and skin care regimens in the elderly. Arch 
Dermatol. 1987; 123(12): 1638-43. 
12. Chang AL, Wong JW, Endo JO, Norman RA. Geriatric dermatology review: major changes in skin function 
in older patients and their contribution to common clinical challenges. J Am Med Dir Assoc. 2013; 14(10): 
724-30. 
13. Gilchrest BA. Photoaging. J Invest Dermatol. 2013; 133(E1): E2-6. doi: 10.1038/skinbio.2013.176. 
14. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013; 381(9868): 752-62. 
15. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic 
medical diseases. N Engl J Med. 1998; 338(21): 1516-20. 
16. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying 
UK clinical guidelines to people with multimorbidity. Age Ageing. 2013; 42(1): 62-9. 
17. Smith DR, Leggat PA. Prevalence of skin disease among the elderly in different clinical environments. 
Australas J Ageing. 2005; 24(2): 71-6. 
18. Chan SW. Prevalence of skin problems in elderly homes residents in Hong Kong. Hong Kong J Dermatol 
Venereol. 2006; 14: 66-70. 
19. Roodsari MR, Malekzad F. The prevalence of skin diseases among nursing-home patients in North 
Tehran. Clinical Dermatol. 2008; 24(3): 43-45. 
|
Dermatologic care of institutionalized older adults: the role of dermatologists 77 
 
 
20. Kilic A, Gul U, Aslan E, Soylu S. Dermatological findings in the senior population of nursing homes in 
Turkey. Arch Gerontol Geriatr. 2008; 47(1): 93-8. 
21. Gorecki C, Brown JM, Nelson EA, et al. Impact of pressure ulcers on quality of life in older patients: a 
systematic review. J Am Geriatr Soc. 2009; 57(7): 1175-83. 
22. Kim EK, Kim HO, Park YM, et al. Prevalence and risk factors of depression in geriatric patients with 
dermatological diseases. Ann Dermat. 2013; 25(3): 278-84. 
23. Shah M, Coates M. An assessment of the quality of life in older patients with skin disease. Br J Dermatol. 
2006; 154(1): 150-3.  
24. Schäfer W, Kroneman M, Boerma W, et al. The Netherlands: health system review. Health Syst Transit. 
2010; 12(1): v-xxviii,1-228. 
25. Balzer K, Butz S, Bentzel J, Boulkhemair D, Luhmann D. Medical specialist attendance in nursing homes. 
Health Technol Assess. 2013; 9: Doc02. doi: 10.3205/hta000108.  
26. Schippinger W, Hartinger G, Hierzer A, Osprian I, Bohnstingl M, Pilgram EH. Mobile geriatric consultant 
services for rest homes. Study of the effects of consultations by internal medicine specialists in the 
medical care of rest home residents. Z Gerontol Geriatr. 2012; 45(8): 735-41. German. 
27. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma 
skin cancer. Br J Dermatol. 2012; 166(5): 1069-80. 
28. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014; 383(9919): 816-27. 
  
|
 
 
  
12 
3
5
6
7
8
9
10
11
12
44 Improving dermatological care for older adults living in permanent healthcare institutions: suggestions from Dutch dermatologistsS.F.K. Lubeek, E.R. van der Geer, M.M.H.J. van Gelder P.C.M. van de Kerkhof, M.J.P. GerritsenActa Derm Venereol. 2016; 96: 253-254doi: 10.2340/00015555-2217
 
 
  
Improving dermatological care for institutionalized older adults 81 
 
Introduction 
 
Dermatologists are increasingly confronted with frail, institutionalized older adult patients, 
as the world population is aging rapidly and the demand for permanent healthcare 
institutions is growing.1, 2 Skin problems are common among institutionalized older adults 
and can have a significant impact on quality of life.3–6 Furthermore, dermatological care can 
be challenging and the possibility to visit an outpatient dermatology clinic may be limited 
within this population due to factors such as immobility, multimorbidity, and cognitive 
impairment. The aim of this study was to investigate possible ways to improve 
dermatological care in this vulnerable population. 
 
 
Methods 
 
In 2014, dermatologists and dermatology residents in the Netherlands were asked for 
suggestions to improve dermatological care in institutionalized older adults in a nationwide 
web-based survey of geriatric dermatology. Baseline characteristics and years of experience 
(or training in case of a resident) of respondents were included. Suggestions were 
categorized into several topics. Data analyses were performed using Statistical Package for 
Social Sciences (SPSS, version 20.0, IBM Corporation, Armonk, New York, United States). 
 
 
Results 
 
Respondent characteristics are shown in Table 1. In total, 83 (63.8%) dermatologists and 
dermatology residents suggested 149 possible ways to improve dermatological care among 
institutionalized older adults.  
 
The most commonly made suggestions were: more and/or better utilization of telemedicine 
applications (27.5%), more visits to permanent healthcare institutions by dermatologists 
when indicated (22.1%), and more and/or better medical training of healthcare providers 
(21.5%). According to most respondents medical training should be targeted especially at 
elderly care physicians (78.1%), nursing staff (15.6%) and, to a lesser extent, dermatologists 
(6.3%). An overview of the suggested items is shown in Figure 1.  
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Table 1  Baseline characteristics for respondents to a web-based survey considering geriatric 
dermatology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: NA, not applicable; SD, standard deviation; y, years; YoE, years of experience. 
 
 
Figure 1  Suggestions (n=149) for improvement of dermatologic care in permanent healthcare 
institutions, arranged by topic, in % 
 
 
27.5 
22.1 21.5 
9.4 
4.7 
14.8 
Telemedicine 
Visits by dermatologists 
Medical training 
Logistics 
Financial compensation 
Other 
Characteristics Total (n=83) Dermatologists 
(n=59) 
Dermatology 
residents (n=24) 
Age, mean (SD), y 42.9 (10.6) 47.1 (9.3) 32.0 (3.4) 
Male gender, n (%) 33 (39.8) 30 (50.8) 3 (12.5) 
YoE, mean (SD)   NA 13.8 (8.7) NA 
Year of training, n (%) NA NA 1: 3 (12.5) 
2: 4 (16.7) 
3: 4 (16.7) 
4: 5 (20.8) 
5: 8 (33.3) 
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Discussion 
 
This study provides some important suggestions to improve dermatological care in the 
institutionalized older adult population. This is essential due to the growing population of 
older adults who depend on institutionalized healthcare worldwide, and the high prevalence 
of skin problems within this vulnerable population.  
 
More and/or better utilization of telemedicine was the most common suggestion made. 
Several studies have shown that telemedicine applications could be of great value in 
improving medical care in institutionalized older adults and have a positive effect on 
healthcare efficacy, quality of life, and a reduction in healthcare costs. The acceptance and 
feasibility of telemedicine applications were observed to be excellent among patients and 
caregivers.7–10 Furthermore, both Zelickson & Homan7 and Binder et al.8 showed that 
teledermatology consultations were able to replace some outpatient clinic visits. 
 
Secondly, more visits to permanent healthcare institutions by dermatologists was another 
commonly made suggestion, which seems to be in concordance with previous studies 
showing considerable demands for consultation by different medical specialists and that 
availability of a consultant service by specialists could improve medical care for 
institutionalized older adults.11,12  
 
The final commonly made suggestion was more and better training of healthcare providers, 
especially elderly care physicians. This is despite the fact that basic dermatological training is 
currently included in most specialist training programmes for elderly care physicians across 
the Netherlands. A previous study showed a considerable demand for more and better 
continuing medical education among nursing home physicians, which emphasizes the 
importance of further development of educational programmes in the future.13 Finally, the 
Dutch Order of Medical Specialists is currently focussing more attention on older adult care 
in medical specialty training, including dermatology.14  
 
In conclusion, more (telemedicine) consultations and better medical training of healthcare 
providers seem important ways to improve dermatological care in permanent healthcare 
institutions. Researchers, health policymakers, and physicians should focus their future 
directions on these aspects. 
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Abstract 
 
Background 
The role of nursing home physicians in skin cancer care in institutionalized older adults is 
expected to increase in the future. 
 
Objectives  
To study the current role of nursing home physicians in skin cancer care among nursing 
homes in the Netherlands and to identify recommendations for improvement. 
 
Methods 
We conducted a cross-sectional nationwide study among nursing home physicians in the 
Netherlands using an anonymous self-administered online questionnaire. 
 
Results 
The knowledge and experience of nursing home physicians in diagnosing skin cancer 
appeared to be limited and dermatologists are frequently consulted. Some respondents 
have treated a (pre)malignant skin lesion themselves in the past on their own initiative 
(37.8%) or after consultation of a dermatologist (57.6%). Most of the nursing home 
physicians (94.5%) were willing to perform more treatment in one or more subtypes of 
(pre)malignant skin lesions after more education. More visits of dermatologists to nursing 
homes and more usage of telemedicine applications were other frequently suggested 
improvements. 
 
Conclusion 
The current limited role of nursing home physicians in skin cancer care in institutionalized 
older adults could be extended by more education. The role of the dermatologist remains 
essential and more possibilities for (live) consultation of dermatologists is expected to 
improve current care. 
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Introduction 
 
Skin cancer is common within the oldest-old (people aged 80 years and older) and the 
incidence is still rising.1-6 Although mostly nonlethal, the mortality rates of both melanoma1,2 
as nonmelanoma skin cancer are higher in de oldest-old compared to the overall 
population.7,8 Furthermore skin cancer may cause substantial morbidity, due to infiltration 
and destruction of adjacent tissues and/or metastasis.9-11 
 
Considering that the oldest-old form the fastest growing age group worldwide and that a 
significant part of this vulnerable group is in need of permanent institution-based 
healthcare,12-16 the role of physicians working in these institutions in managing skin cancer is 
expected to increase as well.  
 
There are several differences between nations regarding the organization of permanent 
healthcare facilities.14,17 Residential homes and nursing homes are the two main types of 
permanent healthcare institutions in the Netherlands, discriminated by the type and extent 
of care needed. Older adults living within nursing homes are generally in need of the most 
complex care, which is supplied and coordinated by nursing home physicians (NHPs).18 
 
Previous studies of our group showed that (pre)malignant skin lesions are one of the most 
common skin diseases NHPs are confronted with in nursing home patients (59.4% during 
the last three months).19 Subsequently, (pre)malignant skin lesions were the main reason for 
dermatologist consultation, referral to an outpatient dermatology clinic or a nursing home 
visitation by a dermatologist.20 Skin cancer care in institutionalized older adults could be 
complicated and limited by several factors such as multimorbidity, cognitive impairment, a 
limited life expectancy, and logistic factors (for instance a diminished ability to visit a hospital 
due to physical impairment). Furthermore, the level of knowledge and skills of caregivers 
seems to be another factor of great influence on medical care.19 
 
Primary objective of this study was to assess the current role of NHPs in the diagnosis and 
treatment of different (pre)malignant skin lesions among institutionalized older adults living 
in nursing homes across the Netherlands. Secondary objectives were to assess the 
collaboration with dermatologists, the potential influence of education, and to collect 
recommendations for improvement of skin cancer care among institutionalized older adults. 
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Methods 
 
Q U E S T I O N N A I R E  D E V E L O P M E N T  A N D  S T U D Y  P O P U L A T I O N  
Data were obtained from a nationwide cross-sectional study among NHPs in the 
Netherlands. We used an anonymous self-administered web-based questionnaire with a 
dedicated section on skin cancer care, which was analyzed in this study.  
 
Subtypes of (pre)malignant skin lesions included were: actinic keratosis (AK), Bowen’s 
disease (BD), basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and melanoma. 
Treatment options included were: cryotherapy, surgery (including curettage/shave and/or 
electrodessication), radiotherapy, topical 5-fluorouracil, topical imiquimod, and 
photodynamic therapy. Methods were more extensively described in our previous study.19 
 
S T A T I S T I C A L  A N A L Y S I S  
Continuous data were expressed as mean and standard deviation. Categorical data were 
expressed as number and percentage. Representativeness of the respondents compared to 
the target population was tested by comparing age and gender. Subgroup analyses were 
performed to determine the influence of years of experience (<10 years or ≥ 10 years) and 
continuing medical education (CME) concerning (pre)malignant skin lesions in de past (yes 
or no) on the main outcome measures. Continuous and categorical variables were 
compared using an unpaired two-sample T-test and a Chi-squared test respectively. A 
difference was considered to be statistically significant when p<0.05. A complete case 
approach was used. Statistical analysis was performed using the Statistical Package for 
Social Sciences (SPSS®) for Windows, version 20.0 (IBM Corporation, Armonk, NY). 
 
 
Results 
 
Q U E S T I O N N A I R E  D I S T R I B U T I O N  A N D  R E S P O N S E   
A total of 126 out of 173 nursing home organizations approached consented to participate 
(72.8%). An e-mail invitation with a link to the online questionnaire was spread among the 
1133 associated NHPs, of which 347 (30.6%) completed the questionnaire. A comparison of 
age and gender between the responding NHPs and the target population showed no 
significant differences, indicating an appropriate representativeness regarding these factors. 
The demographics and baseline characteristics of the respondents are shown in Table 1. 
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Table 1  Responder characteristics in this nationwide, cross-sectional study among nursing home 
physicians (NHPs) in the Netherlands (n=347) 
 
Characteristics Values 
Age, mean (SD), y 43.9 (11.5) 
Male gender, n (%) 105 (30.3)  
Physician subgroup, n (%)  
Specialist 244 (70.3) 
Resident 34 (9.8) 
Junior doctor 59 (17.0) 
Other 10 (2.9) 
Experience in elderly care, mean (SD), y 11.8 (9.5) 
 
Abbreviations: NHPs, nursing home physicians; SD, standard deviation; y, years. 
Values may not add up due to missing values and rounding. 
 
D I A G N O S I S  
The vast majority of the NHPs considered their knowledge to be sufficient to recognize AK 
(81.8%) and BCC (78.1%). A small majority considered their knowledge to be sufficient to 
recognize SCC (53.3%) and melanoma (54.5%), whereas a minority of the respondents 
considered their current level of knowledge to be sufficient to recognize BD (18.2%). Data 
are also shown in Table 2. Years of experience did not have a statistically significant 
influence on these results. Respondents who followed CME concerning (pre)malignant skin 
lesions considered their knowledge more often sufficient to recognize all subtypes with the 
exception of AK compared to their colleagues who didn’t follow CME concerning this subject 
(all p<0.05). A complete overview of data is given in Supplemental Table S1. 
 
T R E A T M E N T  
A minority of the responding NHPs considered their knowledge sufficient to perform 
treatment in the different subtypes, shown in Table 2. We did not observe differences in 
knowledge considering treatment between the NHPs with <10 years experiences and those 
with ≥10 years experience. NHPs who followed CME concerning (pre)malignant skin lesions 
considered their knowledge more often sufficient to treat AK and BD compared to their 
counterparts (p=0.020 and p=0.048 respectively). Complete results are presented in 
Supplemental Table S1. 
 
The treatment option known by most NHPs in general was surgical excision (93.9%), 
followed by cryotherapy (81.8%), topical 5-fluorouracil (71.2%), radiotherapy (48.7%), 
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photodynamic therapy (26.8%) and topical imiquimod (20.2%). A complete overview of the 
different treatment options in (pre)malignant skin lesions is provided in Table 3. More 
experienced NHPs and NHPs who followed CME concerning (pre)malignant skin lesions 
were more often familiar with topical 5-fluorouracil (p<0.01 and p=0.015, respectively) and 
radiotherapy (p=0.027 and p<0.01, respectively) compared to their colleagues. However, 
photodynamic therapy was more often known by the less experienced NHPs compared to 
their colleagues with more years of experience (p<0.01). An overview of these data is 
presented in Supplemental Table S2. Seven respondents (2.0%) were not familiar with any of 
the above-mentioned treatment options at all.  
 
Only a limited number of NHPs had used one or more of the above-mentioned treatment 
options in the past on their own initiative (37.8%) or after consultation of a dermatologist 
(57.6%). More experienced NHPs were more likely to have performed treatment with topical 
5-fluorouracil on their own initiative (p<0.01) or after consultation of a dermatologist 
(p<0.01) compared to their less experienced colleagues. Respondents who followed CME 
concerning (pre)malignant skin lesions more often performed treatment with topical 5-
fluorouracil and surgical excision on their own initiative (p=0.019 and p<0.01, respectively) 
and more often performed treatment with topical 5-fluorouracil after consultation of a 
dermatologist (p=0.021) than respondents who didn’t follow CME concerning this subject 
(Supplemental Table S2). Few of the NHPs (27.7%) had the possibility to ask a colleague to 
perform one or more treatment options in (pre)malignant skin lesions, which is also further 
specified in Table 3.  
 
Most respondents thought that treatment by photodynamic therapy (85.0%) and surgical 
excision (59.1%) should solely be performed by dermatologists. In contrast, few NHPs 
answered that cryotherapy (19.6%), topical 5-fluorouracil or imiquimod (both 26.5%) should 
be exclusive treatment options for dermatologists. 
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Table 2  Knowledge and skills in diagnosis and treatment of different subtypes of (pre)malignant skin lesions by nursing home physicians (n=347)  
 
 AK BD BCC SCC M 
Sufficient to diagnose, n (%) 284 (81.8) 63 (18.2) 271 (78.1) 185 (53.3) 189 (54.5) 
Sufficient to perform treatment, n (%) 172 (49.6) 20 (5.8) 42 (12.1) 14 (4.0) 5 (1.4) 
More education requested, n (%) 158 (51.8) 264 (86.2) 193 (63.3) 247 (81.0) 237 (77.7) 
Willing to perform (more) treatment after (more) education, n (%) 206 (59.4) 104 (30.0) 107 (30.8) 64 (18.4) 22 (6.3) 
Abbreviations: AK, actinic keratosis; BCC, basal cell carcinoma; BD, Bowen’s disease; M, melanoma; SCC, squamous cell carcinoma. 
Values may not add up due to missing values and rounding. 
 
 
Table 3  Knowledge and experience of nursing home physicians (n=347) regarding different treatment options in (pre)malignant skin lesions  
 
 CRYO SURa RT 5FU IMI PDT 
Knows treatment option, n (%) 284 (81.8) 326 (93.9) 169 (48.7) 247 (71.2) 70 (20.2) 93 (26.8) 
Used on own initiative, n (%) 71 (20.5) 48 (13.8) NA 59 (17.0) 5 (1.4) 0 (0) 
Used after consultation of a dermatologist, n (%) 41 (11.8) 32 (9.2) NA 165 (47.6) 33 (9.5) 4 (1.2) 
Could ask a colleague to perform, n (%) 41 (11.8) 63 (18.2) NA 43 (12.4) 19 (5.5) 3 (0.9) 
Willing to perform (more) treatment after (more) education, n (%) 166 (47.8) 115 (33.1) NA 151 (43.5) 132 (38.0) 39 (11.2) 
Should be solely performed by dermatologist, n (%) 68 (19.6) 205 (59.1) NA 92 (26.5) 92 (26.5) 295 (85.0) 
 
Abbreviations: 5FU, topical 5-fluorouracil; CRYO, cryotherapy; IMI, topical imiquimod; NA, not applicable; PDT, photodynamic therapy; RT, radiotherapy; SUR, surgery. 
a Including curettage/shave and/or electrodessication. Values may not add up due to missing values and rounding. 
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C O L L A B O R A T I O N  W I T H  D E R M A T O L O G I S T S  
Data about the number of NHPs consulting a dermatologist or referring to a dermatologist 
in different subtypes of (pre)malignant skin lesions in nursing home patients are shown in 
Figure 1. 
 
 
Figure 1  The proportions of nursing home physicians consulting a dermatologist or referring to a 
dermatologist in different subtypes of (pre)malignant skin lesions in nursing home patients  
 
 
Abbreviations: AK, actinic keratosis; BCC, basal cell carcinoma; BD, Bowen’s disease; M, melanoma;  
SCC, squamous cell carcinoma. 
 
 
E D U C A T I O N  
Focusing on education, 105 NHPs (30.3%) followed some form of CME concerning 
(pre)malignant skin lesions. Years of experience did not have a statistically significant 
influence on these results. Furthermore, 305 (87.9%) NHPs would like to receive (more) 
education about one or more subtypes of (pre)malignant skin lesions. The subtype 
requested the most by these NHPs was BD (86.2%), followed by SCC (81.0%) and melanoma 
(77.7%). A complete overview is given in Table 2.  
 
The vast majority of the responding NHPs (94.5%) is willing to perform more treatment of 
(pre)malignant skin lesions themselves after (more) education and the possibility to gain 
75% 60% 45% 30% 15% 0% 15% 30% 45% 60% 75% 90% 
M referral 
M consultation 
SCC referral 
SCC consultation 
BCC referral 
BCC consultation 
BD referral 
BD consultation 
AK referral 
AK consultation 
never rarely sometimes often always 
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more experience. An overview by subtype and by treatment option is presented in Table 2 
and 3 respectively. Approximately one out of twenty respondents (5.5%) are not willing to 
perform more treatment in (pre)malignant skin lesions. 
 
R E C O M M E N D A T I O N S  F O R  I M P R O V E M E N T  
Among the respondent NHPs, 139 (40.1%) had a total of 193 suggestions to improve skin 
cancer care within the nursing home population. The most frequently given suggestions 
were: more visits of dermatologists to nursing homes when indicated (25.4%), improving 
education of physicians involved (20.7%), and more frequent and/or better usage of 
telemedicine applications (11.9%). 
 
Discussion 
 
We present the results of the first study to investigate skin cancer care among 
institutionalized older adults. The current role of NHPs in the diagnosis and treatment of 
different (pre)malignant skin lesions among institutionalized older adults living in nursing 
homes across the Netherlands seems to be limited, especially when considering the 
relatively high incidence rates of (pre)malignant skin lesions in this age group. Possible 
explanations are a lack of knowledge and/or experience, but also logistical issues could be 
of influence. Furthermore, the possibility to ask a more experienced colleague seems to be 
another limiting factor. 
 
The willingness of NHPs to perform more skin cancer care themselves seems to be variable, 
depending on the type of (pre)malignant skin lesion and the type of treatment. To improve 
the level of knowledge and experience proper education is considered to be of great 
importance. In addition, this study shows that NHPs who followed CME concerning 
(pre)malignant skin lesions more often consider their knowledge sufficient to diagnose and 
treat several types of (pre)malignant skin lesions themselves and were also more often 
experienced using some treatment modalities themselves. However, next to proper 
education using the acquired skills in daily practice on a regular basis seems to be important 
as well to maintain a certain level of knowledge and experience. Subspecialty training of 
NHPs with special interest in dermatology may contribute to the development and 
maintenance of skills in daily practice.  
 
Finally, this study shows that a major role in skin cancer care among institutionalized older 
adults is still reserved for dermatologists, both directly (during an outpatient visit or a visit to 
a nursing home) as well as indirectly (long distance consultation of a dermatologist, for 
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instance using a telemedicine application). Therefore it is of importance to have a low 
threshold and a proper logistic possibility to consult a dermatologist.  
 
Moreover, we believe collaboration between NHPs and dermatologists is essential to 
improve the level of skin cancer care, because this multidisciplinary approach: 
(1) May contribute to overcome possible complicating factors within this population (i.e. 
multimorbidity, limited life expectancy, cognitive impairment, impossibility to visit a 
hospital); 
(2) May help choosing the most appropriate care from an individualized, patient-
centered, and holistic point of view, and; 
(3) May be of significant educational value to both NHPs and dermatologists. 
It would be interesting to study these benefits of multidisciplinary care in more detail in the 
future. 
 
L I M I T A T I O N S  
Possible limitations in this study are the self-administered character of the questionnaire 
used and the possible influence of more familiarity with the subject of responders 
compared to non-responders on the results. 
 
Conclusion 
 
The current role of nursing home physicians in skin cancer care in institutionalized older 
adults seems to be limited, depending on the subtype of (pre)malignant skin lesion and the 
type of treatment. More education and more consultation of dermatologists (both directly 
on location within a nursing home, as indirectly for instance by telemedicine applications) is 
expected to improve skin cancer care in institutionalized older adults. 
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Supplemental Table S1  Influence of years of experience (<10 years or ≥ 10 years) and 
continuing medical education concerning (pre)malignant skin lesions in de past (yes or no) on 
knowledge and skills in diagnosis and treatment of different subtypes of (pre)malignant skin 
lesions by nursing home physicians (n=347)a 
 
Lesion 
subtype 
Sufficient to diagnose, n (%) 
<10 YoE ≥10 YoE P-value No CME  CME P-value 
AK 130 (83.9) 153 (80.5) 0.42 196 (81.0) 88 (83.8) 0.53 
BD 26 (16.8) 36 (18.9) 0.60 35 (14.5) 28 (26.7) <0.01* 
BCC 115 (74.2) 154 (81.1) 0.13 181 (74.8) 90 (85.7) 0.024* 
SCC 80 (51.6) 104 (54.7) 0.56 119 (49.2) 66 (62.9) 0.019* 
M 93 (60.0) 96 (50.5) 0.079 123 (50.8) 66 (62.9) 0.039* 
 Sufficient to perform treatment, n (%) 
<10 YoE ≥10 YoE P-value No CME CME P-value 
AK 84 (54.2) 87 (45.8) 0.12 110 (45.5) 62 (59.0) 0.020* 
BD 11 (7.1) 9 (4.7) 0.35 10 (4.1) 10 (9.5) 0.048* 
BCC 23 (14.8) 19 (10.0) 0.17 27 (11.2) 15 (14.3) 0.41 
SCC 7 (4.5) 7 (3.7) 0.70 8 (3.3) 6 (5.7) 0.30 
M 2 (1.3) 3 (1.6) 0.82 3 (1.2) 2 (1.9) 0.63 
 
Abbreviations: AK, actinic keratosis; BCC, basal cell carcinoma; BD, Bowen’s disease; CME, continuing medical  
education; M, melanoma; SCC, squamous cell carcinoma; YoE, years of experience.* p<0.05; a Numbers per subgroup: 
<10 YoE (n=155), ≥10 YoE (n=190), No CME (n=242), CME (n=105). Values may not add up due to missings. 
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Supplemental Table S2  Influence of years of experience (<10 years or ≥ 10 years) and continuing medical education in de past (yes or no) on 
knowledge and experience of nursing home physicians (n=347) regarding different treatment options in (pre)malignant skin lesionsa 
 
Treatment option <10 YoE ≥10 YoE P-value No CME CME P-value 
CRYO       
Knows treatment option, n (%) 128 (83.7) 154 (81.5) 0.60 197 (82.1) 87 (83.7) 0.72 
Used on own initiative, n (%)  38 (25.2) 32 (17.1) 0.069 48 (20.1) 23 (22.8) 0.58 
Used after consultation of a dermatologist, n (%)  17 (11.3) 23 (12.4) 0.74 28 (11.8) 13 (12.9) 0.79 
SURb       
Knows treatment option, n (%) 148 (96.7) 176 (93.1) 0.14 225 (93.8) 101 (97.1) 0.20 
Used on own initiative, n (%)  20 (13.2) 27 (14.4) 0.75 24 (10.0) 24 (23.8) <0.01* 
Used after consultation of a dermatologist, n (%)  12 (7.9) 20 (10.8) 0.37 18 (7.6) 14 (13.9) 0.72 
RT       
Knows treatment option, n (%)  65 (42.5) 103 (54.5) 0.027* 106 (44.2) 63 (60.6) <0.01* 
Used on own initiative, n (%)  NA NA NA NA NA NA 
Used after consultation of a dermatologist, n (%)  NA NA NA NA NA NA 
5FU       
Knows treatment option, n (%)  97 (63.4) 149 (78.8) <0.01* 163 (67.9) 84 (80.8) 0.015* 
Used on own initiative, n (%)  16 (10.6) 42 (22.5) <0.01* 34 (14.2) 25 (24.8) 0.019* 
Used after consultation of a dermatologist, n (%)  52 (34.4) 112 (60.5) <0.01* 106 (44.7) 59 (58.4) 0.021* 
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Supplemental Table S2  Influence of years of experience (<10 years or ≥ 10 years) and continuing medical education in de past (yes or no) on 
knowledge and experience of nursing home physicians (n=347) regarding different treatment options in (pre)malignant skin lesionsa (continued) 
 
Treatment option <10 YoE ≥10 YoE P-value No CME CME P-value 
IMI       
Knows treatment option, n (%) 35 (22.9) 34 (18.0) 0.26 47 (19.6) 23 (22.1) 0.59 
Used on own initiative, n (%)  2 (1.3) 3 (1.6) 0.83 2 (0.8) 3 (3.0) 0.14 
Used after consultation of a dermatologist, n (%)  10 (6.6) 22 (11.9) 0.10 24 (10.1) 9 (8.9) 0.73 
PDT       
Knows treatment option, n (%) 58 (37.9) 35 (18.5) <0.01* 63 (26.2) 30 (28.8) 0.62 
Used on own initiative, n (%)  0 (0) 0 (0) NA 0 (0) 0 (0) NA 
Used after consultation of a dermatologist, n (%)  1 (0.7) 3 (1.6) 0.42 3 (1.3) 1 (1.0) 0.83 
 
Abbreviations: 5FU, topical 5-fluorouracil; CME, continuing medical education; CRYO, cryotherapy; IMI, topical imiquimod; NA, not applicable; PDT, photodynamic therapy; RT, 
radiotherapy; SUR, surgery; YoE, years of experience. * p<0.05; a numbers per subgroup: <10 YoE (n=153), ≥10 YoE (n=189), No CME (n=240), CME (n=104); b Including 
curettage/shave and/or electrodessication. Values may not add up due to missings and rounding. 
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Abstract  
 
Background  
Appropriate medical decision making in patients with nonmelanoma skin cancer (NMSC; 
including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)) can be challenging, 
especially in patients with a limited life expectancy (LE). Treatment should be beneficial for 
the individual patient and deviation from guideline recommendations might be necessary. 
 
Objective 
To determine the influence of age and comorbidity, both factors strongly related to limited 
LE, on NMSC management in daily clinical practice. 
 
Methods 
Retrospective analysis of management decisions and guideline-adherence in NMSC patients 
from one university medical center providing regional dermato-oncologic care. A logistic 
regression model was used to study the influence of age (<80 years and ≥80 years) and 
comorbidity (Charlson comorbidity index; CCI) on these outcomes. Various patient and 
tumor characteristics were included as potential confounders. 
 
Results 
401 patients were included (128 ≥80 years). In patients with BCC Mohs micrographic surgery 
was less often performed in patients ≥80 years compared with younger patients (1.1% vs 
8.4%; p=0.019), also after correction for previous treatment (p=0.042) and H-zone location 
(p=0.014). Correction for CCI showed a trend, not reaching statistical significance (p=0.056). 
Radiotherapy in BCC was more frequently performed in patients ≥80 years (10.3% vs 2.5%; 
p=0.003), also after consecutive correction for previous treatment (p=0.007), tumor location 
(p=0.033), and CCI (p=0.011). In SCC no significant treatment differences were found 
between the age groups. Overall guideline-adherence was high (88%-90%) and guideline-
deviation was not influenced by age (OR=0.834; 95%CI 0.508-1.371; p=0.475) or CCI 
(OR=0.919; 95%CI 0.764-1.106; p=0.373). 
 
Conclusion 
In contradiction with our expectations, management in patients with NMSC is not or only 
minimally influenced by high age and comorbidity. We believe that better integration of 
aspects related to a limited LE in NMSC management might optimize care and prevent 
overtreatment. Future research on the general prognostication, prediction of the patient 
burden caused by tumor and treatment, and time to benefit in NMSC management is 
strongly recommended.  
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Introduction 
 
Nonmelanoma skin cancer (NMSC) is the most common cancer worldwide. NMSC includes 
basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Dermatologists are expected 
to be more and more confronted with older adults with NMSC, considering (1) the 
increasing incidence rates of NMSC in general, (2) the rising incidence rates of NMSC with 
increasing age, (3) and the aging world population.1,2 In general, the majority of NMSC has a 
relatively low malignant potential compared to many other cancer types. However, potential 
morbidity and even mortality should not be underestimated.1 Adequate medical decision 
making in patients with NMSC requires physicians to be aware of several important aspects, 
including patient and tumor characteristics (e.g. tumor subtype, comorbidity, and life 
expectancy), treatment goals, and the availability of diagnostic and treatment options. 
Treatment should be beneficial for the individual patient and both the risk of over- and 
undertreatment should be carefully weighed. Consequently, management decisions in 
patients with NMSC may be challenging, especially in the growing population of frail older 
adults with a limited life expectancy (LE).3,4  
 
The main purpose of clinical practice guidelines (CPGs) is to assist physicians in medical 
decision making, based on the best evidence available and thereby optimizing healthcare.5 
However, CPG-recommendations might not be applicable for every individual, and guidance 
by CPGs in older adult patients and patients with multiple comorbidities was shown to be 
limited.6-8 Therefore, properly reasoned deviation from CPG-recommendations may be in 
the best interest of a patient and should be considered in some situations. Estimating a 
patient’s LE is difficult. Besides age, a patient’s LE may be influenced by several factors, of 
which comorbidity is considered the strongest and best studied predictor.9-13 It might be 
expected that a limited LE and influencing factors might contribute to the extent of CPG-
deviation in NMSC, but little is known regarding these decisions from daily practice. Hence, 
the aim of this study was to determine the influence of high age and comorbidity on 
management in patients with NMSC in daily clinical practice.  
 
 
Methods 
 
S E T T I N G  A N D  P A T I E N T  S E L E C T I O N  
Patients with NMSC seen in the outpatient dermatology department of the Radboud 
university medical center in Nijmegen, the Netherlands, were retrospectively analyzed. 
Selection of histological proven BCCs or SCCs diagnosed in 2012 or 2013 took place using 
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the national pathology database (PALGA) combined with the patient charts. Patients were 
sorted in two age groups (<80 years or ≥80 years), based on the United Nations age 
stratification2 and the Dutch LE data by Statistics Netherlands (mean residual LE of 4.5 years 
at an age of 80 years).14,15 Since every lesion suspicious for NMSC is histopathologically 
confirmed in our hospital, it is assumed that no cases were missed. In case multiple tumors 
per patient were found, only the first tumor was included. Exclusion criteria were: (1) tumors 
other than BCC or SCC (including basosquamous carcinoma), (2) non-cutaneous tumors (e.g. 
mucosal), (3) patients using chronic immunosuppressive medication, (4) patients having a 
genetic disorder resulting in an increased risk to develop NMSC (e.g. basal cell nevus 
syndrome, oculocutaneous albinism, and epidermodysplasia verruciformis), (5) clinical trial 
subjects, and (6) patients in which diagnosis and/or treatment was not performed within our 
hospital.  
 
D A T A  C O L L E C T I O N  A N D  Q U A L I T Y  C O N T R O L  
Data of all patients included were independently collected by two data-collectors (SL and 
CM) using a standardized form. Discrepancies were discussed between the two data 
collectors and in case no consensus could be reached a third author was consulted (RB or 
MG). A pilot study of 20 patients was initially performed as a data-collection training (to test 
the standardized form, to discuss doubtful cases, and to increase interobserver agreement). 
A data-collector manual was created to document all definitions and agreements.  
 
Patient and tumor characteristics 
Several patient and tumor characteristics were collected (Table 1). Comorbidity was 
classified using the Deyo adaptation of the Charlson Comorbidity Index (CCI; ICD-10 version), 
which is the most commonly used tool to assess comorbidity, validated in several 
populations. This includes assigning a weighted score to 17 groups of comorbid conditions 
when present in a patient (resulting in a score ranging from 0-30). Weights are based on 
their relative risk on 1-year mortality.12,13,16-18 When tumor characteristics were inconsistently 
reported, the pathology report after surgical excision overruled the biopsy report.  
 
Management decisions 
Data regarding management decisions and guideline-adherence, including reasons for non-
adherence, were collected. Guideline-adherence was based on two AUDIT-checklists for BCC 
and SCC, respectively (Supplemental File S1 and S2). The 16-item checklist for BCC was 
based on a previously developed and tested checklist.19 The 21-item checklist used for SCC 
was newly developed using the same principles as the BCC-checklist. Both checklists 
included items related to risk factors, diagnosis, staging, treatment, prevention, and follow-
up. All included items were directly based on recommendations from the Dutch 
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guidelines.20,21 Guideline-adherence was calculated dividing the number of items fulfilled by 
the total number of items. Only items applicable for that specific patient were included in 
the calculation (e.g. in case a tumor was solely treated by radiotherapy the items regarding 
surgical excision were not included).  
 
S T A T I S T I C S  
Primary outcome in this study was guideline-adherence (which included data regarding 
management decisions). Age and comorbidity are the main factors of influence on guideline-
adherence studied. Interobserver agreement was measured using Cohen’s κ for each 
relevant variable. Since the amount of missing data was small, no imputation of missing data 
was performed and only the available data per variable was analyzed. For a detailed 
description of the univariate and multivariable logistic regression models used in this study 
see Supplemental File S3. Statistical analysis was performed using the Statistical Package for 
Social Sciences (SPSS), version 22.0 (IBM Corporation, Armonk, NY). 
 
 
Results 
 
P A T I E N T  A N D  T U M O R  C H A R A C T E R I S T I C S  
A total of 401 patients were included, of which 128 patients were aged ≥80 years. 
Interobserver agreement was substantial to excellent for all variables (median, κ=0,971; 
range, 0.646 to 1.000).  All discrepancies could be solved during consensus-meetings 
between the two data collectors. Comparison between the two age groups showed that 
more patients within the older age group had a positive history for NMSC and a higher CCI. 
Furthermore, tumors within the older age group were more often SCC, less often superficial 
BCC, more often located within the head and neck area and had a larger diameter. A full 
overview of patient and tumor characteristics is given in Table 1.  
 
M A N A G E M E N T  D E C I S I O N S   
 
Univariate analysis 
In both SCC and BCC, conventional surgical excision was the treatment option performed 
most frequently (Table 2 and 3). Comparison between both age groups in BCC showed that 
Mohs micrographic surgery (MMS) was performed less often, and radiotherapy (RT) was 
performed more often in the older age group. In SCC, no differences regarding treatment 
options were found comparing both age groups.  
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Table 1  Patient and tumor characteristics  
 
Characteristics Overall population 
(n=401) 
Patients aged <80 y  
(n=273) 
Patients aged ≥80 y  
(n=128) 
P-value 
Patient     
Age, median (range), y 71.0 (30-97) 64.0 (30-79) 83.0 (80-97) <0.001* 
Male sex, n (%) 203 (50.6) 133 (48.7) 70 (54.7) 0.265 
Positive history for NMSC, n (%)a 222 (55.5) 131 (48.0) 91 (71.7) 0.001* 
CCI, median (range) 1 (0-7) 0 (0-7) 2 (0-7) 0.001* 
Tumor-related complaintsb, n (%):     
Yes 138 (34.4) 96 (35.2) 42 (32.8) 0.897 
No 235 (58.6) 158 (57.9) 77 (60.2)  
Unknown 28 (7.0) 19 (7.0) 9 (7.0)  
Tumor     
Histopathological subtype, n (%):     
SCC 75 (18.7) 34 (12.5) 41 (32.0) 0.001* 
Nodular BCC 81 (20.2) 59 (21.6) 22 (17.2)  
Superficial BCC 89 (22.2) 77 (28.2) 12 (9.4)  
Infiltrative BCC 47 (11.7) 30 (11.0) 17 (13.3)  
Micronodular BCC 40 (10.0) 31 (11.4) 9 (7.0)  
Mixed type BCC 69 (17.2) 42 (15.4) 27 (21.1)  
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Table 1  Patient and tumor characteristics (continued)  
 
Characteristics Overall population 
(n=401) 
Patients aged <80 y  
(n=273) 
Patients aged ≥80 y  
(n=128) 
P-value 
Tumor     
Location, n (%):     
Head and neck area 215 (53.6) 126 (46.2) 89 (69.5) 0.001* 
Trunk 121 (30.2) 101 (37.0) 20 (15.6)  
Upper limbs 27 (6.7) 18 (6.6) 9 (7.0)  
Lower limbs 38 (9.5) 28 (10.3) 10 (7.8)  
High-risk location, n (%):     
H-zonec 129 (39.6) 82 (34.3) 47 (54.0) 0.001* 
Lip or eard 4 (5.3) 2 (5.9) 2 (4.9) 1.000 
Largest diameter, median (range), in mme 9.0 (2-45) 8.0 (2-30) 10.0 (2-45) 0.027* 
Tumor depth, median (range), in mmd,f 2.0 (1-9) 2.0 (1-8) 2.5 (1-9) 0.267 
Degree of histological differentiationd, n (%):     
Well-differentiated 26 (34.7) 17 (50.0) 9 (22.0) 0.029* 
Moderately-differentiated 43 (57.3) 15 (44.1) 28 (68.3)  
Poorly-differentiated 2 (2.7) 0 (0) 2 (4.9)  
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Table 1  Patient and tumor characteristics (continued)  
 
Characteristics Overall population 
(n=401) 
Patients aged <80 y  
(n=273) 
Patients aged ≥80 y  
(n=128) 
P-value 
Tumor     
Perineural invasiond,g, n (%) 6 (8.5) 1 (3.2) 5 (12.5) 0.222 
Vascular and/or lymphatic invasiond,g, n (%) 1 (1.4) 0 (0) 1 (2.5) NA 
Previously treated (recurrence), n (%) 24 (6.0) 15 (5.5) 9 (7.0) 0.545 
TNM-staged,h:     
Stage I 58 (77.3) 28 (82.4) 30 (73.2) 0.344 
Stage II or higher 17 (22.7) 6 (17.6) 11 (26.8)  
 
Abbreviations: BCC, basal cell carcinoma; CCI, Charlson comorbidity index; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma; y, years.  
a 1 missing; b Tumor-related complaints mentioned were bleeding, itch, pain and/or ulceration; c BCC only; d SCC only; e 33 missing; f 2 missing: g 4 missing.h Staging  
based on the classification of the American Joint Commission on Cancer (AJCC) TNM system26; * p≤0.05. Values may not add up due to missing data and rounding. 
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Table 2  Management decisions and guideline-adherence in squamous cell carcinoma 
 
Characteristics Overall popu-
lation (n=75) 
Patients aged 
<80 y (n=34) 
Patients aged 
≥80 y (n=41) 
P-value 
Treatment performed, n (%):     
Conventional SE 72 (96.0) 33 (97.1) 39 (95.1) 1.000 
RT 3 (4.0) 2 (4.9) 1 (2.9)  
Compliance (guideline-adherence ≥90%), n (%) 23 (30.7) 12 (35.3%) 11 (26.8%) 0.429 
Guideline-adherence, median (range), in % 88 (56-100) 87 (63-100) 88 (56-100) 0.898 
Guideline-adherence, per recommendation, n (%):     
Prevention and risk factor evaluation:     
Advice on appropriate sun protection 47 (62.7) 21 (61.8) 26 (63.4) 0.883 
Evaluation of risk factorsa 45 (60.0) 19 (55.9) 26 (63.4) 0.507 
Diagnosis / staging:     
Palpation regional lymph nodes performed 53 (70.7) 25 (73.5) 28 (68.3) 0.620 
Histological confirmation by skin biopsy 74 (98.7) 33 (97.1) 41 (100) 0.453 
Ultrasound of regional lymph nodes in high-risk SCCb 8 (47.1) 3 (50.0) 5 (45.5) 1.000 
Reporting and/or photographing exact location 75 (100) 34 (100) 41 (100) NA  
Primary or recurrent tumor reported 69 (92.0) 30 (88.2) 39 (95.1) 0.401 
Maximum tumor diameter reported and adequately included in staging 40 (53.3) 18 (52.9) 22 (53.7) 1.000 
Perineural invasion reported and adequately included in staging 70 (93.3) 31 (91.2) 39 (95.1) 0.654 
Vascular invasion reported and adequately included in staging 70 (93.3) 31 (91.2) 39 (95.1) 0.654 
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Table 2  Management decisions and guideline-adherence in squamous cell carcinoma (continued) 
 
Characteristics Overall popu-
lation (n=75) 
Patients aged 
<80 y (n=34) 
Patients aged 
≥80 y (n=41) 
P-value 
Diagnosis/staging (continued):     
Histological differentiation reported and adequately included in staging 75 (100) 34 (100) 41 (100) NA 
Tumor depth reported and adequately included in staging 71 (94.7) 31 (91.2) 40 (97.6) 0.323 
Treatment:     
Using 5 mm excision margin when recommended 50 (100) 25 (100) 25 (100) NA 
Using 10 mm excision margin when recommended 1 (12.5) 0 (0) 1 (14.3) NA 
Re-excision in high- risk SCCb with <2 mm tumor-free margin  4 (50.0) 2 (100) 2 (33.3) 0.429 
Reason for choosing other suitable treatment option reported 6 (100) 2 (100) 4 (100) NA 
Did not perform treatment option which is discouraged in guideline 75 (100) 34 (100) 41 (100) NA 
Follow-up:     
At least 6-monthly follow-up during the first year for low-risk SCC 49 (89.1) 24 (96.0) 25 (83.3) 0.204 
At least 3-monthly follow-up during the first year for high-risk SCCb 9 (69.2) 5 (100) 4 (50.0) 0.105 
Follow-up examination at least included inspection and palpation of 
treated area and regional lymph nodes, together with total-body skin 
examination 
59 (100) 29 (100) 30 (100) 1.000 
Primary care physician is informed about diagnosis and management 62 (82.7) 27 (79.4) 35 (85.4) 0.498 
 
Abbreviations: NA, not applicable; RT, radiotherapy; SCC, squamous cell carcinoma; SE, surgical excision; y, years. a Sun exposure behavior, medical history (including history of skin 
cancer), current medication and smoking should have at least been included in the evaluation of risk factors; b High-risk SCC defined as T2 or higher according to the classification of 
the American Joint Commission on Cancer (AJCC) TNM system.26 Values may not add up due to missing data and rounding.  
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Table 3  Management decisions and guideline-adherence in basal cell carcinoma 
 
Characteristics Overall popu-
lation (n=326) 
Patients aged 
<80 y (n=239) 
Patients aged 
≥80 y (n=87) 
P-value 
Treatment performed, n (%)a:     
Conventional SE 237 (72.7) 172 (72.0) 65 (74.7) 0.004* 
PDT 34 (10.4) 25 (10.5) 9 (10.3)  
IMI 17 (5.2) 15 (6.3) 2 (2.3)  
MMS 21 (6.4) 20 (8.4) 1 (1.1)  
RT 15 (4.6) 6 (2.5) 9 (10.3)  
No treatment 2 (0.6) 1 (0.4)b 1 (1.1)c  
Compliance (guideline-adherence ≥90%), n (%) 178 (54.6) 134 (56.1) 44 (50.6) 0.378 
Guideline-adherence, median (range), in % 90 (44-100) 90 (50-100) 90 (44-100) 0.301 
Guideline-adherence, per recommendation, n (%):     
Prevention:     
Advice on appropriate sun protection 230 (70.6) 185 (77.4) 45 (51.7) <0.001* 
Diagnosis:     
Histological confirmation by skin biopsy 323 (99.1) 236 (98.7) 87 (100) 0.568 
Histopathological subtype reported 326 (100) 239 (100) 87 (100) NA 
Reporting and/or photographing exact location 326 (100) 239 (100) 87 (100) NA 
Primary or recurrent tumor reported 293 (89.9) 212 (88.7) 81 (93.1) 0.244 
Maximum tumor diameter reported 160 (49.1) 116 (48.5) 44 (50.6) 0.745 
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Table 3  Management decisions and guideline-adherence in basal cell carcinoma (continued) 
 
Characteristics Overall popu-
lation (n=326) 
Patients aged 
<80 y (n=239) 
Patients aged 
≥80 y (n=87) 
P-value 
Treatmenta:     
Using 3 mm excision margin when recommended 90 (97.8) 76 (98.7) 14 (93.3) 0.301 
Using 5 mm excision margin when recommended 117 (90.0) 80 (88.9) 37 (92.5) 0.753 
Using PDT only in primary, superficial BCC 30 (88.2) 22 (88.0) 8 (88.9) 1.000 
Using IMI only in superficial BCC <20 mm and outside of the H-zone 12 (70.6) 11 (73.3) 1 (50.0) 0.515 
Reason for choosing other treatment option reported 35 (94.6) 26 (96.3) 9 (90.0) 0.473 
Follow-up     
At least yearly follow-up for high-risk and/or multiple BCCs 205 (91.9) 143 (90.5) 62 (95.4) 0.224 
Follow-up examination at least included inspection of treated area and 
sun-exposed skin 
204 (99.5) 142 (99.3) 62 (100.0) 1.000 
Primary care physician is informed about diagnosis and management 293 (89.9) 209 (87.4) 84 (96.6) 0.016* 
 
Abbreviations: BCC, basal cell carcinoma; IMI, topical imiquimod; MMC, Mohs micrographic surgery; NA, not applicable; SE, surgical excision; PDT, photodynamic therapy; RT, 
radiotherapy; y, years. a Data regarding cryosurgery and curettage and cautery were not shown since these treatment options were not performed among the patients within this 
study;  b Since no clinical tumor residu was seen after punch biopsy a wait-and-see policy was chosen; c: Patient died before treatment; * p≤0.05.  
Values may not add up due to missing data and rounding. 
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Table 4  Multiple logistic regression model on the correlation of different factors with guideline-
adherence of at least 90% as dependent variable 
 
Variables Odds ratio 95% CI P-value 
Age (<80 y vs. ≥80 y) 0.834 0.508-1.371 0.475 
Charlson comorbidity index (0-30) 0.919 0.764-1.106 0.373 
Previous treatment (yes vs. no) 0.608 0.241-1.536 0.293 
Treatment method   0.754 
Conventional SE Reference   
PDT 0.985 0.371-2.616 0.976 
IMI 0.558 0.164-1.902 0.351 
MMS 2.020 0.669-6.094 0.212 
RT 1.085 0.381-3.095 0.878 
Other 0.867 0.049-15.208 0.922 
Tumor type   0.026* 
SCC Reference   
Nodular BCC 1.950 0.878-4.331 0.101 
Superficial BCC 5.309 2.042-13.804 0.001* 
Infiltrative BCC 1.875 0.791-4.448 0.154 
Micronodular BCC 1.419 0.577-3.489 0.445 
Mixed type BCC 1.540 0.710-3.342 0.274 
Location   0.227 
Head and neck area Reference   
Trunk 0.684 0.350-1.336 0.266 
Upper limbs 0.563 0.215-1.477 0.243 
Lower limbs 0.397 0.160-0.984 0.046* 
Location (high- vs. low-risk)a 1.402 0.728-2.700 0.312 
Complaints   0.280 
No Reference   
Yes 1.449 0.915-2.294 0.114 
Unknown 1.045 0.452-2.419 0.918 
 
Abbreviations: 95% CI, 95% confidence interval; BCC, basal cell carcinoma; IMI, topical imiquimod; MMC, Mohs 
micrographic surgery; SCC, squamous cell carcinoma; SE, surgical excision; PDT, photodynamic therapy; RT, 
radiotherapy; y, years. a A BCC located in the H-zone or a SCC located on an ear or lip; * p≤0.05.  
|
118 Chapter 6 
 
Multivariate analyses 
Secondary multivariate logistic regression analyses were performed to study the 
management differences found in the univariate analysis in more detail. As the number of 
treatments with MMS and RT were performed in BCC was rather small (21 and 15 times, 
respectively), a large logistic regression model was not possible. Hence, three consecutive 
analyses were performed for each treatment option, each with age and one important 
confounder (location, previous treatment, and CCI, respectively). Inclusion of BCC subtype in 
the model was not possible due to (1) the relatively low number of BCC treated by MMS and 
RT, and (2) the extent of variance found in different BCC subtypes treated by both treatment 
options. MMS was less often performed in BCC in the older age group compared with the 
younger patients (1.1% vs 8.4%; p=0.019). This finding persisted after consecutive correction 
for previous treatment (primary vs. recurrent BCC (p=0.042) and location (within or without 
the H-zone; p=0.014). After correction for CCI the model failed to show a statistical 
significant difference of treatment of BCC by MMS between the two age groups, although a 
trend could be seen (p=0.056). The opposite was observed for RT in BCC, which was more 
frequently performed in the older patient group compared to the younger (10.3% vs 2.5%; 
p=0.003), also after consecutive correction for previous treatment (p=0.007), location 
(p=0.033), and CCI (p=0.011).  
 
G U I D E L I N E - A D H E R E N C E  
 
Univariate analyses 
Overall guideline-adherence was high (88% vs. 90% for SCC and BCC, respectively) and did 
not differ between the two age groups (p=0.898 and p=0.301, respectively). When focusing 
more specifically on the individual guideline-recommendations advice on appropriate sun 
protection was less frequently provided in the older age group with BCC (77.4% vs. 51.7%, 
p<0.001), while the primary care physician was more frequently informed about the 
diagnosis and management in the older age group with BCC (87.4% vs. 96.6%, p=0.016). All 
other guideline-recommendations showed no difference in adherence between both age 
groups. In 4.5% (n=25) of the deviations from guideline recommendations, the reason was 
extractable from the patient chart. The most frequently mentioned reasons for guideline-
deviation were: (1) a limited LE, (2) severe impaired mobility, and (3) a patient’s refusal. 
 
Multivariate analyses 
Guideline adherence below 90% was considered as “low” guideline-adherence (cut-off based 
on approximate median). The multiple logistic regression model for this dependent variable 
is presented in Table 4. The results of this model show that guideline-adherence is not 
influenced by age (OR=0.834; 95%CI 0.508-1.371; p=0.475) or comorbidity (OR=0.919; 
95%CI 0.764-1.106; p=0.373), after correction for the other variables. Of the other variables 
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in the model, the effect of tumor type is by far the most clear (p=0.026). A much better 
guideline-adherence in patients with a superficial BCC as opposed to patients with a SCC 
(OR=5.309; 95%CI 2.042-13.804; p=0.001) was noted. 
 
 
Discussion 
 
The results in the present study show that management decisions in BCC are influenced by 
high age to some extent, while the influence of comorbidity seems only minimal to absent. 
Furthermore, high age and comorbidity did not have a significant influence on management 
decisions in SCC, or on overall guideline-adherence in both BCC and SCC. The possibility to 
draw direct conclusions from the results found in this study with respect to quality of care is 
limited and the definition of optimal skin cancer care remains open for discussion. However, 
one might expect deviation from regular treatment protocols and guideline 
recommendations in NMSC to be more common among frail older adults with a limited LE, 
which was not shown by the results in this study.  
 
Former studies on the impact of high age and comorbidity on treatment decisions in NMSC 
patients are scarce. Two studies from the United States showed that a limited LE did not 
influence treatment decisions in patients with NMSC, including treatment with MMS.22,23 
These studies show important agreement with our findings that high age and comorbidity 
do not have a significant influence on treatment choice in SCC and the decision not to treat 
NMSC is rare. On the other hand, our finding that MMS is less frequently performed in 
patients ≥80 years with BCC, while RT is more frequently used in this population, seems to 
contradict these studies, which might be explained by intercountry differences in healthcare 
systems and guidelines. 
 
It should be pointed out that medical decision making solely based on age might be a pitfall, 
since age alone is just one factor influencing life expectancy and the population of older 
adults is heterogeneous. For instance, on the one hand MMS is a treatment option which 
might lead to a significant patient burden and overtreatment in some (frail) older patients, 
especially in case a patient will not live long enough to benefit from this treatment (time to 
benefit principle).22,23 On the other hand, MMS is a suitable treatment option in some (less 
frail) older adults and exclusion solely based on age seems to be an insufficient selection 
method.24 We believe (more extensive) inclusion of patient characteristics related to frailty 
and a limited LE in medical decision making in older adults optimizes NMSC care. Examples 
of these characteristics are: comorbidity, cognition, and functional status. Clinicians may be 
stimulated to act on this to a greater extent through education, more cooperation with 
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elderly care specialists, and further inclusion of these considerations within clinical practice 
guidelines.8 Furthermore, we believe watchful waiting is a suitable alternative for treatment 
in some patients with an asymptomatic low-risk NMSC, which should be considered more 
frequently in patients with a limited LE. Instruments to determine (the extent of) frailty and a 
patient’s general prognosis can assist in these management decisions, however currently 
these are not validated for NMSC patients.25 Consequently, since reliable and validated 
methods for general prognostication, prediction of the patient burden caused by tumor and 
treatment, and time to benefit data are lacking in current NMSC literature, management 
decisions in daily practice might remain complex. We strongly recommend to focus future 
research on these aspects in order to provide guidance for clinicians.  
 
L I M I T A T I O N S  
Generalization of the results in this single-center study from one university hospital in the 
Netherlands should be performed with care, since population and management differences 
can exist between different healthcare institutions and countries. Since patient records were 
retrospectively studied non-reporting bias might have occurred, which could have 
influenced guideline-adherence data. However, it is unlikely this potential non-reporting bias 
differed among the compared patient groups and therefore its influence on the main 
outcomes in this study is expected to be limited. 
 
 
Conclusion 
 
In contradiction with our expectations, the present study shows that management in 
patients with NMSC is not or only minimally influenced  by high age and comorbidity. We 
believe that better integration of aspects related to a limited LE in NMSC management might 
optimize care and prevent overtreatment. Future research on general prognostication, 
prediction of the patient burden caused by tumor and treatment, and time-to-benefit in 
NMSC management is strongly recommended. 
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Supplemental File S1  Checklist on guideline-adherence in patients with squamous cell 
carcinoma (SCC) 
 
Based on the clinical practice guideline “Squamous cell carcinoma of the skin” of the Dutch Society of Dermatology 
and Venereology.1 
 
PREVENTION: 
1. The patient received advice on appropriate sun protective behavior: 
 Yes  
 No  
Comment: 
 
2. Risk factors to develop squamous cell carcinoma were adequately evaluated: 
 Yes  
 No  
Comment: 
 
DIAGNOSIS / STAGING: 
3. Regional lymph nodes were palpated before therapy was started: 
 Yes  
 No  
Comment: 
 
4. A punch biopsy of the SCC was performed before therapy was started:  
 Yes  
 No  
Comment: 
 
5. An ultrasound (including biopsy in case of a suspicion of a lymph node metastasis) of regional 
lymph nodes was performed in high-risk SCCa: 
 Yes  
 No  
 Not applicable 
Comment: 
 
6. The exact location of the SCC was reported and/or photographed: 
 Yes  
 No  
Comment: 
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7. It was documented if the SCC was previously treated: 
 Yes  
 No  
Comment: 
 
8. The maximum tumor diameter was reported and adequately included in staging: 
 Yes  
 No  
Comment: 
 
9. Pathologic assessment on perineural invasion was reported and adequately included in staging: 
 Yes  
 No  
Comment: 
 
10. Pathologic assessment on vascular invasion was reported and adequately included in staging: 
 Yes  
 No  
Comment: 
 
11. Pathologic assessment on histological differentation was reported and adequately included in 
staging: 
 Yes  
 No  
Comment: 
 
12. Pathologic assessment on depth of tumor growth was reported and adequately included in 
staging: 
 Yes  
 No  
Comment: 
 
TREATMENT: 
Conventional surgical excision: 
13. An excision margin of 5 mm was used when recommended (in case of primary and low-risk 
SCCa): 
 Yes  
 No  
 Not applicable 
Comment: 
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14. An excision margin of 10 mm was used when recommended (in case of recurrent and/or high-
risk SCCa): 
 Yes  
 No  
 Not applicable 
Comment: 
 
15. Re-excision was performed in case of a high-risk SCCa with <2 mm tumor-free margin: 
 Yes  
 No  
 Not applicable 
Comment: 
 
Other treatment options: 
16. The reason(s) to choose for another suitable treatment option (e.g. radiotherapy, cryosurgery, 
or curettage and cautery) are well-documented: 
 Yes  
 No  
 Not applicable 
Comment: 
 
17. Treatment options discouraged by the guideline (e.g. topical imiquimod, intralesional 
interferon alfa, of photodynamic therapy) were not performed: 
 Yes  
 No  
Comment: 
 
FOLLOW-UP: 
18. A follow-up examination was performed at least 6-monthly during the first year after 
treatment in case of a low-risk SCCa: 
 Yes  
 No  
 Not applicable 
 Unknown 
Comment: 
 
19. A follow-up examination was performed at least 3-monthly during the first year after 
treatment in case of a high-risk SCCa: 
 Yes  
 No  
 Not applicable 
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 Unknown 
Comment: 
 
20. Follow-up examination at least included inspection and palpation of the treated area, 
palpation of the regional lymph nodes and total-body examination: 
 Yes  
 No  
 Unknown 
Comment: 
 
21. The primary care physician (general practitioner or elderly care physician) of the patient was 
informed about the diagnosis and therapy of the SCC: 
 Yes  
 No  
Comment: 
 
a High-risk SCC defined as T2 or higher according to the classification of the American Joint Commission on Cancer 
(AJCC) TNM system2  
 
References:  
1. Krekels GA, van Berlo CL, van Beurden M, et al. Richtlijn Plaveiselcelcarcinoom van de huid. Utrecht, 
Netherlands: Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV), 2010. Available 
from: http://www.nvdv.nl/informatie-voor-de-professional-2/informatie-voor-de-professional/richtlijnen-
2/. Accessed January 21, 2014. Dutch. 
2. Dinehart SM, Peterson S. Evaluation of the American Joint Committee on cancer Staging System for 
cutaneous squamous cell carcinoma and proposal of a new staging system. Dermatol Surg. 2005; 31: 
1379-84. 
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 Unknown 
Comment: 
 
20. Follow-up examination at least included inspection and palpation of the treated area, 
palpation of the regional lymph nodes and total-body examination: 
 Yes  
 No  
 Unknown 
Comment: 
 
21. The primary care physician (general practitioner or elderly care physician) of the patient was 
informed about the diagnosis and therapy of the SCC: 
 Yes  
 No  
Comment: 
 
a High-risk SCC defined as T2 or higher according to the classification of the American Joint Commission on Cancer 
(AJCC) TNM system2  
 
References:  
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Netherlands: Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV), 2010. Available 
from: http://www.nvdv.nl/informatie-voor-de-professional-2/informatie-voor-de-professional/richtlijnen-
2/. Accessed January 21, 2014. Dutch. 
2. Dinehart SM, Peterson S. Evaluation of the American Joint Committee on cancer Staging System for 
cutaneous squamous cell carcinoma and proposal of a new staging system. Dermatol Surg. 2005; 31: 
1379-84. 
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 Unknown 
Comment: 
 
20. Foll -up examination at least included inspection and palpation of the treated area, 
palpatio  of the regional lymph nodes and total-body examination: 
 Yes  
 No  
 Unknown
Comment: 
 
21. The primary care physician (general practitioner or elderly care physician) of the patient was 
infor d about the diagnosis and therapy of the SCC: 
 Yes  
 No  
Com nt: 
 
a High-risk SCC defined as T2 or higher according to the classification of the American Joint Commission on Cancer 
(AJCC) TNM system.2  
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Supplemental File S2  Checklist on guideline-adherence in patients with basal cell carcinoma 
(BCC) 
 
Based on previously developed and tested AUDIT-checklist,1 originally based on the clinical practice guideline  
“Evidence-based guideline on the treatment of basal cell carcinoma” of the Dutch Society of Dermatology and 
Venereology.2 
 
PREVENTION: 
1. The patient received advice on appropriate sun protective behavior: 
 Yes  
 No  
Comment: 
 
DIAGNOSIS: 
2. A punch biopsy of the BCC was performed before therapy was started:  
 Yes  
 No  
Comment: 
 
3. The histopathological subtype of the BCC was reported: 
 Yes  
 No  
Comment: 
 
4. The exact location of the BCC was reported and/or photographed: 
 Yes  
 No  
Comment: 
 
5. It was documented if the BCC was previously treated: 
 Yes  
 No  
Comment: 
 
6. The maximum tumor diameter was reported: 
 Yes  
 No  
Comment: 
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TREATMENT: 
Conventional surgical excision: 
7. An excision margin of 3 mm was used when recommended (in case of a non-infiltrative and 
primary BCC with a maximum diameter ≤10 mm):  
 Yes  
 No  
 Not applicable 
Comment: 
 
8. An excision margin of 5 mm was used when recommended (in case of an infiltrative and/or 
recurrent BCC with a maximum diameter >10 mm): 
 Yes  
 No  
 Not applicable 
Comment: 
 
Photodynamic therapy: 
9. Only performed in a primary, superficial BCC: 
 Yes  
 No  
 Not applicable 
Comment: 
 
Cryosurgery: 
10. Only performed in a superficial or nodular BCC with a maximum diameter ≤20 mm: 
 Yes  
 No  
 Not applicable 
Comment: 
 
Topical imiquimod: 
11. Only performed in a primary and superficial BCC with a maximum diameter ≤20 mm and 
outside of the H-zone: 
 Yes  
 No  
 Not applicable 
Comment: 
 
Curettage and cautery:  
12. Only performed in a primary, superficial or nodular BCC with a maximum diameter ≤5 mm and 
outside of the H-zone: 
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TREATMENT: 
Conventional surgical excision: 
7. An excision margin of 3 mm was used when recommended (in case of a non-infiltrative and 
primary BCC with a maximum diameter ≤10 mm):  
 Yes  
 No  
 Not applicable 
Comment: 
 
8. An excision margin of 3 mm was used when recommended (in case of an infiltrative and/or 
recurrent BCC with a maximum diameter >10 mm): 
 Yes  
 No  
 Not applicable 
Comment: 
 
Photodynamic therapy: 
9. Only performed in a primary, superficial BCC: 
 Yes  
 No  
 Not applicable 
Comment: 
 
Cryosurgery: 
10. Only performed in a superficial or nodular BCC with a maximum diameter ≤20 mm: 
 Yes  
 No  
 Not applicable 
Comment: 
 
Topical imiquimod: 
11. Only performed in a primary and superficial BCC with a maximum diameter ≤20 mm and 
outside of the H-zone: 
 Yes  
 No  
 Not applicable 
Comment: 
 
Curettage and cautery:  
12. Only performed in a primary, superficial or nodular BCC with a maximum diameter ≤5 mm and 
outside of the H-zone: 
The impact of high age and comorbidity on skin cancer management 129 
 
 Yes  
 No  
 Not applicable 
Comment: 
 
Other treatment options (e.g. radiotherapy, Mohs micrographic surgery): 
13. The reason(s) to choose for another treatment option are well-documented: 
 Yes  
 No  
 Not applicable 
Comment: 
 
FOLLOW-UP: 
 
14. A follow-up examination was performed at least within one year after treatment in case of a 
high-risk BCC and/or in case of multiple BCC: 
 Yes  
 No  
 Not applicable 
 Unknown 
Comment: 
 
15. Follow-up examination at least included inspection of the treated area and the sunexposed 
skin: 
 Yes  
 No  
 Not applicable 
 Unknown 
Comment: 
 
16. The primary care physician (general practitioner or elderly care physician) of the patient was 
informed about the diagnosis and therapy of the BCC: 
 Yes  
 No  
Comment: 
 
References: 
1. Borgonjen RJ, van Everdingen JJ, Bruijnzeel-Koomen CA, van de Kerkhof PC, Spuls PI. A national study 
on adherence to a basal cell carcinoma guideline; development of a tool to assess guideline 
adherence. Br J Dermatol. 2015; 172(4): 1008-13. 
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 Yes  
 No  
 Not pplicable 
Comment: 
 
Other treatment options (e.g. radiotherapy, Mohs micrographic surgery): 
13. The reason(s) to choose for another treatment option are well-documented: 
 Yes  
 No  
 Not applicable 
Comment: 
 
FOLLOW-UP: 
 
14. A follow-up examination was performed at least within one year after treatment in case of a 
high-risk BCC and/or in case of multiple BCC: 
 Yes  
 No  
 Not applicable 
 Unknown
Comment: 
 
15. Follow-up examination at least included inspection of the treated area and the sunexposed 
skin:
 Yes  
 No  
 Not applicable 
 Unknown 
Co ment: 
 
16. The primary care physician (general practitioner or elderly care physician) of the patient was 
informed about the diagnosis and therapy of the BCC: 
 Yes  
 No  
Comment: 
 
References: 
1. Borgonjen RJ, van Everdingen JJ, Bruijnzeel-Koomen CA, van de Kerkhof PC, Spuls PI. A national study 
on adherence to a basal cell carcinoma guideline; development of a tool to assess guideline 
adherence. Br J Dermatol. 2015; 172(4): 1008-13. 
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 Yes  
No 
t applicable 
Comment: 
 
Other treatment options (e.g. radiotherapy, Mohs micrographic surgery): 
13. The reaso (s) to choose for another treatment ption are well-documented: 
 Yes  
No 
t applicable 
Comment: 
 
FOLLOW-UP: 
 
14. A follow-up examination was performed at least within one year after treatment in case of a 
high-risk BCC and/or i  case of multiple BCC:
 Yes  
No 
t applicable 
Unknown 
Comment: 
 
15. Follow-up examination at least included inspection of the treated area and the sunexposed 
skin: 
 Yes  
No 
t applicable 
Unknown 
Comment: 
 
16. The primary care physician (general practitioner or elderly care physician) of the patient was 
inf rm d about the diagnosis and th py of he BCC: 
 Yes  
No 
Comm nt: 
 
References: 
1. Borgonjen RJ, van Everdingen JJ, Bruijnzeel-Koomen CA, van de Kerkhof PC, Spuls PI. A national study 
on adherence to a basal cell carcinoma guideline; development of a tool to assess guideline 
adherence. Br J Dermatol. 2015; 172(4): 1008-13. 
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logie (NVDV), 2007. Available from: https://www.nvpc.nl/uploads/stand/473d%20Richtlijn_BCC_ 
herziene%20versie_20122007.pdf. Accessed January 21, 2014. Dutch. 
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 Yes  
 No  
 Not applicable 
Comment: 
 
Other treatment options (e.g. radiotherapy, Mohs micrographic surgery): 
13. The reason(s) to choose for another treatment option are well-documented: 
 Yes  
 No  
 Not applicable 
Comment: 
 
FOLLOW-UP: 
 
14. A follow-up examination was performed at least within one year after treatment in case of a 
high-risk BCC and/or in case of multiple BCC: 
 Yes  
 No  
 Not applicable 
 Unknown 
Comment: 
 
15. Follow-up examination at least included inspection of the treated area and the sunexposed 
skin: 
 Yes  
 No  
 Not applicable 
 Unknown 
Comment: 
 
16. The primary care physician (general practitioner or elderly care physician) of the patient was 
informed about the diagnosis and therapy of the BCC: 
 Yes  
 No  
Comment: 
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on adherence to a basal cell ca cinoma guideline; development of  tool to assess guideline
adherence. Br J Dermatol. 2015; 172(4): 1008-13. 
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logie (NVDV), 2007. Available from: https://www.nvpc.nl/uploads/stand/473d%20Richtlijn_BCC_ 
herziene%20versie_20122007.pdf. Accessed January 21, 2014. Dutch. 
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Supplemental File S3  Details of the regression models on the correlation of different factors 
with guideline-adherence used in this study 
 
First, a descriptive, univariate analysis was performed. Categorical variables were 
expressed as numbers (and proportions) and compared using a Chi-squared test or 
Fisher’s exact test when appropriate. Numerical variables were expressed as medians with 
ranges, and compared using a Mann-Whitney test.  
 
Since the distribution of guideline-adherence was expected to be very skew and since the 
relation of age and comorbidity with guideline-adherence is likely to be confounded by 
various patient- and tumor characteristics (Table 4), a multivariable logistic regression 
analysis was performed afterwards.  
 
As no well established cut-off for a satisfactory level of guideline-adherence is known from 
literature, a cut-off close to the median was selected and two categories were formed 
(“high” vs “low” guideline-adherence). This would yield two groups of approximately equal 
size, which maximizes the power of the study. A priori estimates of study precision would 
require extensive knowledge about the correlation between all variables to be included in 
the model. That information is not available. Therefore, we applied the rule of thumb that 
for multivariable logistic regression at least 10 observations per variable in the model are 
required on the least prevalent of the two outcomes. Therefore, at least 360 (18x10x2) 
observations were needed in the case guideline-adherence has a 50:50 distribution over 
“high” vs “low”. To allow for an unbalance we decided to aim for inclusion of 400 patients. 
The distribution with regard to age is not required to be balanced, but a large unbalance 
would result in a relatively low precision for the effect of age on guideline-adherence. Since 
it became clear during the study that the consecutive inclusion in the younger group was 
much faster than in the old group, after the inclusion of 336 patients (274 aged <80 years; 
62 aged ≥80 years), we continued by only including patients from the older age group. In 
addition, secondary multivariate logistic regression analyses were performed to study 
differences in management decisions found in the univariate analyses in more detail. 
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Abstract 
 
Importance 
The number of oldest-old (persons aged ≥80 years) is rapidly growing worldwide. Basal cell 
carcinoma (BCC) are common in this age group and the management could be challenging 
in this population.  
 
Objective  
Obtaining an overview of the epidemiology and clinicopathological features of BCC in the 
oldest-old to guide healthcare providers and policy makers. 
 
Evidence review 
A systematic review of literature was performed using PubMed, Excerpta Medica Database 
(EMBASE), and the Cochrane Library. Study selection, quality assessment and data 
extraction was performed by 2 independent reviewers. For quality assessment (including 
the risk of bias) the STrengthening the Reporting of OBservational studies in Epidemiology 
(STROBE) checklist was used, combined with the Quality Rating Scheme for Studies and 
Other Evidence. Data were described through a narrative synthesis and tabulation. 
 
Findings 
High and increasing incidence rates of BCC in the oldest-old were found ranging from 13 to 
12 112 per 100 000 person-years, strongly depending on factors like study population and 
clinical setting. Basal cell carcinoma in the oldest-old are more common in men, mostly of 
the nodular subtype, and located within the head and neck region. Interpretation and 
generalization of the data was limited by the heterogeneity of study populations, methods 
and outcomes. Data concerning impact on health-related quality of life (HRQoL) and 
prognostication are scarce. 
 
Conclusions and relevance 
The incidence of BCC among the oldest-old is high and increasing. Epidemiologic and 
clinicopathological data from current literature provide only limited guidance in clinical 
decision making due to heterogeneity and scarcity. Future research should focus more 
specifically on BCC in the oldest-old, together with prognostication and their relation with 
HRQoL in both the short and longer term. 
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Introduction 
 
A rapid expansion of the oldest-old (persons aged ≥80 years) is currently being seen 
worldwide, with an expected global increase in this age group from 125 million people in 
2015 to 434 million in 2050 (1.7% and 4.5% of the world population, respectively).1 Basal cell 
carcinoma (BCC) is a common skin tumor among older adults. Although mortality caused by 
BCC is exceptional, a considerable morbidity may be caused owing to pain, secondary 
infection, and disfigurement. Consequently, early detection and treatment of BCC are 
considered key elements in appropriate skin cancer care. Decisions about what constitutes 
appropriate medical care in oldest-old patients with BCC is often complicated by several 
factors, like logistical difficulties, multimorbidity, quality of life dilemmas, and a limited life 
expectancy. To develop the best possible individualized care for oldest-old patients with 
BCC, it is important for clinicians and policy makers to have  insight into the epidemiological 
and clinicopathological aspects of BCC in this population. Therefore, the purpose of this 
systematic review was to obtain an overview of the epidemiology and clinicopathological 
features of BCC in the oldest-old. 
 
 
Methods 
 
S E A R C H  S T R A T E G Y ,  S E L E C T I O N  C R I T E R I A  A N D  D A T A  C O L L E C T I O N   
 
Search strategy 
A comprehensive literature review was conducted to identify relevant articles containing 
data about epidemiology and clinicopathological features of BCC in the oldest-old. A search 
strategy was developed with the support of a medical librarian and performed by 2 
independent reviewers (SL and LvV). PubMed, Excerpta Medica Database (EMBASE), and the 
Cochrane Library were searched for articles published up to July 18, 2015. A detailed 
overview of the search strategy and strings used is presented in Supplemental Table S1. 
 
Selection criteria 
Overall exclusion criteria were the following: full-text not available, non-English/Dutch 
publications, and conference abstracts. All epidemiologic studies reporting age-specific rates 
in the oldest-old were included. Incidence rates had to be specifically identifiable and/or 
sufficient data allowing incidence rate calculation had to be described. In addition, the 
reviewers could decide to include studies without these strict age-specific rates if they were 
consensually considered of great value. When multiple studies reported about identical 
study populations over an identical period of time the data were included only once. 
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Data collection 
Data were gathered using the reference management software EndNote, version X5.0.1 
(Thomson Reuters, New York City, USA). When full-text articles were not online-available, a 
paper copy was tried to obtain in our local medical library, and/or the Dutch Central 
Catalogue (PiCarta), and/or the first author was tried to contact. Selection of studies for 
eligibility (by title, abstract and full-text screening respectively) and data extraction using a 
predefined data sheet were performed by two independent reviewers (SL and LvV). 
Secondly, inconsistencies were discussed until consensus could be reached. In case no 
consensus could be reached a third reviewer (MG) was involved. No blinding of the 
reviewers to the authors names, institutions or journals was performed. In case a study was 
considered of potential value the first author was contacted to request for additional data or 
clarification when: (1) no specific stratification of data for BCC, or (2) no age-specific rates 
were provided or data needed to calculate age-specific rates were incomplete. 
 
Q U A L I T Y  A S S E S S M E N T  O F  I N C L U D E D  S T U D I E S  
The included observational studies were independently assessed on 22 criteria for 
methodological and reporting quality by the 2 reviewers using the STrengthening the 
Reporting of OBservational studies in Epidemiology (STROBE) checklist and the Quality 
Rating Scheme for Studies and Other Evidence, as proposed before by others.2,3,4 The 
assessment of risk of bias in individual studies at both study and outcome level was 
included within this quality evaluation. Studies were categorized depending on the 
proportion of STROBE criteria fulfilled (category A-B-C, respectively fulfilling >80%, 50-
80%,and <50% of the criteria).  
 
S Y N T H E S I S  O F  R E S U L T S  A N D  R E P O R T I N G  
Data were described though a narrative synthesis and tabulation. Results were presented 
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement on reporting systematic reviews and meta-analyses of epidemiological 
studies.5 Since most studies solely presented crude incidence rates (IRs), these were 
primarily reported. Standardized IRs were reported only when crude IRs were unavailable. 
Since the highest age category included in both the European standard population as the 
World standard population is 85 or older the influence of standardization on the 
comparability of IRs in the population of patients aged 80 years or older seems limited and 
was not additionally performed.6 A summary of key findings based on the quality of evidence 
found is provided. Quality of evidence was rated as previously suggested by Robinson et al.7 
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Results 
 
As shown in the Figure 1, 13 628 studies were initially identified, of which 83 studies were 
ultimately included. Quality assessment using the STROBE checklist was performed in 76 
studies, and resulted in the following classification: category A, 18 (23.7%); category B, 48 
(63.2%); and category C, 10 (13.2%). In the remaining 7 studies the STROBE checklist was not 
considered appropriate owing to the nonobservational design and therefore was not used 
for quality assessment.  
 
E P I D E M I O L O G Y  
 
Incidence 
In total, 27 studies were found reporting age-specific incidence rates (IRs) of BCC in the 
oldest-old, or sufficient data to calculate age-specific IRs (Table 1).8-34 In most studies (n=19) 
IRs based on no more than 1 tumor per patient were presented,8,10,11,13-18,20-23,25-28,30,34 while 
in some studies (n=4) multiple tumors per patient were included19,24,31,32 or no coding 
method was presented (n=4).9,12,29,33 Crude IRs (based on no more than 1 tumor per patient) 
ranged from 13 to 12 112 per 100 000 person-years in the oldest-old, strongly influenced by 
factors such as sex, geographical location, ethnical background, and time period.  
 
Stratification by sex 
Higher IRs for males compared with females were shown in most studies, with a 
male:female ratio ranging from 1.1-4.4:1 (Table 1).8-12,14,16-29,31-33 Chuang et al.15 found IRs 
were 4 times higher among Japanese women aged 85 years or older in Hawaii compared 
with men. Traditional occupational differences were stated by the authors as a possible 
explanation.  
 
Comparison with other age groups 
Most studies show IRs keep rising with increasing age for both sexes.9,10,13-15,17,19,22,24-31 
However, some studies indicate a rise until the eighth or ninth decade, after which a slight 
decrease in IRs was seen for 1 or both sexes.8,11,12,16,18,20,21,32,34 One Jordanian study23 found 
highest IRs among women in the seventh decade, while the IRs for men kept increasing with 
increasing age. The authors considered inadequate sampling and differences in sun 
exposure as possible explanatory factors.  
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Figure 1  Study selection in this systematic review 
 
 
 
 
 
 
 
 
 
Records screened by  
title/abstract (n = 7788) 
Records after removal  
of duplicates (n = 7701) 
Records identified by reference 
screening (n = 87) 
Excluded (n = 7115), with reasons: 
Irrelevant (n=6658), full-text not 
available (n=115), non-English/Dutch 
(n=145), conference abstract (n=148), 
and basal cell carcinoma not included 
(n=49) 
 
Excluded (n = 590), with reasons: 
Oldest-old (≥80 years) patients not 
included (n = 12), no age-specific rates 
for oldest-old patients ≥80 years (n = 
105), no stratification for basal cell 
carcinoma (n=68); basal cell carcinoma 
not included (n=8), non-English/Dutch 
(n=10), and irrelevant (n = 387) 
Full-text articles assessed  
for eligibility (n = 673) 
Studies included in synthesis (n = 83) 
Records identified from literature 
search (n = 13 628) 
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Table 1  Incidence rates of basal cell carcinoma in the oldest-old (patients aged 80 years or older) 
 
Source Data source Hist. 
confir-
mation 
Coding 
bya 
Period Age-
group, y 
IRsb M:F 
ratio 
STROBE / 
QRS 
M F Total 
McKnight, 1979 
(Iceland)8 
Cancer registry Y Patient 1955-1974 80-84 75 58 NR 1.3 B / 3 
≥85 13 53 0.2 
Dahl, 1991 
(Sweden)9 
One pathology 
laboratory 
Y NR 1970-1971 ≥80 622 529 NR 1.2 B / 3 
1975-1976 970 562 1.7 
1980-1981 1126 564 2.0 
1985-1986 1361 819 1.7 
Levi, 1998 
(Switzerland)10 
Cancer registry Y Patient 1974-1994 ≥80 550 364 NR 1.5 B / 3 
Chuang, 1990 
(US)11 
Local health group 
database 
Y Patient 1976-1984 ≥85 1028 928 950 1.1 B / 3 
Magnus, 1993 
(Australia)12 
Cancer registry Y NR 1976-1982 80-89 387 293 327 1.3 C / 3 
≥90 325 275 292 1.2 
Kaldor, 1993 
(Australia)13 
Cancer registry N Patient 1978-1987 ≥80 NR NR 703 NR B / 3 
Coebergh, 1991 
(Netherlands)14 
Cancer Registry  Y Patient 1978-1988 80-84 463 344 NR 1.3 B / 3 
≥85 496 384 1.3 
Chuang, 1995 
(US)15 
Prospective physicians 
registry 
Y Patient 1983-1987 ≥85 290 1148 838 0.3 B / 2 
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Table 1  Incidence rates of basal cell carcinoma in the oldest-old (patients aged 80 years or older) (continued) 
 
Source Data source Hist. 
confir-
mation 
Coding 
bya 
Period Age-
group, y 
IRsb M:F 
ratio 
STROBE / 
QRS 
M F Total 
Reizner, 1993 
(US)16 
Prospective physicians 
registry 
Y Patient 1983-1987 ≥85 3252 3093 3182 1.1 B / 2 
Harris, 2001  
(US) 17,d 
Cancer registry Y Patient 1985-1996  ≥80 7550 2898 NR 2.6 B / 3 
Holme, 2000 
(UK)18 
Cancer registry  N Patient 1988  80-84 989 549 684 1.8 A / 3 
 ≥85 686 895 846 1.6 
1998 80-84 1188 730 883 0.8 
 ≥85 1387 785 927 1.8 
Hoy, 1996 (US)19,e Local health group 
database 
Y Tumor 1989-1991 ≥80 10987 2670 NR 4.1 C / 3 
Stang, 2003 
(Germany)20 
Cancer registry N Patient 1995-1999 80-84 455 332 NR 1.4 B / 3 
≥85 566 274 2.1 
Bath-Hextall, 2007 
(UK)21 
Primary care 
database 
N Patient 1996-2003 ≥80 742 491 574 1.5 A / 3 
Raasch, 2002 
(Australia)22 
Cancer registry Y Patient  1997-1999 ≥80 12112 5525 NR 2.2 B / 2 
Omari, 2004 
(Jordan)23 
Cancer registry Y Patient 1997-2001 >80 162 80 121 2.0 B / 3 
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Table 1  Incidence rates of basal cell carcinoma in the oldest-old (patients aged 80 years or older) (continued) 
 
Source Data source Hist. 
confir-
mation 
Coding 
bya 
Period Age-
group, y 
IRsb M:F 
rati
o 
STROBE / 
QRS 
M F Total 
Brougham, 2010 
(New Zealand)24 
Pathology 
laboratories 
Y Tumor 1997-2007 ≥80 3764 1816 2716 2.1 B / 2 
Revenga Arranz, 
2004 (Spain)25  
Hospital database Y Patient 1998-2000 80-100 909 326 550 2.8 B / 3 
Stang, 2007 
(Germany)26 
Prospective 
physicians registry 
NR Bothf 1998-2003 ≥80 1066f 464f NR 2.3 B / 3 
Eisemann, 2013 
(Germany)27,g 
Cancer registry  Y Patient 1998-2000 ≥80 703 399 NR 1.8 A / 3 
2008-2010 812 498 1.6 
Asgari, 2015 
(US)28 
Health insurance 
database 
Y Patient 1998-2012 ≥80 4941 2537 3484 1.9 A / 3 
Celic, 2009 
(Croatia)29 
Dermatologists survey 
and cancer registry  
Y NR 2003-2005 ≥80 652 327 NR 2.0 B / 3 
Musah, 2013 
(UK)30,g 
Primary care database N Patient 2004 ≥80 NR NR 660 NR A / 3 
2005 677 
2006 716 
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Table 1  Incidence rates of basal cell carcinoma in the oldest-old (patients aged 80 years or older) (continued) 
 
Source Data source Hist. 
confir-
mation 
Coding 
bya 
Period Age-
group, y 
IRsb M:F 
rati
o 
STROBE / 
QRS 
M F Total 
Musah, 2013 
(UK)30,g (cont.) 
Primary care database N Patient 2010    718   
De La Torre-
Lugo, 2010 
(Puerto Rico)31 
Pathology laboratories Y Tumor 2005 ≥85 1260 610 860 2.1 B / 3 
Bielsa, 2009 
(Spain)32 
Prospective 
dermatologists registry  
N  Tumor 2006-2007 80-84 3444 1523 2197 2.3 B / 3 
≥85 3910 1156 1914 3.4 
Saint-Yves, 1988 
(Australia)33,c 
Cancer registry Y NR 1981-1985 80-84 16(W) 9(W) NR 1.8 B / 3 
≥85 18(W) 14(W) 1.3 
Sella, 2015 
(Israel)34,c 
Health insurance 
database 
Y Patient 2006-2011 ≥80 NR NR 999(E) NR B / 3 
 
Abbreviations: cont, continued; (E), European; F, females; Hist, histological; IRs, incidence rates; M, males; N, no; NR, not reported; QRS, quality rating scheme; STROBE, STrengthening 
of Reporting of OBservational studies in Epidemiology; United Kingdom; US, United States; (W), World; y, years; Y, yes (all cases histologically confirmed). a Coding by patient means no 
more than one tumor per patient was included, coding by tumor means multiple tumors per patient might have been included; b IRs are given per 100 000 person-years and 
reported as crude rates unless otherwise specified; c Only standardized IRs available and reported, the population used for standardization given between parentheses (World or 
European); d Age-specific incidence rates only available for the year 1996; e Only rates for non-Hispanic whites are shown (rates for Hispanic whites also available but not shown); f 
Rates coded by patient were shown (rates coded by tumor also available but not shown); g Additional information was obtained after contact with the first author. STROBE 
classification based on criteria fulfilled (A: >80%; B: 50-80%; C: <50%); quality rating scheme (1, properly powered and conducted randomized clinical trial; systematic review with 
meta-analysis; 2, well-designed controlled trial without randomization; prospective comparative cohort trial; 3, case-control studies; retrospective cohort study; 4, case series with or 
without intervention; cross-sectional study; 5, opinion of respected authorities; case reports). 
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Time trends 
Six studies report age-specific changes of IRs over time, with annual percentage changes 
(APCs) ranging from -2.2% to 6.4%.21,24,28,30,35,36 All studies but 1 showed significant increases 
in APCs over time in the oldest-old. In 1 study from the United Kingdom21 no significant 
changes in IRs were found in a primary care database over the period 1996 to 2003 (APC, -
2.2%; 99%CI: -4.6 to 0.2). Most studies show lower APCs among the oldest-old compared 
with younger patients, indicating a relatively faster increasing incidence in younger 
patients.21,24,30,35,36 In contrast, 1 study reported highest APCs in patients aged 80 years or 
older, especially in men.28 
 
Prevalence 
Point-prevalences of BCC in geriatric populations range broadly (median 0.8%; range, 0% to 
21%),37-59 strongly influenced by the clinical setting (i.e. dermatology outpatient clinic, 
geriatric ward, nursing home), definition of older adults and population characteristics like 
size and racial and cultural differences (e.g. over half of the included studies was performed 
in Asian countries). All studies providing prevalence data of BCC in geriatric populations 
(regardless of age categories) are summarized in Table 2.  
 
Mortality 
Only 2 studies provide specific mortality rates (MRs) for BCC in the oldest-old, reporting 
crude MRs of 6.49 and 2.88 per 100 000 person-years in people aged 85 years or older in 2 
consecutive cohorts of Rhode Island residents.60,61 Although death owing to BCC is very 
uncommon, both studies showed that MRs owing to BCC were highest in patients aged 85 
years or older compared with younger patients. In general, the potential influence of 
misclassification of causes of death should always be taken into account in studies reporting 
MRs. 
 
Multiple basal cell carcinoma 
In a meta-analysis published in 2013, a mean 5-year cumulative risk of 36.2% to develop a 
subsequent BCC after an initial BCC was calculated in patients of all ages combined.62 
Conflicting data were found concerning the relationship between increasing age and the risk 
of developing a subsequent BCC.63-70 The proportion of oldest-old developing multiple BCC 
ranges from 26.3% to 48.8% (Table 3).63,64,66,70  
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Table 2  Prevalence of basal cell carcinoma in geriatric populations  
 
Source Period Popu-
lation 
size 
Setting Examined by Histo. 
confir-
mation 
Age range, 
y 
Prevalence BCC, 
% (n)a 
STROBE/
QRS 
Bilgili, 2012 
(Turkey)37 
2007-2010 5961  2 DOCs Dermatologist NR 65-102 0.5 (30) B / 3 
Bradley, 1991 
(Australia)38 
1988-1989 568 PHI  General practitioner N  65-100 6.0/10.2 (34/58b) C / 3 
Chan, 2006 (Hong 
Kong)39 
2005 257 4 PHI’s  NR N 69-99 0.8 (2) B / 4 
Chopra, 1999 
(India)40 
1996 214 DOC Dermatologist NA 60-85 None C / 3 
Darjani, 2013 
(Iran)41 
2010-2011 440  DOC Dermatologist Y NS (all ≥60) Overall: 8.9 (39) B / 3 
≥80: 13.0 (6) 
Kilic, 2007 
(Turkey)42 
2006 300 3 PHI’s  Dermatologist NA 57-104 None B / 4 
Liao, 2001 
(Taiwan)43 
1993-1999 16 924 DOC Dermatologist NR NS (all ≥65) 0.6 (108) B / 3 
Nair, 2013 
(India)44 
2009-2010 457 DOC Dermatologist NR NS (all ≥60) 0.2 (1) B / 2 
Patange, 1995 
(India)45 
NR 200 NR NR NA 55-85 None C / 4 
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Table 2  Prevalence of basal cell carcinoma in geriatric populations (continued) 
 
Source Period Popu-
lation 
size 
Setting Examined by Hist. 
confir-
mation 
Age range, 
y 
Prevalence BCC, 
% (n)a 
STROBE / 
QRS 
Polat, 2009 
(Turkey)46 
2006 209 DOC Dermatologist Y 65-91 4.3 (9) B / 2 
Roodsari, 2008 
(Iran)47 
NR 456 12 PHI’s  Dermatologist NR 29-107 0.4 (2) C / 4 
Shah, 2005 (UK)48 NR 100 DOC Dermatologist NR 66-90 21.0 (21) B / 4 
Smith, 2002 
(Australia)49 
2000 360 PHI  NH physician, 
podiatrist and nurse 
NR 34-103 3.9 (11) B / 3 
Smith, 2002 
(Taiwan)50 
1999-2000 398 11 PHI’s  Dermatologist NR 22-108 0.3 (1) B / 4 
Swetter, 2003 
(US)51 
1997-2000 374  7 DOCs Dermatologist N 28-92 Overall: 11.0 (41) B / 4 
≥80:13.8 (4) 
Templier, 2015 
(France)52 
2013 204 Hospital-
based 
acute 
geriatric 
unit 
Dermatologist Y NR 4.4 (9) A / 3 
Thapa, 2012 
(Nepal)53 
2010-2011 330 DOC Dermatologist NR 60-97 0.3 (1) B / 3 
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Table 2  Prevalence of basal cell carcinoma in geriatric populations (continued) 
 
Source Period Popu-
lation 
size 
Setting Examined by Hist. 
confir-
mation 
Age range, 
years 
Prevalence BCC, 
% (n)a 
STROBE / 
QRS 
Tseng, 2015 
(Taiwan)54 
2011 337  PHI  Dermatologist Y 46-99 1.2 (4) B / 2 
Verbov, 1975 
(UK)55 
1975 170 DOC and 
inpatients 
from two 
hospitals 
Dermatologist NR 60-90 8.2 (14) C / 2 
Weismann, 1980 
(Denmark)56 
1976 584  Multiple 
PHI 
(unknown 
number) 
Dermatologist NR 55-106 None C / 3 
Yap, 1994 (S)57 1990 2571  DOC Dermatologist Y NR (all ≥65) 0.3 (8) B / 3 
Young, 1958 
(US)58 
NS 330 DOC and 
private 
practice 
Dermatologist NR 60-94 8.2 (27) C / 3 
Zagula-Mally, 
1974 (US)59 
1969-1971 978  Household 
visits 
Nurse, partly revisited 
by dermatologist 
N NR Overall: 3.4 (33) B / 4 
≥75: 10 (7) 
 
Abbreviations: BCC, basal cell carcinoma; DOC, dermatology outpatient clinic; Hist, histological; N, no; NA, not applicable; NH, nursing home; NR, not reported; PHI, permanent 
healthcare institution; QRS, quality rating scheme; S, Singapore; STROBE, STrengthening of Reporting of OBservational studies in Epidemiology; UK, United Kingdom; US, United 
States; y, years; Y, yes (all cases histologically confirmed). a Stratification by age group only viewed if provided; b Depending on clinical and/or histopathological diagnosis made. 
STROBE and QRS classification as mentioned in Table 1.  
14
6 
Ch
ap
te
r 7
 
 Ta
bl
e 
2 
 P
re
va
le
nc
e 
of
 b
as
al
 c
el
l c
ar
ci
no
m
a 
in
 g
er
ia
tr
ic
 p
op
ul
at
io
ns
 (c
on
tin
ue
d)
 
 
So
ur
ce
 
Pe
ri
od
 
Po
pu
-
la
ti
on
 
si
ze
 
Se
tt
in
g 
Ex
am
in
ed
 b
y 
H
is
t. 
co
nf
ir
-
m
at
io
n 
Ag
e 
ra
ng
e,
 
ye
ar
s 
Pr
ev
al
en
ce
 B
CC
, 
%
 (n
)a
 
ST
RO
BE
 / 
Q
RS
 
Ts
en
g,
 2
01
5 
(T
ai
w
an
)54
 
20
11
 
33
7 
 
PH
I  
D
er
m
at
ol
og
is
t 
Y 
46
-9
9 
1.
2 
(4
) 
B 
/ 2
 
Ve
rb
ov
, 1
97
5 
(U
K)
55
 
19
75
 
17
0 
D
O
C 
an
d 
in
pa
tie
nt
s 
fr
om
 tw
o 
ho
sp
ita
ls
 
D
er
m
at
ol
og
is
t 
N
R 
60
-9
0 
8.
2 
(1
4)
 
C 
/ 2
 
W
ei
sm
an
n,
 1
98
0 
(D
en
m
ar
k)
56
 
19
76
 
58
4 
 
M
ul
tip
le
 
PH
I 
(u
nk
no
w
n 
nu
m
be
r) 
D
er
m
at
ol
og
is
t 
N
R 
55
-1
06
 
N
on
e 
C 
/ 3
 
Ya
p,
 1
99
4 
(S
)57
 
19
90
 
25
71
  
D
O
C 
D
er
m
at
ol
og
is
t 
Y 
N
R
 (
a
ll 
≥
6
5
) 
0.
3 
(8
) 
B 
/ 3
 
Yo
un
g,
 1
95
8 
(U
S)
58
 
N
S 
33
0 
D
O
C 
an
d 
pr
iv
at
e 
pr
ac
tic
e 
D
er
m
at
ol
og
is
t 
N
R 
60
-9
4 
8.
2 
(2
7)
 
C 
/ 3
 
Za
gu
la
-M
al
ly
, 
19
74
 (U
S)
59
 
19
69
-1
97
1 
97
8 
 
H
ou
se
ho
ld
 
vi
si
ts
 
N
ur
se
, p
ar
tly
 re
vi
si
te
d 
by
 d
er
m
at
ol
og
is
t 
N
 
N
R 
O
ve
ra
ll:
 3
.4
 (3
3)
 
B 
/ 4
 
≥
7
5
: 1
0
 (
7
) 
 Ab
br
ev
ia
tio
ns
: B
CC
, b
as
al
 c
el
l c
ar
ci
no
m
a;
 D
O
C,
 d
er
m
at
ol
og
y 
ou
tp
at
ie
nt
 c
lin
ic
; 
H
ist
, h
ist
ol
og
ic
al
; N
, n
o;
 N
A,
 n
ot
 a
pp
lic
ab
le
; N
H
, n
ur
sin
g 
ho
m
e;
 N
R,
 n
ot
 r
ep
or
te
d;
 P
H
I, 
pe
rm
an
en
t 
he
al
th
ca
re
 in
st
itu
tio
n;
 Q
RS
, q
ua
lit
y 
ra
tin
g 
sc
he
m
e;
 S
, S
in
ga
po
re
; S
TR
O
BE
, S
Tr
en
gt
he
ni
ng
 o
f 
Re
po
rt
in
g 
of
 O
Bs
er
va
tio
na
l s
tu
di
es
 in
 E
pi
de
m
io
lo
gy
; 
U
K,
 U
ni
te
d 
Ki
ng
do
m
; U
S,
 U
ni
te
d 
St
at
es
; y
, y
ea
rs
; Y
, y
es
 (a
ll 
ca
se
s 
hi
st
ol
og
ic
al
ly
 c
on
fir
m
ed
). 
a  
St
ra
tif
ic
at
io
n 
by
 a
ge
 g
ro
up
 o
nl
y 
vi
ew
ed
 if
 p
ro
vi
de
d;
 b
 D
ep
en
di
ng
 o
n 
cl
in
ic
al
 a
nd
/o
r 
hi
st
op
at
ho
lo
gi
ca
l d
ia
gn
os
is 
m
ad
e.
 
ST
RO
BE
 a
nd
 Q
RS
 c
la
ss
ifi
ca
tio
n 
as
 m
en
tio
ne
d 
in
 T
ab
le
 1
. 
 
|
Basal cell carcinoma in patients aged 80 years and older 147 
 
Table 3  Development of multiple basal cell carcinoma in the oldest-old 
 
Source Period Population 
sizea 
Effect of increasing age 
on BCC to BCC riskb 
Definition 
mult. BCCc 
Age-group, y Proportion 
mult. BCCd, % 
STROBE / 
QRS 
Czarnecki, 1991 
(Australia)63 
1989-1990 575  NR ≥3 75-84 48.8 C / 3 
≥85 45.5 
Flohil, 2011 
(Netherlands)64 
2004-2009 2483  Increasement ≥2 ≥80 27.6 A / 3 
Karagas, 1992 (US)65  1980-1986 1735 Increasement NR NRe NR A / 2 
Kiiski, 2010 
(Netherlands)66 
1990-2007 524 (10 296 
controls) 
Decreasement ≥2 ≥75 26.3 A / 2 
Levi, 2006 
(Switzerland)67 
1976-2003 1868 Decreasement NR NR NR B / 3 
Ramachandran, 
2002 (UK)68  
1991-1998 747 Increasement NR NR NR B / 2 
Robinson, 1987 
(US)69 
NR (5-year 
period) 
1000 No correlation found NR NR NR B / 2 
Van Iersel, 2005 
(Netherlands)70 
1993-1998 237 Increasement ≥2 >75 43 B / 3 
 
Abbreviations: BCC, basal cell carcinoma; mult, multiple; NR, not reported; QRS, quality rating scheme; STROBE, STrengthening of Reporting of OBservational studies in Epidemiology; 
UK, United Kingdom; US, United States; y, years.a Numbers of patients with at least one basal cell carcinoma; b Risk to develop a subsequent basal cell carcinoma after an initial basal 
cell carcinoma; c Numbers of tumors;  d In case only numbers were described proportions were calculated; e Patients aged 85 years or older at baseline were excluded. STROBE and 
QRS classification as mentioned in Table 1. 
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C L I N I C O P A T H O L O G I C A L  F E A T U R E S  
 
Subtypes of basal cell carcinoma 
Two studies found provide exact data considering the different subtypes of BCC among the 
oldest-old (Table 4).71,72 In both studies nodular BCC (nBCC) was the most common subtype 
of BCC (51.7%-60.7%). In the oldest study71 no significant correlations were found between 
subtypes of BCC and the age categories described. The other study72 showed that 
superficial BCC (sBCC) were relatively more common among younger patients compared 
with older adult patients (43% vs 27%; OR, 2.0; 95%CI, 1.1-3.8), whereas no significant 
influence of age was found for the other subtypes. No data regarding changes of subtype-
distribution among the oldest-old over time were found. 
 
Body site distribution 
It was shown in different studies that the proportion of BCC in the head and neck region 
increases with increasing age, while the proportion of truncal BCC seems to decrease.12,72 
Three studies were found presenting specific data on body site distribution in the oldest-old 
(Table 5).72-74  Since different categories of body sites are used within the studies, 
comparison is limited to the categories universally mentioned. A notable higher proportion 
of truncal BCC is described by Betti et al.72 compared to the 2 older studies, which could be 
an indication for a shift over time with a relative increase of truncal BCC. 
 
Tumor size and depth 
There is conflicting literature regarding the relation between increasing age and both tumor 
size and depth. In 1 study, larger BCC were independently associated with increasing age,75 
while another study showed no significant association.76 It was shown in several studies that 
the mean age of patients with giant BCC (≥5 cm or ≥10 cm in greatest diameter, definition 
dependent on study) was comparable with patients with smaller BCC.77-79 Furthermore, 
Welsch et al.80 showed a significant correlation of increasing age with increasing tumor 
depth in patients with BCC, while Takenouchi et al.81 could not find this correlation. 
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Table 4  Subtypes of basal cell carcinoma in the oldest-old 
 
Source Period Population 
sizea 
Hist. 
confirmation 
Age-group, y Subtype 
classification 
Proportion per 
subtypeb, % 
STROBE / 
QRS 
Betti, 1995 
(Italy)71 
NR (5-year 
period) 
693 (693) Y 81-90 nBCC 60.7 B / 3 
sBCC 12.5 
i/morfBCC 25.0 
Pinkus 1.8 
>90 nBCC 72.7 
sBCC 9.1 
i/morfBCC 18.2 
Pinkus 0.0 
Both (≥81)  nBCC 62.7 
sBCC 11.9 
i/morfBCC 23.9 
Pinkus 1.5 
Betti, 2009 
(Italy)72 
1994-2006 173 (175) Y ≥90 nBCC 51.7 B / 3 
sBCC 27.0 
i/morfBCC 21.3 
 
Abbreviations: hist, histological; i/morfBCC, infiltrative/morpheaform basal cell carcinoma; nBCC, nodular basal cell carcinoma; NR, not stated; Pinkus, fibroepithelioma of Pinkus; 
QRS, quality rating scheme; sBCC, superficial basal cell carcinoma; STROBE, STrengthening of Reporting of OBservational studies in Epidemiology; y, years; Y, yes (all cases 
histologically confirmed). a Numbers of patients with basal cell carcinoma (number of basal cell carcinoma); b In case only numbers were described proportions were calculated. 
STROBE and QRS classification as mentioned in Table 1. 
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Table 5  Body site distribution of basal cell carcinoma in the oldest-old 
 
Source Period Population 
sizea 
Hist. 
confir-
mationb 
Age-
group, 
y 
Body site 
classifica-
tion 
Proportions per body 
sitec,  
IRsd STROBE / 
QRS 
M F Total M F Total  
Betti, 
2009 
(Italy)72 
1994-
2006 
173 (175) Y ≥90 Head/neck: NR NR 57.3 NR NR NR B / 3 
Trunk: 31.5 
Limbs: 11.2 
Fears, 
1982 
(US)73 
1971-
1972 
and 
1977-
1978 
6645 (6645) N 
(>95%)  
75-84 Head/necke: 91.4 87.6 NR 615.4 307.5 NR B / 2 
84.8 85.4 588.0 297.4 
84.3 85.1 436.6 280.4 
85.6 87.8 541.4 268.3 
Other4: 8.6 12.4 NR 57.9 43.5 NR 
15.2 14.6 105.0 50.9 
15.7 14.9 81.5 49.3 
14.4 12.2 91.3 37.1 
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15
0 
C
h
a
p
te
r 
7
 
 Ta
bl
e 
5 
 B
o
d
y 
si
te
 d
is
tr
ib
u
ti
o
n
 o
f 
b
a
sa
l c
e
ll 
ca
rc
in
o
m
a
 in
 t
h
e
 o
ld
e
st
-o
ld
 
 
So
ur
ce
 
Pe
ri
od
 
Po
pu
la
tio
n 
si
ze
a  
H
is
t. 
co
nf
ir
-
m
at
io
nb
 
Ag
e-
gr
ou
p,
 
y 
Bo
dy
 s
it
e 
cl
as
si
fic
a-
ti
on
 
Pr
op
or
tio
ns
 p
er
 b
od
y 
si
te
c , 
 
IR
sd
 
ST
RO
BE
 / 
Q
RS
 
M
 
F 
To
ta
l 
M
 
F 
To
ta
l 
 
B
e
tt
i, 
2
0
0
9
 
(I
ta
ly
)7
2
 
1
9
9
4
-
2
0
0
6
 
1
7
3
 (
1
7
5
) 
Y
 
≥
9
0
 
H
e
a
d
/n
e
ck
: 
N
R
 
N
R
 
5
7
.3
 
N
R
 
N
R
 
N
R
 
B
 /
 3
 
T
ru
n
k:
 
3
1
.5
 
Li
m
b
s:
 
1
1
.2
 
Fe
a
rs
, 
1
9
8
2
 
(U
S
)7
3
 
1
9
7
1
-
1
9
7
2
 
a
n
d
 
1
9
7
7
-
1
9
7
8
 
6
6
4
5
 (
6
6
4
5
) 
N
 
(>
9
5
%
) 
 
7
5
-8
4
 
H
e
a
d
/n
e
ck
e
: 
9
1
.4
 
8
7
.6
 
N
R
 
6
1
5
.4
 
3
0
7
.5
 
N
R
 
B
 /
 2
 
8
4
.8
 
8
5
.4
 
5
8
8
.0
 
2
9
7
.4
 
8
4
.3
 
8
5
.1
 
4
3
6
.6
 
2
8
0
.4
 
8
5
.6
 
8
7
.8
 
5
4
1
.4
 
2
6
8
.3
 
O
th
e
r4
: 
8
.6
 
1
2
.4
 
N
R
 
5
7
.9
 
4
3
.5
 
N
R
 
1
5
.2
 
1
4
.6
 
1
0
5
.0
 
5
0
.9
 
1
5
.7
 
1
4
.9
 
8
1
.5
 
4
9
.3
 
1
4
.4
 
1
2
.2
 
9
1
.3
 
3
7
.1
 
Le
vi
, 
1
9
8
8
 
(S
w
it
-
ze
r-
la
n
d
)7
4
 
1
9
7
6
-
1
9
8
5
 
3
8
1
1
 (
3
8
1
1
) 
N
 
(>
9
9
%
) 
7
5
-8
4
  
 
H
e
a
d
/n
e
ck
: 
7
3
.8
 
8
2
.5
 
7
8
.2
 
3
2
6
.3
 
2
1
9
.5
 
N
R
 
B
 /
 3
 
T
ru
n
k:
 
1
6
.3
 
9
.8
 
1
3
.0
 
7
2
.2
 
2
6
.0
 
 
U
p
p
e
r 
lim
b
s:
 
3
.2
 
1
.1
 
2
.1
 
1
4
.2
 
2
.9
 
 
Lo
w
e
r 
lim
b
s:
 
3
.2
 
5
.3
 
4
.3
 
1
4
.2
 
1
4
.2
 
 
O
th
e
r:
 
3
.5
 
1
.3
 
2
.4
 
1
5
.2
 
3
.5
 
 
 
|
Basal cell carcinoma in patients aged 80 years and older 151 
 
Table 5  Body site distribution of basal cell carcinoma in the oldest-old (continued) 
 
Source Period Population 
sizea 
Hist. 
confir-
mationb 
Age-
group, 
y 
Body site 
classifica-
tion 
Proportions per body 
sitec,  
IRsd STROBE / 
QRS 
M F Total M F Total  
Levi, 
1988 
(Swit-
zer-
land)74 
(conti-
nued) 
1976-
1985 
3811 (3811) N 
(>99%) 
≥85 Head/neck: 83.4 83.1 83.4 496.3 299.1 NR  
Trunk: 9.5 9.4 9.4 56.4 33.7  
Upper 
limbs: 
4.8 2.5 3.4 28.2 9.0  
Lower limbs: 1.0 1.9 1.5 5.6 6.7  
Other: 1.0 3.1 2.3 5.6 11.2  
 
Abbreviations: F, female; hist, histological; IRs, incidence rates; M, male; N, no; NR, not reported; QRS, quality rating scheme; STROBE, STrengthening of Reporting of OBservational 
studies in Epidemiology; US, United States; y, years; Y, yes (all cases histologically confirmed). a Numbers of patients with basal cell carcinoma (number of basal cell carcinoma); b 
proportions of histopathologically confirmed tumors given between parentheses when reported;  c In case only numbers were described proportions were calculated, proportions 
given in %; d Crude age-specific IRs per 100 000 person-years; e Separate proportions and incidence rates are given for the two periods and the two locations included in the study (in 
descending order: Minneapolis 1971-1972, Minneapolis 1977-1978, San Francisco 1971-1972, San Francisco 1977-1978). STROBE and QRS classification as mentioned in Table 1. 
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Metastatic basal cell carcinoma 
Metastases from BCC rarely occur, with an incidence of .0028% to .55%.82-84 In metastatic 
basal cell carcinoma (mBCC) the mean age of onset of the primary tumor was shown lower 
compared with the general population of patients with BCC,82-86 ranging from 47.4 to 57.1 
years with a mean interval to the diagnosis of mBCC of 8.0 to 16.9 years.83,84,86 Von Domarus 
et al.82 suggested 2 possible explanations for this discrepancy in age distribution: (1) older 
adults patients may not live long enough to develop metastases from BCC, and (2) BCC in 
younger patients may have a more aggressive clinical behavior. Moreover, a review and 
survival analysis of all mBCC cases published in English literature between 1981 and 2011 
did not show a relation between age and either the incidence of mBCC or the survival.86 
 
Impact on quality of life 
Nonmelanoma skin cancer (including BCC) seem to have little overall impact on 
(dermatology-specific) health-related quality of life (HRQoL) and conflicting data exist 
regarding the influence of age on HRQoL in patients with BCC (Table 6).87-91 No studies 
focusing specifically on the oldest-old were found. 
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Table 6  The relationship of age and impact on health-related quality of life in patients with nonmelanoma skin cancer  
 
Source Setting Tumor 
type 
Period Popula-
tion size 
Instrument(s) 
used 
Findings STROBE / 
QRS 
Rhee, 2004 
(US)87 
MMS clinic NMSC 2001-
2002 
121a DLQI Low impact of NMSC on HRQoL, no overall 
change in DLQI pre- and post-treatment, 
no influence of age on outcomes 
A / 2 
Rhee, 2004 
(US)88 
MMS clinic NMSC 2001-
2002 
121a SF-36, FACT-G Low impact of NMSC on HRQoL, no overall 
change in DLQI pre- and post-treatment, 
no influence of age on outcomes 
A / 2 
Rhee, 2007 
(US)89 
MMS clinic NMSC 2005-
2006 
211 Skin cancer index A greater impact of NMSC on HRQoL and 
a greater improvement of HRQoL after 
treatment was noticed in younger patients 
compared to older patients (<50 years vs. 
≥50 years) 
A / 2 
Chen, 2007 
(US)90 
Private practice 
and veterans 
affair clinic 
NMSC 1999-
2000 
633 Skindex-16 Pre- and post-treatment impact of NMSC 
on HRQoL was not found to be related to 
age 
A / 2 
Caddick, 
2013 (UK)91 
Skin cancer 
clinic 
NMSC 2008-
2010 
53 Skin cancer index Overall and emotional domain HRQoL 
scores improved more after surgical 
treatment with increasing age 
A / 2 
 
Abbreviations: DLQI, Dermatology Life Quality Index; FACT-G, Functional Assessment of Cancer Therapy-General; HRQoL, health-related quality of life; MMS, Mohs micrographic 
surgery; NMSC, nonmelanoma skin cancer; QRS, quality rating scheme; SF-36, 36-Item Short Form Health Survey; STROBE, STrengthening of Reporting of OBservational studies in 
Epidemiology; UK, United Kingdom; US, United States. a Same study population used in both studies. STROBE and QRS classification as mentioned in Table 1. 
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Discussion 
 
This systematic review emphasizes the high and growing incidence of BCC in the oldest-old 
and often frail population. An overview of both previous research as well as knowledge gaps 
regarding BCC in the oldest-old is provided. A summary of key findings based on the quality 
of evidence found in this systematic review is given in Table 7.  
 
In the oldest-old population incidence rates of BCC are higher among men and most BCCs 
are of the nodular subtype and found in the head and neck region. Inconclusive data exists 
regarding increasing age and the risk to develop a subsequent BCC. No data regarding 
impact of BCC on quality of life in patients aged 80 years and over were found and 
inconclusive data regarding the relationship of age and impact of BCC on quality of life were 
found.  
 
It was previously shown that the burden of BCC is often underestimated in the literature, for 
instance because most population-based cancer registries do no register data regarding 
BCC. Several other reasons that might especially apply to the oldest-old could attribute to 
this underestimation: (1) data in most studies are derived from pathology databases, 
although a significant number of BCC (ranging from 0.7-24.1%) is clinically diagnosed 
without histological confirmation,92 and (2) most BCC registries solely register the first 
primary BCC in a patient, although subsequent BCC are common.62 Cases of BCC in the 
oldest-old are relatively often of the nodular subtype and located in the H&N region 
compared with younger patients, while the number of sBCC and truncal localization seems 
to decrease with older age. With the aging of the current younger populations, it could be 
expected the subtype and body site distribution in the oldest-old will change along over the 
course of the next couple of decades.  
 
Medical decision making in the oldest-old might be challenging, especially in a typically 
nonfatal slowly progressive condition like BCC. Therefore, recommendations for screening 
and treatment are not easily made. For instance, patients may not live long enough to 
benefit from treatment, while treatment complications could result in a reduced HRQoL. On 
the other hand, general prognostication could be difficult and a decision not to treat a BCC 
could have a substantial adverse outcome if a patient lives longer than expected. Data 
regarding the expected impact of BCC on HRQoL on both the short and longer term could 
be of value in these situations, but is currently lacking as shown in this review.  
 
Given the rising incidence of BCC and aging of the world population, dermatologists are 
expected to be increasingly confronted with dilemmas in medical decision making. Guidance 
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from epidemiologic and clinicopathological data could be of value to overcome these 
dilemmas. However, as shown in this systematic review, available data from the current 
literature is limited. Therefore, future research should focus more specifically on BCC in the 
oldest-old, together with prognostication and their relation with HRQoL on both the short 
and  longer term. 
 
L I M I T A T I O N S  
Several limitations in this systematic review should be addressed. Important differences 
between the study populations (e.g. geographic location, population size, racial and cultural 
differences) and used methods (e.g. diagnostic criteria, definitions and categorization of 
outcome variables, handling multiple or recurrent tumors) were noted among the included 
studies. Therefore, comparison, interpretation, and generalization was limited between the 
included studies. Furthermore, based on the exclusion criteria in this study, potential 
studies of interest could have been missed (e.g. language bias owing to exclusion of studies 
not available in English or Dutch). 
 
 
Conclusion 
 
The incidence of BCC among the oldest-old is high and increasing. Epidemiologic and 
clinicopathological data from current literature provide only limited guidance in clinical 
decision making owing to heterogeneity and scarcity. Future research should focus more 
specifically on BCC in the oldest-old, together with prognostication and their relation with 
HRQoL on both the short and longer term. 
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Table 7  Summary of findings based on the quality of evidence found in this systematic review 
 
Finding based on this systematic review QoEa Related references 
IRs of BCC increase with increasing age until the 8th decade;  A 8-22,24-32,34 
After the 8th decade conflicting data exists regarding a further increase of IRs with increasing age B 
IRs of BCC in the oldest-old (patients aged 80 years and older) have increased over the past decades; A 21,24,28,30,35,36 
IRs of BCC in younger populations increased more compared to the oldest-old B 
IRs of BCC in the oldest-old are higher among men compared to women in most populations A 8-12,14,16,17-23,24-
29,31-33 
Nodular BCC is the most common subtype of BCC among the oldest-old B 71,72 
Most BCC are located within the head and neck region in the oldest-old B 72-74 
IRs of metastatic BCC do not increase with increasing age; B 86 
In metastatic BCC the mean age of onset of the primary tumor is lower compared with the general population 
of patients with BCC 
B 82-85 
Although death owing to BCC is very uncommon, mortality rates are higher for oldest-old patients compared 
with younger patients  
B 60-61 
Inconclusive data exists regarding increasing age and the risk to develop a subsequent BCC B 63-70 
No data regarding impact of BCC on quality of life in oldest-old patients  were found and inconclusive data 
regarding the relationship of age and impact of BCC on quality of life was found 
B 87-91 
 
Abbreviations: BCC, basal cell carcinoma; IRs, incidence rates; QoE, quality of evidence.  
a Quality of evidence: A, based on systematic review/meta-analysis of good quality cohort studies that can apply to most patients; B, based on systematic review/meta-analysis of 
lower quality cohort studies with inconsistent results that may vary depending on circumstances or patients or societal values; retrospective cohort studies; case-control study; C, 
based on consensus guidelines, usual practice, expert opinion, case series (levels of evidence for most individual studies in this review are described in Tables 1-6). 
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Supplemental Table S1  Search strategy and strings used in this systematic review  
 
Search strategy  
Databases searched: PubMed, Excerpta Medica Database (EMBASE), and Cochrane Library 
Period of time searched: Articles published up to July 18th, 2015 were included 
Key words used: 
“basal cell carcinoma” or “nonmelanoma skin cancer”, combined with each of the following: “epidemiology”, 
“incidence”, “prevalence”, “morbidity”, “mortality”, “elderly”, and “long-term care facility”. The combination of “skin” and 
“long-term care facility” was also added. Furthermore, all related synonyms found in the Medical Subject Headings 
(MeSH) database were used 
Limit(s): All search terms were limited to title and/or abstract 
Additional studies: References of all included articles were screened to identify supplementary relevant studies 
Search stringsa: 
Basal cell carcinoma combined with epidemiology, including synonyms/related terms: 
(((((((((((((((((((((basal cell carcinoma[Title/Abstract]) OR basal cell carcinomas[Title/Abstract]) OR BCC[Title/Abstract]) OR BCCs[Title/Abstract]) OR 
sBCC[Title/Abstract]) OR sBCCs[Title/Abstract]) OR nBCC[Title/Abstract]) OR nBCCs[Title/Abstract]) OR rodent ulcer[Title/Abstract]) OR rodent 
ulcers[Title/Abstract]) OR basalcell carcinoma[Title/Abstract]) OR basalcell carcinomas[Title/Abstract]) OR basal cell neoplasm[Title/Abstract]) 
OR basal cell neoplasms[Title/Abstract]) OR basal cell tumor[Title/Abstract]) OR basal cell tumour[Title/Abstract]) OR basal cell tumors 
[Title/Abstract]) OR basal cell tumours[Title/Abstract]) OR basalioma[Title/Abstract]) OR basaliomas[Title/Abstract])) AND ((((((((((( epidemiology 
[Title/Abstract]) OR epidemiological[Title/Abstract]) OR prevalence[Title/Abstract]) OR incidence[Title/Abstract]) OR frequency [Title/Abstract]) 
OR surveillance[Title/Abstract]) OR occurrence[Title/Abstract]) OR morbidity[Title/Abstract]) OR mortality[Title/Abstract]) OR survival[Title/ 
Abstract]) OR death rate[Title/Abstract]) 
Basal cell carcinoma combined with elderly, including synonyms: 
(((((((((((((((((((((basal cell carcinoma[Title/Abstract]) OR basal cell carcinomas[Title/Abstract]) OR BCC[Title/Abstract]) OR BCCs[Title/Abstract]) OR 
sBCC[Title/Abstract]) OR sBCCs[Title/Abstract]) OR nBCC[Title/Abstract]) OR nBCCs[Title/Abstract]) OR rodent ulcer[Title/Abstract])  
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Supplemental Table S1  Search strategy and strings used in this systematic review (continued) 
 
Search stringsa: 
Basal cell carcinoma combined with elderly, including synonyms (continued): 
OR rodent ulcers[Title/Abstract]) OR basalcell carcinoma[Title/Abstract]) OR basalcell carcinomas[Title/Abstract]) OR basal cell 
neoplasm[Title/Abstract]) OR basal cell neoplasms[Title/Abstract]) OR basal cell tumor[Title/Abstract]) OR basal cell tumour[Title/Abstract]) OR 
basal cell tumors[Title/Abstract]) OR basal cell tumours[Title/Abstract]) OR basalioma[Title/Abstract]) OR basaliomas[Title/Abstract])) AND 
(((((((((((((((elderly[Title/Abstract]) OR aged [Title/Abstract]) OR geriatric[Title/Abstract]) OR older population[Title/Abstract]) OR oldest 
[Title/Abstract]) OR sexagenarian[Title/Abstract]) OR sexagenarians[Title/Abstract]) OR septuagenarian[Title/Abstract]) OR septuagenarians 
[Title/Abstract]) OR octogenarian[Title/Abstract]) OR octogenarians[Title/Abstract]) OR nonagenarian[Title/Abstract]) OR nonagenarians 
[Title/Abstract]) OR centenarian[Title/Abstract]) OR centenarian [Title/Abstract]) 
Basal cell carcinoma combined with long-term care facility, including synonyms: 
(((((((((((((((((((((basal cell carcinoma[Title/Abstract]) OR basal cell carcinomas[Title/Abstract]) OR BCC[Title/Abstract]) OR BCCs[Title/Abstract]) OR 
sBCC[Title/Abstract]) OR sBCCs[Title/Abstract]) OR nBCC[Title/Abstract]) OR nBCCs[Title/Abstract]) OR rodent ulcer[Title/Abstract]) OR rodent 
ulcers[Title/Abstract]) OR basalcell carcinoma[Title/Abstract]) OR basalcell carcinomas[Title/Abstract]) OR basal cell neoplasm[Title/Abstract]) OR 
basal cell neoplasms[Title/Abstract]) OR basal cell tumor[Title/Abstract]) OR basal cell tumour[Title/Abstract]) OR basal cell tumors[Title/Abstract]) 
OR basal cell tumours[Title/Abstract]) OR basalioma[Title/Abstract]) OR basaliomas[Title/Abstract])) AND (((((((((((((((((((((((((((halfway house[Title/ 
Abstract]) OR halfway houses[Title/Abstract]) OR long-term care facility[Title/Abstract]) OR long-term care facilities[Title/Abstract]) OR longterm 
care facility[Title/Abstract]) OR longterm care facilities[Title/Abstract]) OR assisted living facility [Title/Abstract]) OR assisted living facilities 
[Title/Abstract]) OR residential care facility[Title/Abstract]) OR residential care facilities [Title/ Abstract]) OR nursing home[Title/Abstract]) OR 
nursing homes[Title/Abstract]) OR old age home[Title/Abstract]) OR old age homes [Title/ Abstract]) OR home for the aged[Title/Abstract]) OR 
homes for the aged[Title/Abstract]) OR retirement life care centre[Title/Abstract]) OR retirement life care centres[Title/Abstract]) OR retirement 
life care center[Title/Abstract]) OR retirement life care centers[Title/Abstract]) OR continuing care retirement center[Title/Abstract]) OR continuing 
care retirement centers[Title/Abstract]) OR continuing care retirement centre [Title/Abstract]) OR continuing care retirement 
centres[Title/Abstract]) OR housing for the elderly[Title/Abstract]) OR permanent health care institution[Title/Abstract]) 
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Supplemental Table S1  Search strategy and strings used in this systematic review (continued) 
 
Search stringsa: 
Nonmelanoma skin cancer combined with epidemiology, including synonyms/related terms: 
((((nonmelanoma[Title/Abstract]) OR non melanoma[Title/Abstract]) OR NMSC[Title/Abstract])) AND (((((((((((epidemiology[Title/Abstract]) OR 
epidemiological[Title/Abstract]) OR prevalence[Title/Abstract]) OR incidence[Title/Abstract]) OR frequency[Title/Abstract]) OR surveillance 
[Title/Abstract]) OR occurrence[Title/Abstract]) OR morbidity[Title/Abstract]) OR mortality[Title/Abstract]) OR survival[Title/Abstract]) OR death 
rate[Title/Abstract]) 
Nonmelanoma skin cancer combined with elderly, including synonyms: 
((((nonmelanoma[Title/Abstract]) OR non melanoma[Title/Abstract]) OR NMSC[Title/Abstract])) AND (((((((((((((((elderly[Title/Abstract]) OR 
aged[Title/Abstract]) OR geriatric[Title/Abstract]) OR older population[Title/Abstract]) OR oldest[Title/Abstract]) OR sexagenarian [Title/ 
Abstract]) OR sexagenarians[Title/Abstract]) OR septuagenarian[Title/Abstract]) OR septuagenarians[Title/Abstract]) OR octogenarian [Title/ 
Abstract]) OR octogenarians[Title/Abstract]) OR nonagenarian[Title/Abstract]) OR nonagenarians[Title/Abstract]) OR centenarian [Title/ 
Abstract]) OR centenarian[Title/Abstract]) 
Nonmelanoma skin cancer combined with long-term care facility, including synonyms: 
((((nonmelanoma[Title/Abstract]) OR non melanoma[Title/Abstract]) OR NMSC[Title/Abstract])) AND (((((((((((((((((((((((((((halfway house [Title/ 
Abstract]) OR halfway houses[Title/Abstract]) OR long-term care facility[Title/Abstract]) OR long-term care facilities[Title/Abstract]) OR longterm 
care facility[Title/Abstract]) OR longterm care facilities[Title/Abstract]) OR assisted living facility[Title/Abstract]) OR assisted living 
facilities[Title/Abstract]) OR residential care facility[Title/Abstract]) OR residential care facilities[Title/Abstract]) OR nursing home[Title/Abstract]) 
OR nursing homes[Title/Abstract]) OR old age home[Title/Abstract]) OR old age homes[Title/Abstract]) OR home for the aged[Title/Abstract]) 
OR homes for the aged[Title/Abstract]) OR retirement life care centre[Title/Abstract]) OR retirement life care centres[Title/Abstract]) OR 
retirement life care center[Title/Abstract]) OR retirement life care centers[Title/Abstract]) OR continuing care retirement center[Title/Abstract]) 
OR continuing care retirement centers[Title/Abstract]) OR continuing care retirement centre[Title/Abstract]) OR continuing care retirement 
centres[Title/Abstract]) OR housing for the elderly[Title/Abstract]) OR permanent health care institution[Title/Abstract]) OR permanent health 
care institutions[Title/Abstract]) 
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Supplemental Table S1  Search strategy and strings used in this systematic review (continued) 
 
Search stringsa: 
Skin combined with long-term care facility, including synonyms: 
(((((((skin[Title/Abstract]) OR cutaneous[Title/Abstract]) OR dermis[Title/Abstract]) OR epidermis[Title/Abstract]) OR dermal[Title/Abstract]) OR 
epidermal[Title/Abstract])) AND (((((((((((((((((((((((((((halfway house[Title/Abstract]) OR halfway houses[Title/Abstract]) OR long-term care facility 
[Title/Abstract]) OR long-term care facilities[Title/Abstract]) OR longterm care facility[Title/Abstract]) OR longterm care facilities[Title/Abstract]) 
OR assisted living facility[Title/Abstract]) OR assisted living facilities[Title/Abstract]) OR residential care facility[Title/Abstract]) OR residential 
care facilities[Title/Abstract]) OR nursing home[Title/Abstract]) OR nursing homes[Title/Abstract]) OR old age home[Title/Abstract]) OR old age 
homes[Title/Abstract]) OR home for the aged[Title/Abstract]) OR homes for the aged[Title/Abstract]) OR retirement life care centre 
[Title/Abstract]) OR retirement life care centres[Title/Abstract]) OR retirement life care center[Title/Abstract]) OR retirement life care centers 
[Title/Abstract]) OR continuing care retirement center[Title/Abstract]) OR continuing care retirement centers[Title/Abstract]) OR continuing 
care retirement centre[Title/Abstract]) OR continuing care retirement centres[Title/Abstract]) OR housing for the elderly[Title/Abstract]) OR 
permanent health care institution[Title/Abstract]) OR permanent health care institutions[Title/Abstract]) 
a The search strings used in PubMed are shown; comparable search strings were used for the other databases (only slightly adapted when necessary to fit in the model of the 
concerning database; complete search strings are available on request). 
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Abstract 
 
Background 
Balancing treatment decisions in frail older adults with nonmelanoma skin cancer (NMSC) 
can be challenging. Clinical practice guidelines (CPGs) could provide assistance. 
 
Objectives 
To collect and prioritize items related to frail older adults with NMSC for integration into 
CPGs and to assess the current extent of this integration. 
 
Methods 
Items were collected and prioritized by a multidisciplinary working group (29 members) 
using a modified Delphi procedure and a 5-point Likert scale. To assess current integration 
of these items in CPGs, a systematic review was subsequently performed by 2 independent 
reviewers using 5 medical databases (Pubmed, Excerpta Medica Database (EMBASE), the 
Cochrane Library, SUMsearch, and the Trip Database), websites of guideline developers/ 
databases, and (inter)national dermatological societies. 
 
Results 
Prioritization of a final 13-item list showed “limited life expectancy” (mean (SD), 4.5 (0.9)) and 
“treatment goals other than curation” (4.4 (0.7)) were most desired to be integrated in CPGs; 
both included in 6 (46%) of the CPGs found (n=13). Attention to “tumor characteristics” and 
“comorbidities” were included in CPGs most often (100% and 77%, respectively).  
 
Conclusion 
More attention to items related to frail older adults in NMSC CPGs is broadly desired, but 
CPG integration of these items is currently limited. More integration might stimulate more 
holistic, personalized and patient-centered care in frail older adults. 
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Introduction 
 
Frailty is described mostly as the vulnerability of an individual to poor homeostatic 
resolution after a stressor event, which is considered the result of a cumulative decline in 
the functioning of various physiological systems with increasing age.1 Medical decision 
making will be challenging within the growing population of frail older adults worldwide, 
especially as factors such as limited life expectancy, comorbidities, and logistical limitations 
(e.g. travel distance, availability of support by relatives) have to be taken into account.2 
Furthermore, guidance from clinical evidence is limited, as frail older adults are often 
excluded or under-represented in clinical trials.3-5  
 
A common dermatological condition among frail older adults in which these challenges are 
frequently faced is nonmelanoma skin cancer (NMSC).6-8 On the one hand, most NMSCs 
generally have a relatively low malignant potential compared to many other types of cancer. 
This might favor conservative management, especially in case of a limited life expectancy. On 
the other hand, NMSC can cause considerable morbidity (e.g. pain, secondary infection, or 
functional impairment) and, in the longer term, even mortality.9-11 Therefore, weighing 
potential benefits and risks of treatment together with preferences from patients and/or 
their families is essential, but not always easily performed.  
 
Clinical practice guidelines (CPGs) are defined as a set of general recommendations 
intended to optimize patient care, which assist healthcare providers in daily clinical 
practice.12 Obviously, it is not possible to include specific guideline recommendations for 
every possible situation in every individual patient. Therefore, it could be desirable and in 
the best interest of a patient to depart from a CPG in some circumstances. However, 
balancing the extensiveness of the content and the specificity of recommendations in a CPG 
with generally accepted or self-evident aspects of daily clinical practice might be a challenge.  
 
Various studies have shown the potential benefits of integration of certain topics, including 
healthcare structures, physician’s behavior, and patient outcomes in CPGs.13 Nevertheless, 
implementation and adherence to CPGs are often suboptimal and influenced by many 
factors like appropriate inclusion of the needs and preferences of all relevant professional 
groups, feasibility, and the flexibility to individualize recommendations.14-15 Previous studies 
have shown that guidance from CPGs in frail older adults is limited. Firstly, CPGs (together 
with most healthcare systems) often focus on curative care and pay little or no attention to 
other treatment goals, like palliation or preservation of function. Furthermore, CPGs often 
fail to address issues related to frail older adults and, therefore, provide little guidance in the 
care for this group of patients.16-20 
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In the present study, we aimed to collect items that are considered important in medical 
decision making in frail older adults with NMSC, and to prioritize them based on whether 
they should be integrated into NMSC CPGs. Additionally, we assessed how these items are 
included in the current NMSC CPGs worldwide and provide recommendations for the 
future. 
 
 
Materials and methods 
 
M U L T I D I S C I P L I N A R Y  W O R K I N G  G R O U P  F O R M A T I O N  
A multidisciplinary working group of Dutch experts was formed. Age, sex, years of 
experience, and healthcare setting were taken into account to ensure a well-balanced 
working group.21 An overview of the working group formation process and represented 
parties is given in Supplemental Table S1. 
 
I T E M  L I S T  C O M P O S I T I O N  A N D  P R I O R I T I Z A T I O N   
A conceptual list of 10 items influencing medical decision making in frail older adults with 
NMSC composed by the authors. This list was discussed and adapted by a condensed 
version of the multidisciplinary working group (including at least 1 expert per medical 
specialty), using a modified Delphi procedure to reach consensus.22 Consensus was defined 
as agreement to include an item by all condensed working group members. During the 
consensus procedure, 5 items were added to the list and 2 items were removed. 
Furthermore, 2 items were rephrased to enhance distinctness. Consensus was reached 
after two rounds, and 13 items were included on the final item list. In addition, to prioritize 
items for integration into CPGs, participants in the extended working group were asked to 
provide the items with a score using a 5-point Likert scale. A higher score indicates the item 
is more desired to be included in CPGs.  
 
S Y S T E M A T I C  R E V I E W  O F  L I T E R A T U R E  
A comprehensive review of literature was performed independently by 2 authors (SL and 
LvV) to identify CPGs concerning NMSC. An initial search was performed using PubMed, 
Excerpta Medica Database (EMBASE), and the Cochrane Library. In addition, websites of 
guideline developers/databases and (inter)national dermatological societies, as well as 
SUMsearch and the Trip Database, were searched for relevant guidelines not yet identified.  
An overview of the search strategy, selection criteria, and data sources used is presented in 
Supplemental Tables S2 and S3. This review was conducted and reported according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.23 
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G U I D E L I N E  A S S E S S M E N T  
Included CPGs were assessed for inclusion of each item from the developed item list (yes or 
no) and the place in the CPG (in recommendations, only in plain text, or not further 
specified). Furthermore, the overall quality and reporting of the CPGs were assessed using 
the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument, an 
internationally recognized and validated instrument to evaluate the quality of guidelines.24  
The AGREE II instrument consists of 23 items distributed over 6 domains. Every item is 
scored by a 7-point Likert-scale (from 1 = strongly disagree to 7 = strongly agree), after 
which domain scores could be calculated and presented as proportions, following the user 
manual (http://www.agreetrust.org). Guideline assessment was performed by 2 independent 
reviewers (SL and RB), both experienced in guideline appraisal. All available appendices and 
supplementary documents were included in the assessment.  
 
S T A T I S T I C S  
Statistics were reported following the Statistical Analyses and Methods in the Published 
Literature (SAMPL) guidelines.25 Categorical variables were expressed as numbers and 
percentages. Continuous variables were expressed as means and standard deviations (SD) 
or medians and ranges, dependent on the distribution of data. Representativeness of the 
working group members was tested by separately comparing the distribution in age, sex 
and healthcare setting for the members working in primary care (general practitioners and 
elderly care physicians) and secondary (or tertiary care) with the corresponding overall 
populations of physicians in the Netherlands.26-27 Data collection and analysis was 
performed using the Statistical Package for Social Sciences (SPSS) for Windows, version 22.0 
(IBM Corporation, Armonk, New York, United States). 
 
 
Results 
 
M U L T I D I S C I P L I N A R Y  W O R K I N G  G R O U P  C H A R A C T E R I S T I C S  
The condensed and extended working group, the former for composition and the latter for 
prioritization of the item list, consisted of 11 and 29 members, respectively. The working 
group characteristics are given in Table 1. A relatively large number of medical specialists in 
the working group works in academic hospitals as compared to the overall population of 
medical specialists (57% vs. 20%, respectively). 
 
P R I O R I T I Z A T I O N  O F  T H E  F I N A L  L I S T   
The final list of prioritized items to be integrated in CPGs is shown in Table 2. The mean 
overall items score (SD) was 3.9 (0.9). Highest scores were given to the items “limited life 
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expectancy” and “treatment goals other than curation”: 4.5 (0.9) and 4.4 (0.7), respectively. 
The lowest scores were given to the items “performance of skin self-examination” and “legal 
status / impaired capacity to give informed consent”: 3.3 (0.7) and 3.3 (0.9), respectively. No 
scores were missing. 
 
 
Table 1  Multidisciplinary working group characteristics (n=29) 
 
Characteristics Values 
Age, mean (SD), y 50.1 (7.4) 
Male sex, n (%) 18 (62)  
Discipline, n (%):  
Dermatologist 13 (45) 
Plastic surgeon, otorhinolaryngologist, oral and maxillofacial 
surgeon, radiation therapist, and geriatrician 
2 (7) each 
Elderly care physician 3 (10) 
General practitioner 3 (10) 
Experiencea, mean (SD), y 17.3 (7.0) 
Healthcare setting, n (%)b:   
General hospital 11 (38) 
Academic hospital 13 (45) 
Other 9 (31) 
 
Abbreviations: SD, standard deviation; y, years. a Residency years excluded; b Some working group  
members work in multiple healthcare settings. No missing data. 
 
 
G U I D E L I N E  S E A R C H  A N D  S E L E C T I O N  
The initial search for NMSC CPGs resulted in 6878 results, of which 3682 remained after 
removal of duplicates. After the additional search and screening by title and abstract, 37 full-
text articles were assessed for eligibility, and eventually 13 articles were included (28-40). 
Figure 1 shows the guideline selection process. 
 
G U I D E L I N E  A S S E S S M E N T  
Most guidelines are from Europe (n=11) and less than 5 years old (n=7). Squamous cell 
carcinoma CPGs were most often found (n=6), followed by basal cell carcinoma CPGs (n=5), 
and CPGs combining both (n=2). The median AGREE II overall score was 50% (range, 36% to 
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86%) and the median number of items included per guideline was 3 (23%; range, 1 to 9). 
The guideline characteristics, together with the AGREE II scores and the number of items 
included per guideline are summarized in Table 3.  
 
All of the individual items from the prioritized list were included in at least 1 guideline. Two 
items were included in the majority of the CPGs: tumor characteristics (n=13, 100%) and  
comorbidities (n=10, 77%). The 2 items with the highest prioritization scores (“limited life 
expectancy” and “treatment goals other than curation”) were each included in 6 (46%) CPGs. 
All other items were included less frequently. Most items were mentioned only in plain text 
(n=20, 49%), followed by recommendations (n=15, 31%), and “not further specified” (n=10, 
20%). A full overview of the individual items and their CPG inclusion is shown in Table 2. 
 
 
Figure 1  An overview of the guideline selection process in this systematic review on 
nonmelanoma skin cancer guidelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Pubmed, Excerpta Medica Database (EMBASE), and the Cochrane library; b Websites of guideline developers/ 
databases, (inter)national dermatological societies, SUMsearch, and the Trip Database. 
Records identified from initial literature 
searcha (n=6878) 
Records after removal of duplicates and 
screened by title/abstract (n=3683) 
Excluded, with reasons (n=24): 
no guideline (n=9), irrelevant (n=1), 
newer version available (n=7), other 
(n=7)  
Full-text articles assessed for eligibility 
(n=37) 
Studies included in synthesis 
(n=13) 
Records identified by additional 
screeningb (n=6) 
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Table 2  Items desired to be integrated into nonmelanoma skin cancer clinical practice guidelines related to medical decision making in frail older 
adults, prioritized by the multidisciplinary working group (n=13) 
 
Item Prioritization 
score, mean (SD) 
Included in 
CPG, n (%) 
Place in CPG, n (%) 
Recomm.a Plain texta NFSa 
Limited life expectancy 4.5 (0.9) 6 (46) 0  4 (67) 2 (33) 
Treatment goals other than curation 4.4 (0.7) 6 (46) 1 (17) 4 (67) 1 (17) 
Comorbidities 4.2 (0.7) 10 (77) 0  8 (80) 2 (20) 
Tumor characteristics 4.1 (0.8) 13 (100) 10 (77) 0  3 (23) 
Cognitive impairment 4.0 (0.7) 2 (15) 0  2 (100) 0  
Limited possibilities to visit hospital/clinic 4.0 (0.9) 4 (31) 2 (50) 1 (25) 1 (25) 
Option of follow-up by primary care physician 4.0 (0.9) 1 (8) 0  1 (100) 0  
Family involvement in medical decision making 3.9 (1.0) 1 (8) 0  1 (100) 0  
Functional impairment 3.9 (0.6) 1 (8) 0  1 (100) 0  
Treatment compliance 3.8 (0.9) 2 (16) 1 (50) 1 (50) 0  
Primary care physicians involvement in medical decision making 3.7 (1.0) 1 (8) 1 (100) 0  0  
Legal status / impaired capacity to give informed consent 3.3 (0.9) 1 (8) 0  1 (100) 0  
Performance of skin self-examination 3.3 (0.7) 1 (8) 0  0  1 (100) 
 
Abbreviations: CPG, clinical practice guideline; NFS, not further specified; Recomm, recommendations; SD, standard deviation. Higher scores indicate the item is more desired to be 
included in clinical practice guidelines; Values may not add up due to rounding. a items included in CPG-recommendations, only in plain text or not further specified 
1
7
4
 
C
h
a
p
te
r 
8
 
 Ta
b
le
 2
  I
te
m
s 
d
e
si
re
d
 t
o
 b
e
 i
n
te
g
ra
te
d
 i
n
to
 n
o
n
m
e
la
n
o
m
a
 s
ki
n
 c
a
n
ce
r 
cl
in
ic
a
l 
p
ra
ct
ic
e
 g
u
id
e
lin
e
s 
re
la
te
d
 t
o
 m
e
d
ic
a
l 
d
e
ci
si
o
n
 m
a
ki
n
g
 i
n
 f
ra
il 
o
ld
e
r 
a
d
u
lt
s,
 p
ri
o
ri
ti
ze
d
 b
y 
th
e
 m
u
lt
id
is
ci
p
lin
a
ry
 w
o
rk
in
g
 g
ro
u
p
 (
n
=
1
3
) 
 
It
e
m
 
P
ri
o
ri
ti
za
ti
o
n
 
sc
o
re
, 
m
e
a
n
 (
S
D
) 
In
cl
u
d
e
d
 i
n
 
C
P
G
, 
n
 (
%
) 
P
la
ce
 i
n
 C
P
G
, n
 (
%
) 
Re
co
m
m
.a  
Pl
ai
n 
te
xt
a  
N
FS
a  
Li
m
it
e
d
 li
fe
 e
xp
e
ct
a
n
cy
 
4
.5
 (
0
.9
) 
6
 (
4
6
) 
0
  
4
 (
6
7
) 
2
 (
3
3
) 
T
re
a
tm
e
n
t 
g
o
a
ls
 o
th
e
r 
th
a
n
 c
u
ra
ti
o
n
 
4
.4
 (
0
.7
) 
6
 (
4
6
) 
1
 (
1
7
) 
4
 (
6
7
) 
1
 (
1
7
) 
C
o
m
o
rb
id
it
ie
s 
4
.2
 (
0
.7
) 
1
0
 (
7
7
) 
0
  
8
 (
8
0
) 
2
 (
2
0
) 
T
u
m
o
r 
ch
a
ra
ct
e
ri
st
ic
s 
4
.1
 (
0
.8
) 
1
3
 (
1
0
0
) 
1
0
 (
7
7
) 
0
  
3
 (
2
3
) 
C
o
g
n
it
iv
e
 im
p
a
ir
m
e
n
t 
4
.0
 (
0
.7
) 
2
 (
1
5
) 
0
  
2
 (
1
0
0
) 
0
  
Li
m
it
e
d
 p
o
ss
ib
ili
ti
e
s 
to
 v
is
it
 h
o
sp
it
a
l/
cl
in
ic
 
4
.0
 (
0
.9
) 
4
 (
3
1
) 
2
 (
5
0
) 
1
 (
2
5
) 
1
 (
2
5
) 
O
p
ti
o
n
 o
f 
fo
llo
w
-u
p
 b
y 
p
ri
m
a
ry
 c
a
re
 p
h
ys
ic
ia
n
 
4
.0
 (
0
.9
) 
1
 (
8
) 
0
  
1
 (
1
0
0
) 
0
  
Fa
m
ily
 in
vo
lv
e
m
e
n
t 
in
 m
e
d
ic
a
l d
e
ci
si
o
n
 m
a
ki
n
g
 
3
.9
 (
1
.0
) 
1
 (
8
) 
0
  
1
 (
1
0
0
) 
0
  
Fu
n
ct
io
n
a
l i
m
p
a
ir
m
e
n
t 
3
.9
 (
0
.6
) 
1
 (
8
) 
0
  
1
 (
1
0
0
) 
0
  
T
re
a
tm
e
n
t 
co
m
p
lia
n
ce
 
3
.8
 (
0
.9
) 
2
 (
1
6
) 
1
 (
5
0
) 
1
 (
5
0
) 
0
  
P
ri
m
a
ry
 c
a
re
 p
h
ys
ic
ia
n
s 
in
vo
lv
e
m
e
n
t 
in
 m
e
d
ic
a
l d
e
ci
si
o
n
 m
a
ki
n
g
 
3
.7
 (
1
.0
) 
1
 (
8
) 
1
 (
1
0
0
) 
0
  
0
  
Le
g
a
l s
ta
tu
s 
/ 
im
p
a
ir
e
d
 c
a
p
a
ci
ty
 t
o
 g
iv
e
 in
fo
rm
e
d
 c
o
n
se
n
t 
3
.3
 (
0
.9
) 
1
 (
8
) 
0
  
1
 (
1
0
0
) 
0
  
P
e
rf
o
rm
a
n
ce
 o
f 
sk
in
 s
e
lf
-e
xa
m
in
a
ti
o
n
 
3
.3
 (
0
.7
) 
1
 (
8
) 
0
  
0
  
1
 (
1
0
0
) 
 Ab
br
ev
ia
tio
ns
: C
PG
, c
lin
ic
al
 p
ra
ct
ic
e 
gu
id
el
in
e;
 N
FS
, n
ot
 fu
rt
he
r 
sp
ec
ifi
ed
; R
ec
om
m
, r
ec
om
m
en
da
tio
ns
; S
D
, s
ta
nd
ar
d 
de
vi
at
io
n.
 H
ig
he
r 
sc
or
es
 in
di
ca
te
 th
e 
ite
m
 is
 m
or
e 
de
sir
ed
 to
 b
e 
in
cl
ud
ed
 in
 c
lin
ic
al
 p
ra
ct
ic
e 
gu
id
el
in
es
; V
al
ue
s 
m
ay
 n
ot
 a
dd
 u
p 
du
e 
to
 ro
un
di
ng
. a
 it
em
s 
in
cl
ud
ed
 in
 C
PG
-r
ec
om
m
en
da
tio
ns
, o
nl
y 
in
 p
la
in
 te
xt
 o
r n
ot
 fu
rt
he
r s
pe
ci
fie
d.
 
|
Nonmelanoma skin cancer guidelines in frail older adults 175 
 
Table 3  An overview of included guidelines and the results of the guideline assessment (n=13) 
 
First author, yeara Country 
or region 
Initiating 
organi-
zation(s) 
CPG 
topicb 
AGREE II Domain scores, %c AGREE II 
Overall 
score, % 
Items 
included in 
CPG, n (%)d 1 2 3 4 5 6 
Marks, 200828  Australia CCA, ACN Both 69 79 38 90 59 61 64 6 (46) 
Stratigos, 201529 Europe EDF, EADO, 
EORTC  
SCC 64 38 49 60 18 68 50 4 (31) 
Trakatelli, 201230 Europe EDF BCC 48 31 31 71 27 68 43 2 (15) 
Bonerandi,200931 France SFD SCC 88 81 77 93 45 82 86 9 (69) 
Dandurand, 200432 France SFD, ANAES BCC 76 57 41 74 39 14 50 3 (23) 
Breuningen, 201233 Germany DKG, DDG SCC 31 36 26 71 21 61 36 2 (15) 
Hauschild, 201234 Germany DKG , DDG BCC 31 36 24 71 21 61 36 4 (31) 
Kelleners, 201435 NL NVDV BCC 88 76 88 90 54 64 86 5 (38) 
Krekels, 201036 NL NVDV SCC 90 83 80 88 38 39 79 2 (15) 
Proby, 201437 Scotland SIGN SCC 98 83 79 88 95 75 86 3 (23) 
Motley, 200938 UK BAD SCC 71 33 30 60 41 14 43 3 (23) 
Telfer, 200839 UK BAD BCC 60 36 34 71 43 43 50 4 (31) 
Miller, 201240 US NCCN Both 57 45 25 69 38 50 43 1 (8) 
Median 67 55 48 77 41 54 50 3 
Range 31-98 31-83 24-88 60-93 18-95 14-82 36-86 1-9 
 
Abbreviations: ACN, Australian Cancer Network; AGREE II, Appraisal of Guidelines for Research and Evaluation II instrument; ANAES, French National Agency for Accreditation and 
Evaluation in Healthcare; BAD, British Association of Dermatologists; BCC, basal cell carcinoma; CCA, Cancer Council Australia; CPG, clinical practice guideline; DDG, German Society 
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of Dermatology; DKG, German Cancer Society; EADO, European Association of Dermato-Oncology; EDF, European Dermatology Forum; EORTC, European Organization for Research 
and Treatment of Cancer;NCCN, National Comprehensive Cancer Network; NL, the Netherlands; NVDV, Dutch Dermatological and Venereological Society; SFD, French Dermatology 
Society; SIGN, Scottish Intercollegiate Guidelines Network; SCC, squamous cell carcinoma; UK, United Kingdom; US, United States.  
a Year of authorization; b BCC, SCC, or both; c AGREE II Domains include (1) scope and purpose, (2) stakeholder involvement, (3) rigour of development, (4) clarity of presentation, (5) 
applicability, and (6) editorial independence; d Items related to frail older adults in relation to nonmelanoma skin cancer care.  
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Discussion 
 
In this study we collected items considered important in medical decision making in frail 
older adults with NMSC and prioritized them based on whether they should be integrated 
into NMSC CPGs. It was shown that many items were desired to be integrated in NMSC CPG, 
but currently the overall CPG integration is limited.  
 
The importance of frailty among older adult patients with cancer and integration of 
appropriate considerations into CPGs is increasingly acknowledged. Multiple organizations 
and taskforces have published position papers and guidelines on this topic.41-43 However, in 
agreement with this study, previous studies in various fields of medicine showed that 
attention to frailty-related items like comorbidity and treatment goals other than curation in 
CPGs is still limited.16-20,44-45  
 
The items from this study show a high level of agreement with existing literature on 
important domains in geriatric oncology.43,46-47 The expert panel in geriatric oncology in the 
study from O’Donovan et al. rated functional status, followed by comorbidities and cognition 
as the most important domains influencing treatment decisions, which were also included in 
this study although differently prioritized.47 On the other hand, other domains like mood 
and nutritional status were not included in this study. Although most of these domains were 
initially discussed in the working group, they were not included eventually because they 
were considered of limited additional relevance in the context of treatment of NMSC.  
 
Of course, the items within this study do not apply solely to the population of frail older 
adults and should be integrated in medical decision making in every patient. However, we 
specifically focused on frail older adults because in our experience medical decision making 
is more frequently influenced by the mentioned items in this population, compared to the 
younger, less frail and often less dependent population.  
 
Based on the outcomes of this study we suggest to include at least the following items in a 
CPG on NMSC: (1) limited life expectancy, (2) treatment goals other than curation, (3) 
comorbidities, and (4) tumor characteristics. These items could be integrated in CPG in 
several ways, e.g. in a dedicated section on general considerations or implementation of the 
CPG in daily practice or in the discussion of each individual recommendation. The items 
should be clearly described and easily identifiable. 
 
The other items could certainly be of added value, but we think these should be weighed in 
relation to the objectives and health questions covered by the guideline (e.g. specific focus 
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on prevention, one treatment option), the target population, the target users of the CPG 
(e.g. dermatologists, general practitioners, multiple disciplines), and the characteristics of the 
healthcare system(s) in which the guideline will be applied (e.g. the existence and role of 
general practitioners).  
 
Furthermore, we think that participation of a geriatrician and/or elderly care physician, as 
well as involvement of patients, in the guideline development process will assist in providing 
proper attention to frail older adults.  
 
Integration of frailty-related items within CPGs might stimulate a more holistic, personalized, 
and patient-centered care instead of the more tumor-centered care which seems to have 
become the current standard. Also, integration of more frailty-related items in CPGs might 
lead physicians to feel more empowered to deviate from regular protocols in the best 
interest of a patient, especially since CPGs are more and more used as quality indicators 
and performance incentives by health policy makers.48 
 
Nevertheless, we acknowledge that integration of frailty-related items in CPGs does not 
necessarily mean a change in daily clinical practice and/or patient outcomes. Therefore, 
attention to other factors which could lead to the mentioned change of perspective in 
healthcare (e.g. education of healthcare providers, evaluation and adaptation of current 
healthcare systems, multidisciplinary approaches, usage of screening instruments on frailty 
etc.) remains important as well.  
 
Also, we would like to emphasize the importance of paying enough attention to patient 
preferences and shared-decision-making in busy daily dermatological practice. This is closely 
related to several items collected in this study, like cognitive impairment and an impaired 
capacity to give informed consent. Cognitive impairment is typically defined as the loss of 
one or more cognitive functions (e.g. memory or problem solving), which could be seen as a 
continuum ranging from mild (e.g. mild cognitive impairment) to severe (e.g. end-stage 
dementia).49 It might be difficult to estimate a patient’s cognitive functioning and the ability 
to provide informed consent. Therefore, we think in case of doubt the threshold to consult 
close relatives or other healthcare providers related to the patient should be low.  
 
The recognition of frailty in daily dermatological practice can be challenging, and screening 
tools to detect frailty and assist in medical decision making might be helpful. An increasing 
body of literature is available on detecting frailty in oncology by geriatric assessment (GA) 
and related screening tools.50 The goals of GA is to determine the medical, psychosocial and 
functional capabilities of an older adult patient to compose an integrated treatment 
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plan.43,51 GA can assist in identifying frailty, help making tailored treatment decisions, and 
might optimize patient outcomes.43,49,50  
 
Several methods are described to perform GA, ranging from multidisciplinary but time-
consuming comprehensive geriatric assessment (CGA) to less extensive, derivative screening 
methods like the Vulnerable Elders Survey-13 (VES-13), Geriatric 8 (G8), or Groningen Frailty 
Index (GFI).43,46 However, no studies on NMSC were found and extrapolation of available 
data from studies on other types of cancer seems limited by factors such as the relatively 
low malignant natural course of NMSC and the generally less intense and less complex 
treatment regimes with little adverse events compared  to many other types of cancer. Still, 
the general principles and goals of GA and frailty screening are universal and could be 
useful in the field of NMSC. Future research should focus on the potential effects and added 
value of GA and derivative screening tools in frail older adults with NMSC. 
 
The results and recommendations in this study could be of interest to CPG development in 
general, as most items are not restricted to NMSC. 
 
L I M I T A T I O N S  
Despite the thorough conceptualization and discussion of the different items within the 
working group, some overlap and potential misinterpretation could have occurred. The 
study was performed in the Netherlands including Dutch physicians, which should be kept 
in mind when generalizing the results. No patients were included in the working group. We 
acknowledge the importance of including patient preferences and shared decision making, 
and we would like to suggest future research should focus on this in more detail. The 
working group formed for this study included a relatively large number of medical specialists 
working in academic medicine. This could be explained by the large number of medical 
specialists from academic hospitals directly participating in the activities of medical societies 
(for instance national guideline committees) and who were therefore delegated to the 
working group in this study. However, comparison of the working group members with the 
overall population of physicians showed no important differences considering age and 
gender for both medical specialists and primary care physicians, indicating an appropriate 
representativeness regarding these characteristics. Furthermore, it may be that assessed 
CPGs received low scores on item inclusion despite of the inclusion of frailty-related content, 
when this content could not be classified into the assessed items on the list. Nonetheless, 
neither of the reviewers noticed any important (mis)classification bias.  
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Conclusion 
 
More attention for items related to frail older adults in NMSC CPGs is broadly desired and 
integration of these items into current CPGs is limited. More integration might stimulate a 
more holistic, personalized and patient-centered care. 
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Supplemental Table S1  An overview of represented parties included in a working group 
considering nonmelanoma skin cancer care in frail older adults 
 
Working group formation: 
A multidisciplinary working group of experts was formed consisting of representatives from 
several medical specialities (as shown below). Age, gender, years of experience and 
healthcare setting were taken into account to ensure a well-balanced working group. All 
Dutch medical societies related to the mentioned medical specialties were asked to delegate 
a representative with special affinity regarding nonmelanoma skin cancer and/or frail older 
adults. Moreover, representatives of the national dermato-oncology working group, the 
national guideline committees (in both primary and secondary care), and a national network 
of dermatologists with special interest in geriatric dermatology were also included. Finally, the 
working group was completed and further balanced with members from several regional 
healthcare settings. 
Medical specialties included: Representation from: 
Dermatology Dutch Dermatological and Venereological Societya and 
national network of dermatologists with special interest 
in geriatric dermatology 
Plastic surgery Dutch Society for Plastic Surgery 
Otorhinolaryngology Dutch Society of Otorhinolaryngology and Head & Neck 
Surgery 
Oral and maxillofacial surgery Dutch Society of Oral and Maxillofacial Surgery 
Radiation therapy Dutch Society of Radiotherapy and Oncology 
Geriatric medicine Dutch Geriatric Society 
Elderly care (nursing home) 
medicine 
Dutch Association of Elderly Care Physicians and Social 
Geriatricians 
General practitioner care Dutch College of General Practitionsb 
 
a Including the national dermato-oncology working group and national guideline committees (basal cell carcinoma 
and squamous cell carcinoma) and; b Including national guideline committee (nonmelanoma skin cancer). The working 
group was completed and balanced with members from several regional healthcare settings. 
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Supplemental Table S2  An overview of the databases and websites searched in this systematic 
review on nonmelanoma skin cancer guidelines 
 
Medical search engines searched: 
 Pubmed (http://www.ncbi.nlm.nih.gov/pubmed) 
 EMBASE (Excerpta Medica Database) (http://ospguides.ovid.com) 
 Cochrane Library (http://www.cochranelibrary.com) 
 SUMsearch (http://sumsearch.org) 
 Trip Database (https://www.tripdatabase.com)  
Guideline developers/databases searched: 
 Guidelines International Network (http://www.g-i-n.net) 
 National Guidelines Clearinghouse / Agency for Healthcare Research and Quality 
(http://guideline.gov and http://www.ahrq.gov) 
 Ärztliches Zentrum für Qualität in der Medizin (http://www.aezq.de/) 
 National Institute for Clinical Excellence (https://www.nice.org.uk/) 
 New Zealand Guidelines Group (http://www.health.govt.nz) 
 Scottish Intercollegiate Guidelines Network (http://www.sign.ac.uk) 
 Dutch Association of Comprehensive Cancer Centers (http://www.oncoline.nl) 
 Kwaliteitskoepel Medisch Specialisten (http://www.kwaliteitskoepel.nl)   
 Dutch College of General Practitioners (http://www.nhg.artsennet.nl) 
(Inter)national dermatological societies searched: 
 American Academy of Dermatology (https://www.aad.org) 
 Australasian College of Dermatologists (https://www.dermcoll.edu.au) 
 British Association of Dermatologists (http://www.bad.org.uk) 
 Canadian Dermatology Association (http://www.nzdsi.org) 
 Deutsche Dermatologische Gesellschaft (http://www.derma.de) 
 Dutch Dermatological and Venereological Society (http://www.huidarts.info) 
 European Dermatology Forum (http://www.euroderm.org)   
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Supplemental Table S3  Search strategy and selection criteria used in this systematic review on 
nonmelanoma skin cancer guidelines  
 
Key word selection and search limitations: 
The key words (and synonyms) “basal cell carcinoma, “cutaneous squamous cell carcinoma”, 
or “nonmelanoma skin cancer”, combined with “guideline” (both as keyword and separately 
as limitation) were used. All related synonyms found in the Medical Subject Headings 
(MeSH) database were also used. All search terms were limited to title and/or abstract. 
Complete search strategies are shown below: 
Search strings: 
“Basal cell carcinoma “combined with “guidelines”, including synonyms/related termsa: 
(((((((((((((((((((((basal cell carcinoma[Title/Abstract]) OR basal cell carcinomas 
[Title/Abstract]) OR BCC[Title/Abstract]) OR BCCs[Title/Abstract]) OR sBCC[Title/Abstract]) 
OR sBCCs[Title/Abstract]) OR nBCC[Title/Abstract]) OR nBCCs[Title/Abstract]) OR rodent 
ulcer[Title/Abstract]) OR rodent ulcers[Title/Abstract]) OR basalcell carcinoma [Title/ 
Abstract]) OR basalcell carcinomas[Title/Abstract]) OR basal cell neoplasm[Title/ 
Abstract]) OR basal cell neoplasms[Title/Abstract]) OR basal cell tumor[Title/Abstract]) OR 
basal cell tumour[Title/Abstract]) OR basal cell tumors[Title/Abstract]) OR basal cell 
tumours [Title/Abstract]) OR basalioma[Title/Abstract]) OR basaliomas[Title/Abstract])) 
AND ((((((((guideline[Title/ Abstract]) OR guidelines[Title/Abstract]) OR recommendation 
[Title/Abstract]) OR recommendations[Title/Abstract]) OR protocol[Title/Abstract]) OR 
protocols [Title/Abstract]) OR standard[Title/Abstract]) OR standards[Title/Abstract]); with 
and with-out “guidelines” as limitation 
“Cutaneous squamous cell carcinoma” combined with “guidelines”, including synonymsa: 
((((((((skin[Title/Abstract]) OR cutaneous[Title/Abstract]) OR dermis[Title/Abstract]) OR 
epidermis[Title/Abstract]) OR dermal[Title/Abstract]) OR epidermal[Title/Abstract])) AND 
((((((((((((((((((squamous cell carcinoma[Title/Abstract]) OR squamous cell carcinomas 
[Title/Abstract]) OR SCC[Title/Abstract]) OR SCCs[Title/Abstract]) OR SqCC[Title/Abstract]) 
OR SqCCs[Title/Abstract]) OR squamouscell carcinoma[Title/Abstract]) OR squamouscell 
carcinomas[Title/Abstract]) OR squamous cell neoplasm[Title/Abstract]) OR squamous 
cell neoplasms[Title/Abstract]) OR squamous cell tumor[Title/Abstract]) OR squamous 
cell tumour[Title/Abstract]) OR squamous cell tumors[Title/Abstract]) OR squamous cell 
tumours[Title/Abstract]) OR planocellular carcinoma[Title/Abstract]) OR planocellular 
carcinomas[Title/Abstract]) OR epidermoid carcinoma[Title/Abstract]) OR epidermoid 
carcinomas[Title/Abstract])) AND ((((((((guideline[Title/Abstract]) OR guidelines[Title/ 
Abstract]) OR recommendation[Title/Abstract]) OR recommendations[Title/Abstract]) OR 
protocol[Title/Abstract]) OR protocols[Title/Abstract]) OR standard[Title/Abstract]) OR 
standards[Title/Abstract]); with and without “guidelines” as limitation 
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Supplemental Table S3  Search strategy and selection criteria used in this systematic review on 
nonmelanoma skin cancer guidelines  
 
Search strings: 
“Nonmelanoma skin cancer” combined with “guidelines”, including synonymsa: 
((((nonmelanoma[Title/Abstract]) OR non melanoma[Title/Abstract]) OR NMSC[Title/ 
Abstract])) AND ((((((((guideline[Title/Abstract]) OR guidelines[Title/Abstract]) OR recom-
mendation[Title/Abstract]) OR recommendations[Title/Abstract]) OR protocol[Title/ 
Abstract]) OR protocols[Title/Abstract]) OR standard[Title/Abstract]) OR standards[Title/ 
Abstract]); with and without “guidelines” as limitation 
Article selection criteria: 
Title, abstract, full-text screenings were consecutively and independently performed by two 
authors (SL and LvV). Relevant articles published up to 15-05-2015 were included. When 
full-text articles were not available online, the Dutch Central Catalogue (PiCarta) and/or the 
first author was contacted to obtain the article. Exclusion criteria were: full-text not 
available, non-English/Dutch/German publications, and guidelines written on one 
therapeutic option (for instance exclusively on photodynamic therapy). Both guidelines 
regarding only one type of NMSC (basal cell carcinoma or squamous cell carcinoma) as well 
as guidelines regarding NMSC in general were included. Only the most recent version of 
each guideline was included. Inconsistencies between the two reviewers were discussed 
until consensus could be reached. In case no consensus could be reached a third reviewer 
(MG) was involved. 
 
a Pubmed version; comparable strategies were used in other databases.  
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General discussion and future perspectives 
 
The aims of the studies presented in this thesis were to obtain insights in the current need 
for, provision of, and quality of general dermatologic care among nursing home patients 
(Part A of this thesis), and to study current skin cancer care among older adults and provide 
guidance in medical-decision making (Part B of this thesis). In this chapter the research 
questions related to these aims, as formulated in Chapter 1, will be answered and 
discussed. In addition, future perspectives will be provided and integrated in this discussion.  
 
D E R M A T O L O G I C  C A R E  I N  I N S T I T U T I O N A L I Z E D  O L D E R  A D U L T S  
To obtain insights in the current need for, provision of, and quality of general dermatologic 
care among nursing home patients, the following research questions were answered in part 
A of this thesis and will be discussed below: 
 
(1) What is the current need for and provision of dermatologic nursing home care 
according to nursing home physicians (NHPs) in the Netherlands? (Chapter 2) 
 
(2) What is the current role of Dutch dermatologists in dermatologic care provision in 
nursing homes? (Chapter 3) 
 
(3) What are the reasons and barriers for dermatologist consultations in nursing 
homes? (Chapter 3) 
 
(4) How could we improve dermatologic care for nursing home patients? (Chapters 2 
and 4) 
 
In Chapters 2 and 3 the current status of dermatologic care among Dutch nursing homes is 
described from the perspective of Dutch NHPs and dermatologists respectively. In addition, 
recommendations for improvement of dermatologic care among nursing home patients are 
described in Chapters 2 and 4. 
 
It was found that NHPs are frequently confronted with skin conditions in their patients. The 
skin conditions NHPs are most frequently confronted with are (pressure) ulcers, eczema, 
fungal and bacterial infections, pruritus sine material, and skin tumors, which is largely in 
concordance with previous studies.1  
 
Availability of diagnostic and treatment options in nursing homes 
Although most conditions are initially diagnosed and treated by NHPs themselves, a lack of 
availability and experience of NHPs limits the diagnostic and treatment options. This 
limitation was highlighted by NPHs as one of the most important topics to improve 
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dermatologic care within nursing homes (Chapter 2). Examples of diagnostic and treatment 
options for which this especially seems to be the case are dermoscopy, punch biopsy, most 
non-pharmacological treatment options (cryotherapy, curettage, and excision) and some 
pharmacological treatment options (e.g. topical calcineurine inhibitors, topical imiquimod).  
 
Obviously, availability and experience are highly connected to each other. For example, on 
the one hand, a physician lacking the experience to take a punch biopsy will be less prone to 
arrange the logistical possibility to be able to perform this, compared to a more experienced 
physician. On the other hand, physicians working in a nursing home in which the logistics 
are available to perform punch biopsies will probably be more prone to do so.  
 
Availability of diagnostic and treatment options is presumably strongly influenced by the 
balance between the demand and costs. For instance, the costs related to the purchase and 
maintenance of liquid nitrogen to perform cryotherapy (typically including a barrel and 
related materials, but also a maintenance contract with a provider) might outweigh the 
benefits in case of a low demand and/or usage of this treatment option. However, a 
compromise might be made purchasing a portable dimethyl ether propane-based 
cryotherapy system (e.g. Histofreezer® or Verruca-freeze®). Although the efficacy of these 
systems may be inferior to a classic liquid nitrogen system, it provides an opportunity to 
start gaining experience with cryotherapy.2-4 Consequently, the demand for cryotherapy may 
thereby increase and create a situation where the purchase of a classic liquid nitrogen 
system might become cost-effective after all. 
 
Another example illustrating the balance between demand and costs is the punch biopsy. 
To create the logistic possibility to perform punch biopsies materials have to be purchased, 
which is easily organized for a reasonable price. However, setting up an arrangement with a 
pathology laboratory and the related costs for histopathological analysis might be a greater 
threshold in daily practice. This is probably largely explained by the funding system of 
healthcare costs in nursing homes.  
 
Nursing home care is provided under the Long-term Care Act (Dutch: Wet langdurige zorg).5 
This includes an integral budget for all costs related to chronic institutionalized care, 
including meals, assistance in daily living activities, daycare, nursing, medical care provided 
by the NHP etc. The latter includes NHP-initiated costs related to diagnosis and treatment of 
conditions. For example, costs related to a punch biopsy performed by a NHP will be paid 
from this integral budget and therefore influences the other expenses covered by this 
integral budget. In contrast, care provided by a dermatologist is provided under the Health 
Insurance Act (Dutch: Zorgverzekeringswet),5 which is separately arranged and does not 
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directly affect the integral budget provided under the Long-term Care Act. Therefore, a 
punch biopsy performed by a dermatologist is separately financed and will not affect the 
integral nursing home budget. 
 
The above-mentioned funding system probably leads to a higher threshold for NHPs to 
perform certain diagnostic and treatment procedures themselves. An example to illustrate 
this financial friction as once mentioned by a colleague (a NHP): “Although I have the logistical 
possibility and skills to perform a punch biopsy, I still refer mr. Jansen to a dermatology outpatient 
clinic for this, simply because multiple of his nursing home neighbors won’t be able to attend their 
weekly craft hour when I perform the biopsy myself.” 
 
Medical specialist care (including care provided by a dermatologist) should be accessible for 
everybody after adequate referral. This should be driven by a medical demand and not by a 
financial one. In times where substitution of care from medical specialists to primary care 
physicians (including NHPs) is high on the (political) agenda, more attention should be paid 
to the nursing home settings (this will be discussed in more detail later). Therefore, 
reconsideration of the current funding system by health policy makers should be given 
priority. 
 
The experience of nursing home physicians in diagnosing and treating skin conditions 
As mentioned, next to the availability of diagnostic and treatment options, experience is 
considered a key element as well (Chapter 2). Experience can be obtained by education in 
the first place. Several forms of education might contribute to this in varying degrees and on 
different perspectives. Basic education during medical school or in the form of continuing 
medical education might create awareness and basic knowledge and skills regarding 
diagnostic and treatment options in common skin conditions. On the other hand, other 
more interactive forms of education might contribute to the specific development of 
technical skills in a higher extent (e.g. interactive workshops, bed-side teaching, 
accompanying a dermatologist at the outpatient clinic).6-8 
 
Although obtaining knowledge and technical skills is important, using them in daily practice 
on a regular basis is essential to further develop and maintain them. For example, 
dermoscopy is a very useful diagnostic tool in many skin conditions when adapted by a 
properly trained physician. However, dermoscopy performed by untrained physicians does 
not necessarily improve diagnostic accuracy and might even result in misdiagnosis and  
treatment delay.9-12 
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The ability to perform diagnostic and treatment skills on a regular basis obviously relates to 
the demand for certain diagnostic and treatment procedures in daily practice. Therefore, it 
may be helpful to train a restricted number of NHPs with a special interest in dermatology 
(for instance one or two NHP(s) per nursing home organization, who could be consulted by 
colleagues when necessary) to maximize the development and maintenance of skills. 
 
Dermatologist consultation 
Although diagnosis and treatment of various skin conditions is frequently performed by 
NHPs, the demand for dermatologist consultation remains high. As shown in Chapters 2 
and 3, cutaneous (pre)malignancy is by far the most common reason for dermatologist 
consultation. This was additionally studied in more detail, as described in Chapter 5 (Part B 
of this thesis). It was shown that several methods of dermatologist consultation are used, 
ranging from outpatient clinic consultation, to nursing home consultations by 
dermatologists, and consultation by phone or using teledermatology. Both NHPs and 
dermatologists mentioned two forms of dermatologist consultation as important topics to 
improve dermatologic care in nursing homes, as presented in Chapters 2 and 4:  
(1) to make more and better use of teledermatology, and (2) more live consultation of 
dermatologists in nursing homes. Both of these consultation forms are discussed in more 
detail below. 
 
Teledermatology 
The usage of teledermatology, a form of digital consultation of a dermatologist through a 
secured internet connection, is limited in Dutch nursing homes. Only 31.6% of the NHPs 
have ever used teledermatology, while it is estimated that 60-70% of the Dutch general 
practitioners currently uses teledermatology.1,13,14 Telemedicine in nursing homes has 
several potential benefits, since it may improve nursing home care and it might replace 
outpatient clinic visits, which often are more difficult to organize. Furthermore, the 
acceptance of telemedicine by patients, families, and caregivers was generally shown to be 
high.15-22 
 
Previous research has addressed several potential explanations for the discrepancy 
between the relatively low usage of teledermatology by NHPs on the one hand, while more 
usage of teledermatology is suggested as a major topic for improvement of nursing home 
care on the other hand.1 The followings reasons were mentioned most frequently: 
unavailability of ICT facilities (23%), unavailability of a camera or not knowing how to make 
proper photos (23%), unfamiliarity with teledermatology (20%), and financial reasons (17%).  
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Better education regarding teledermatology for NHPs is expected to help overcome most of 
the barriers mentioned. Through education, NHPs might become more familiar with the 
concept of teledermatology, the possibilities, and how to organize this in daily practice. 
Moreover, potential false assumptions regarding teledermatology could be discussed. For 
example, it was shown that NHPs often assume that various ICT facilities and/or an 
expensive, high-tech camera are needed for a teledermatology consultation, while a simple 
smartphone with teledermatology-app usually will suffice.1  
 
Next, as previously mentioned, the funding system seems another important limiting factor 
for teledermatology usage in daily nursing home practice. NHPs might be more inclined to 
refer patients to a dermatologist for live consultation instead of using teledermatology, since 
related costs of diagnostic procedures and treatment after live dermatologist consultation 
don’t have to be paid from the integral budget provided under the Long-term Care Act (but 
by separate funding though the Health Insurance Act instead).  
 
Furthermore, for general practitioners a special financial construction was started in 2006 to 
prevent unnecessary referrals to medical specialists and keep as much of the care as 
possible within the primary care system (the substitution effect). This special financial 
construction, also called “Modernisering & Innovatie” (M&I), arranges (extra) financial 
compensation for a predefined set of diagnostic or treatment procedures including 
teledermatology and small surgical procedures, when performed by a general practitioner. 
Unfortunately, this construction does not apply to NHPs. It is advised to arrange a 
comparable financial construction for NHPs to  optimize care, stimulate the usage of 
teledermatology, and prevent unnecessary dermatologist referrals.23  
 
As described in the introduction of this thesis, it should be mentioned that teledermatology 
has a lot of advantages, but it also has some important limitations. The most important 
limitation in the nursing home population probably is the low diagnostic accuracy in case of 
a solitary (pigmented) lesion, which is the most frequently mentioned reason for a NHP to 
consult a dermatologist. Another important limitation is the restricted availability of 
information regarding the context of a patient when using teledermatology, which might 
limit a holistic care approach. Therefore, availability of other forms of consultation, especially 
live consultation, remains essential. Teledermatology has a lot to offer in the nursing home 
population, but will never be able to fully replace live dermatologist consultation. 
 
Live consultation 
As described in Chapter 3, only one third (30.0%) of the Dutch dermatologists has ever 
visited a patient within a nursing home for consultation. Meanwhile, over two thirds (68.5%) 
|
198 Chapter 9 
 
of the Dutch dermatologists and dermatology residents are willing to visit patients on 
location in a nursing home. Furthermore, more live consultation of dermatologists in 
nursing homes was suggested as one of the most important topics to improve dermatologic 
care in nursing home patients by both NHPs and dermatologists (Chapters 2 and 4). This 
high demand for a nursing home consultant service by medical specialists seems in 
accordance with the limited amount of previous research available from Germany and the 
United States in several fields of medicine.24-26 
 
Examples of advantages of live consultation of a dermatologist in a nursing home are:  
 
(1) Nursing home patients do not have to attend the outpatient clinic, which 
might for instance prevent a lot of stress and discomfort;  
(2) Relatives do not necessarily have to take off from work to attend to the 
dermatologist consultation; 
(3) It might be easier for a dermatologist visiting a nursing home to obtain 
contextual patient information and include this in management 
recommendations; 
(4) It might be easier for a dermatologist to provide more feasible and better 
implementable management recommendations after a nursing home visit 
(e.g. because the availability of local wound care products becomes more 
clear); 
(5) It might enhance proper instruction of the nursing home staff and might 
thereby stimulate treatment compliance; 
(6) Live consultation of a dermatologist might have an important educational 
value for nursing home staff (bed-side teaching). 
 
In Chapter 3 barriers to perform nursing home visits were described as stated by 
dermatologists. The most important barriers mentioned were a lack of time and indistinct 
and/or inadequate financial compensation. Experience from daily practice shows nursing 
home consultations take a relatively large amount of time compared to consultations in the 
outpatient clinic and therefore usually generate a relative loss of income when planned 
instead of regular outpatient clinic consultations. Therefore, a lot of dermatologists plan 
nursing home visits alongside of their regular outpatient clinic consultations (e.g. during 
administration time or a day off).  
 
Several tips and tricks may improve efficacy of nursing home consultations, both in terms of 
time and related costs:  
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(1) Clustering patients: examining multiple patients per single nursing home visit 
enhances efficiency of a nursing home visit and will reduce relative travel and 
preparation time. The past couple of years a trend was seen of scaling down 
(larger) nursing homes by replacing larger locations for smaller, more spread 
out nursing homes. These trends might interfere with the possibility to cluster 
patients during a nursing home visit.  
(2) Using predefined dates and time slots: a smoothly running and effective nursing 
home visit might be enhanced by clear agreements on dates and time slots of 
nursing home consultations. This will often prevent unnecessary waiting times 
for the dermatologist, nursing home staff and patients. Furthermore, this 
might make it easier for relatives of a patient to attend the consultation if 
desired.  
(3) Centralization: using one room in the nursing home for consultations and 
letting patients come to this room when possible -instead of walking from 
patient to patient- might further optimize efficiency of a nursing home visit. 
Obviously, this may not be feasible in some cases (e.g. bedridden patients). 
(4) Optimizing patient referral: to be able to perform effective nursing home 
consultations, NHPs should include all essential information needed in their 
patient referrals, especially when NHPs are not attending the consultations 
themselves. Examples of information which can be essential are a detailed 
and explicit reason for referral, information on the patient’s general health 
status, the patient’s legal status, functional impairment, expectations, 
management goals, and (end-of-life) treatment limitations. Furthermore, 
receiving the patient referrals (including all essential information) prior to the 
nursing home visit will usually improve a proper preparation. 
(5) Communication: clear and concise communication between the dermatologist 
and the nursing home staff on expectations towards each other will enhance 
a smoothly running and effective nursing home visit and might prevent 
indistinctness and friction.  
(6) Support: adequate supporting staff (e.g. a dermatology nurse) might enhance 
the efficiency of a nursing home visit.  
(7) Preparation: proper preparation may assist in an effective nursing home visit 
as well. Preparation might include receiving patient referrals prior to the visit, 
collecting the necessary material for diagnostic and treatment procedures 
which might be needed to perform, and/or to discuss all patients with the 
NHP “on paper” before the actual consultation to further clarify the reason for 
referral, management goals etc.   
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(8) Combination with digital consultation: as mentioned before combining live 
consultation in a nursing home with teledermatology might enhance the 
efficiency of a visit. For example, teledermatology might be used for patient 
triage to select the patients where a live consultation is needed, or to start 
pretreatment prior to live consultation to optimize the possibility for 
examination or treatment (e.g. the removal of crusts or to start preventive 
antibiotics). 
 
In addition, next to potential advantages and tips and tricks, potential pitfalls of nursing 
home visits should be addressed as well. Firstly, nursing home consultations by a 
dermatologist might act as a pull factor. Obviously, lowering the threshold for dermatologist 
consultation in nursing homes might improve dermatologic care as mentioned before. 
However, the level of this threshold should be well-balanced and unnecessary referrals 
(over-referral) should be prevented. Therefore, it is recommendable for both dermatologists 
and NHPs to pay attention to this balance and to critically evaluate referrals together on a 
regular basis.  
 
An example to illustrate the pitfall of over-referral, as once mentioned by a colleague (a 
dermatologist): “When I had visited nursing home B a couple of times, I noticed that NHPs started 
to refer patients with skin complaints which they didn’t even examined themselves yet. It was 
almost like when the nursing staff noticed a skin problem in a patient he or she was immediately 
referred to me.”   
 
Secondly, another potential pitfall of nursing home consultations by a dermatologist on a 
regular basis is the concept of “getting used to it” (habituation). When NHPs, other nursing 
home staff, patients and family members become used to the possibility of nursing home 
consultation, they might start to take this possibility for granted. This doesn’t necessarily 
have to be a problem, but this might jeopardize flexibility and the willingness of a 
dermatologist to perform nursing home consultations.  
 
An example to illustrate the pitfall of habituation, as once mentioned by a colleague (a 
dermatologist): “When I visited nursing home C for the first time a NHP guided me through the 
building from patient to patient and the patients and nursing home staff were very thankful. But 
after a couple of times, people got used to my consultations and seem to took it for granted: NHPs 
stopped guiding me along the patients and nursing home staff told me to come back when their 
coffee break was over. This is very demotivating, especially when you use your day off to perform 
these consultations.” 
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Financial framework 
Time and cost investment are the main barriers for dermatologists to perform nursing 
home visits. A special financial compensation for nursing home visits might stimulate 
dermatologists to provide nursing home consultations on a more regular basis and to a 
greater extent. In the ideal situation, overall earnings of an afternoon of nursing home 
consultations should be comparable with an afternoon of outpatient clinic consultations. 
Although it will be hardly possible to see the same number of patients in a given part of the 
day compared with the outpatient clinic in the same time span, the overall earnings for a 
dermatologist might reach approximate comparability due to elimination of hospital-
overhead costs in case of nursing home consultations. The current developments on 
“anderhalvelijnszorg” (see the introduction of this thesis for more details) may be an 
opportunity to start a discussion on this subject and to organize a financial arrangement for 
dermatologists, performing nursing home consultations.    
 
Educational effects 
As previously discussed, nursing home consultations by a dermatologist might have an 
educational value to NHPs and nursing home staff (bed-side teaching principle).27 However, 
the educational value might also have an effect the other way around, since dermatologists 
may also learn about several aspects concerning geriatric medicine during their nursing 
home visits.  
 
As presented in Chapters 2 and 3, we studied to what extent several patient-related factors 
are taken into account by dermatologists when making medical management decisions in 
nursing home patients. Scores were provided by both NHPs and dermatologists. 
Dermatologists provided themselves with higher scores compared to the scores they 
received from NHPs. Dermatologists also provided themselves with higher scores compared 
to the scores they provided to dermatologists in general, which might be an indication of 
self-overestimation. Close co-operation between a dermatologist and NHP might assist 
leveling out these differences found and help improve care by taking into account each 
other’s points of view and expertise.  
 
Moreover, half of the dermatologists and dermatology residents (50.8%) would like to 
receive more training in geriatric medicine. This seems to fit the trend shown by many 
medical specialties and organizations, where the importance of better training in general 
older adult care medicine is increasingly acknowledged and implemented in medical training 
programmes and daily clinical practice.28,29 In 2014 the “CanBetter project”, initiated by the 
Dutch Order of Medical Specialists, resulted in more implementation of older adult care in 
medical specialty training, including dermatology.30 This included defining the competences 
|
202 Chapter 9 
 
needed to provide proper healthcare for older adults and implementing these competences 
and the ways to develop them in national and local dermatologists training programmes. 
Furthermore, a dedicated session on geriatric dermatology was integrated in the Dutch 
national educational program for dermatology residents (mandatory for every dermatology 
resident in the Netherlands). Proper evaluation and further development of the above-
mentioned measurements is recommended, to optimize the ultimate impact on healthcare 
and to make sure predefined goals are achieved. 
 
Final considerations regarding dermatologic care in nursing home patients 
In conclusion, a close collaboration between NHPs and dermatologists is the key element to 
improve dermatologic care in nursing home patients. Multiple forms of consultation, 
including teledermatology and live consultation of a dermatologist in a nursing home, 
should be available on a regular basis and could complement each other. Several logistical 
and financial barriers should be minimized to enable these consultations to a greater 
extent. 
 
S K I N  C A N C E R  C A R E  I N  F R A I L  O L D E R  A D U L T S  
In part B of this thesis more specific attention was paid to skin cancer care among older 
adults. To study current skin cancer care among older adults and provide guidance in 
medical-decision making, the following research questions were answered and discussed 
below: 
 
(1) What is the current and potential future role of nursing home physicians (NHPs) in 
the diagnosis and treatment of (pre)malignant skin lesions among nursing home 
patients? (Chapter 5) 
 
(2) What is the influence of high age and comorbidity in medical decision making and 
guideline-adherence by dermatologists in older adults with nonmelanoma skin 
cancer (NMSC) in daily clinical practice? (Chapter 6) 
 
(3) What is currently known about the epidemiology and clinicopathological features 
of basal cell carcinoma (BCC) in the oldest-old to guide healthcare providers and 
policy makers? (Chapter 7)  
 
(4) Which items are considered important in medical decision making in frail older 
adults with NMSC and should be integrated in NMSC clinical practice guidelines? 
(Chapter 8) 
 
(5) What is the extent of integration of these items in current NMSC clinical practice 
guidelines worldwide? (Chapter 8) 
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The role of nursing home physicians and dermatologists in skin cancer care 
In addition to part A of this thesis the role of NHPs in skin cancer care among nursing home 
patients was further studied, as described in Chapter 5. Although NHPs are frequently 
confronted with skin cancer or precursor lesions among their patients, the role of 
dermatologists in skin cancer care remains essential and the demand for dermatologist 
consultation is high.  
 
However, due to the high prevalence of skin cancer in this patient group on the one hand 
and the relative barrier to visit a dermatology outpatient clinic or to arrange a dermatologist 
consultation within the nursing home on the other hand, dermatologists might not be able 
to meet this demand.  
 
Therefore, it seems especially important for NHPs to have basic knowledge and skills in skin 
cancer diagnosis and treatment. As shown in Chapter 5, a considerable proportion of NHPs 
provides some extent of skin cancer care, especially in lower risk (pre)malignant lesions (e.g. 
actinic keratosis, BCC). Furthermore, a significant proportion of NHPs would be willing to 
increase their extent of skin cancer care providence after better training. Consequently, the 
demand for better training was high. Comparable results were found in a study among 
Dutch general practitioners on skin cancer care.31 A high demand for more training on skin 
cancer care was also noted by a German study among various caregivers, including NHPs.32 
 
In addition, even if NHPs are not comfortable and/or willing to perform more skin cancer 
care themselves, it is still of vital importance for NHPs to have some basic knowledge 
regarding skin cancer, for the following reasons:  
 
(1) To be able to recognize a (pre)malignant skin lesion; 
(2) To have some understanding about the prognosis and treatment options; 
(3) To be able to properly determine when to consult a dermatologist; 
(4) To prevent making false assumptions regarding skin cancer in daily clinical 
nursing home practice, which unfortunately is very common in my experience 
(e.g. not knowing the tumor prognosis, not knowing some specific (simple) 
treatment options, or overestimating the burden for a patient choosing a 
certain treatment option); 
(5) To eventually enhance the possibility of active and well-informed participation 
of NHPs in the decision-making process in skin cancer care, together with the 
patients, their families, and the dermatologist.  
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As previously discussed, training a restricted number of NHPs with a special interest in 
dermatology, including skin cancer care, might optimize the development and maintenance 
of diagnostic and treatment skills. As in general dermatologic care, the role of NHPs in skin 
cancer care has (and should have) certain limitations and accessible possibilities to consult a 
dermatologists to provide skin cancer care still remains of major importance. 
 
Medical-decision making in patients with nonmelanoma skin cancer: the influence of high 
age and comorbidity and the concept of general prognostication 
In the next chapters more attention was paid to medical-decision making in frail older adults 
with NMSC. Management decisions in frail older adults with NMSC are made on a regular 
basis in daily dermatologic clinical practice and making a well-balanced management 
decision in an individual patient might be challenging due to several factors like a limited life 
expectancy or cognitive impairment.  
 
Clinical practice guidelines (CPGs) are intended to provide a general framework for clinicians 
based on the best evidence available. Obviously, recommendations in CPGs are not 
universally applicable. Therefore, guideline deviation should sometimes be considered and 
may be in the best interest of the individual patient. In Chapter 6 it was hypothesized that 
this might especially be the case in patients with a limited life expectancy. Therefore, the 
influence of two key factors related to limited life expectancy (high age and comorbidity) on 
medical decision making in NMSC were studied in more detail. It was found that medical 
decision making and guideline-adherence was not (in squamous cell carcinoma) or only 
minimally (in BCC) influenced by high age and comorbidity, which contradicted our 
expectations. 
 
These findings do not necessarily tell us something about the actual quality of care, but can 
be used as a starting point for a discussion on skin cancer care in frail older adults. Several 
potential explanations might play a role in these findings. High age and comorbidity may be 
included in management considerations by treating physicians, but simply are not 
considered of important influence in optimal skin cancer management and therefore have 
no or only minor influence. Furthermore, it might also be that high age and comorbidity 
show only minor influence because the awareness for inclusion of these factors in 
management considerations is low, or dermatologists might not know how to implement 
these factors in their management considerations. 
 
Future research should focus in more detail on management decisions in frail older adults 
with skin cancer. Reliable general prognostication of life expectancy is a key element in 
further tailoring skin cancer care in this population. Obviously, adequate prediction of the 
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natural course of a NMSC and the impact on quality of life caused by the tumor and/or 
treatment should be included as well, and are discussed in more detail later. Previous 
research on general prognostication showed that estimating the (remaining) life expectancy 
of a patient is difficult. Although life expectancy closely relates to age, a patient’s life 
expectancy is influenced by several factors, of which comorbidity is considered the strongest 
and best studied predictor.33-37 Consequently, clinical decision making merely based on 
chronological age is considered rather arbitrary, and should therefore be avoided. Although 
comorbidity-based prognostic indices for older adults certainly have limitations (e.g. in 
generalizability) and should be used with caution, they might be of assistance in daily 
practice. Future research on further validation and selection of existing indices in older 
adults with NMSC and on the feasibility of these indices in daily clinical practice are 
recommended. 
 
Guidance in medical-decision making by current literature 
BCC is the type of skin cancer in which medical-decision making in frail older adults seems 
to offer the greatest challenges in daily practice. In Chapter 7 literature was systematically 
reviewed for data on BCC in older adults (≥80 years) in order to guide clinicians in 
management considerations and to detect gaps in current knowledge. BCC is a very 
common tumor in persons aged ≥80 years and the incidence rates are rising. Despite of this 
commonness, relatively less is known regarding BCC in this patient population. Due to the 
relatively low-malignant natural course of BCC compared to many other types of cancer, 
management can be challenging in older adults. Balancing the risk for under- and 
overtreatment, combined with patients and family preferences, is not always easily 
performed. It was shown that current literature lacks essential information on many 
important aspects, like impact on quality of life (in both the short and long term) and 
prognostication. Therefore, clinicians are only very limitedly guided by current literature in 
making these management decisions.  
 
Natural course and impact on health-related quality of life 
Few studies have examined the natural evolution of BCC in more detail. Only a couple of 
studies (mostly retrospective) have tried to obtain some exact information regarding growth 
speed and development of BCC, which mainly include high-risk BCC located within the head 
and neck area. Based on these available studies it is estimated a high-risk BCC would take 
2,4-3,8 years to reach a size of 10 mm in maximal diameter. It is expected these growth 
rates may be less for low-risk BCC, although faster growth is possible and no reliable 
predictors for BCC development are currently known.38 Future studies on the natural course 
of BCC would be very valuable to help overcome treatment dilemma’s in frail older adults. 
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As stated, also less is known regarding the impact of BCC on health-related quality of life 
(HRQoL) in general populations with BCC and no specific studies were identified on HRQoL 
impact of BCC in oldest-old. However, HRQoL is one of the most important keystones on 
which management decisions should be based, and more studies on this topic are therefore 
essential. Studies on the impact of HRQoL in BCC can be especially valuable for daily clinical 
practice when they would be able to detect more information of HRQoL along the natural 
course of BCC. This is especially important for the longer term impact of BCC on HRQoL, 
since the currently available studies only focus on the short term HRQoL impact.  
 
In addition, studies should also include the impact of specific treatments of BCC on HRQoL, 
since these data are essential as well to help balancing the risk for both over- and 
undertreatment. The burden of treatment obviously differs per individual patient and the 
treatment method used. Nevertheless, harms caused by BCC treatment are common, 
although mostly mild to moderate.39-41 Examples of these treatment related harms are 
direct side effects of treatment (e.g. bleeding, infection, pain, poor wound healing, 
numbness or itching, motor function problem, local allergic reaction to bandages or 
antibiotics), but also indirect problems related to treatment (e.g. anxiety, depression, 
problems with scar or appearance). Furthermore, the (additional) burden of treatment in 
frail older adults may be significant due to factors such as functional impairment, the need 
for (repeated) hospital visits, travel distance, support needed by relatives etc. 
 
Combining and implementing more evidence regarding the natural course and impact on 
HRQoL of BCC (treatment) in daily clinical practice, might stimulate a more holistic, patient-
specific approach and thereby improve skin cancer care in frail older adults. These same 
principles could be used for the other subtypes of NMSC. 
 
Balancing under- and overtreatment to a greater extent: the time to benefit principle, 
choosing management goals and the introduction of watchful waiting 
“Time to benefit” is defined as the time between an intervention and the time when a 
significant improvement in health outcomes becomes evident. Previously, this term was 
mainly used and studied in preventive medicine, e.g. cancer screening or the prescription of 
statins.42,43 The same principles used before might be applicable to skin cancer care, 
especially in patients with low-risk asymptomatic NMSC. Therefore, future studies on this 
concept are strongly recommended. Together with the previously mentioned data on 
general prognosis, natural tumor course and impact on health-related quality of life of 
tumor and treatment, balancing under- and overtreatment might become easier in daily 
practice.  
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In addition, it should be pointed out that different management goals can be chosen in skin 
cancer care (curation, prevention of functional impairment, relieving symptoms etc.). The 
management goal(s) should be carefully chosen together with the patient, his or her 
relatives when applicable, and the referring physician. Current healthcare systems and 
caregivers often tend to be preoccupied with curation. This may especially be a pitfall in the 
population of frail older adults, since treatment goals other than curation might be in the 
best interest of a patient. In this context, it is important to remember that most studies and 
guideline-recommendations focus on curation as outcome measure of interest, when using 
these for guidance in daily practice.  
 
Furthermore, after gaining more time to benefit data, the decision not to treat a NMSC and 
to perform watchful waiting might become a better justifiable, evidence-based, and generally 
accepted option in some frail older adults. The option of watchful waiting might lead to 
further optimization of skin cancer care. More research designed to explore this option in 
skin cancer care is recommended. Previous cancer research already showed the added 
value of watchful waiting as an option in different types of cancer with a relatively low-
malignant potential, e.g. some forms of prostate cancer and hematologic malignancies.44,45 
 
It should be mentioned that balancing the risk for under- and overtreatment of NMSC might 
be influenced by financial incentives as well. Although general statements cannot be made, 
one cannot avoid the impression that a caregiver may be influenced by the financial 
compensation gained by performing treatment, while balancing management 
considerations. In other words, the (potential) existence of financial-driven treatment 
decisions should not be forgotten in a discussion on tailoring skin cancer management. 
 
Frailty: conceptualization, determination, and implementation in skin cancer care 
Although the exact conceptional and operational definitions of frailty are still under 
discussion, most experts consider frailty as a clinical state of vulnerability due to a declined 
functional reserve of multiple physiologic systems. Although frailty, aging and comorbidity 
are closely related terms, it is more and more believed frailty is a separate entity with its own 
pathofysiology. It is thought that a cumulative decline in functioning of several processes in 
the body, influenced by genetic, epigenetic and environmental factors related to aging, can 
result in disproportional health status changes due to minor stressor events after reaching 
a certain frailty threshold. Consequently, frailty results in an increased risk for poor health 
outcomes like falls, disability and death.46 
 
As emphasized above, it might be of additional value to include frailty and its potential 
consequences as a separate entity in skin cancer management considerations as well. 
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Determination of frailty in daily dermatological practice might be a challenge. 
Comprehensive geriatric assessment is considered the gold standard for frailty detection 
and several derivative screening tools are available as well (e.g., Vulnerable Elders Survey-13, 
Geriatric 8, or Groningen Frailty Index).47 However, current literature lacks any evidence on 
validation in skin cancer care and feasibility for usage in daily dermatological practice can be 
questioned in some of these tools due to their comprehensiveness. Development of a 
validated and feasible screening tool for dermatologic practice is recommended. Obviously, 
critical evaluation of the benefits of such a screening tool should be performed additionally.  
 
Guidance from clinical practice guidelines in frail older adults with nonmelanoma skin 
cancer 
In Chapter 8 the applicability of CPGs on NMSC in older adults was studied. A broad desire 
was identified on integration of items related to frail older adults in NMSC CPGs, but after 
systematically reviewing current guidelines this integration was shown to be limited. 
 
Consequently, several recommendations were made to improve the attention for frail older 
adults in CPGs. More attention for this population in CPGs might stimulate caregivers to 
further tailor and personalize their management decisions, together with the patient, family 
and other relevant caregivers. Including items in a CPG does not necessarily mean a 
behavioral change in caregivers daily practice, but might be of value as a first step. 
Nevertheless, other measurements are recommended which might increase the awareness 
for this subject and stimulate a behavioral change as well, e.g. generating more evidence-
based guidance by additional studies on the subject (as mentioned before), and including 
more attention for management decisions in frail older adults in educational programs (e.g. 
the CanBetter-program, as discussed before).30,48 
 
Furthermore, intensive collaboration with caregivers which are more experienced in 
management considerations in frail older adults (e.g. geriatricians, elderly care specialist) 
should be encouraged. Principles adapted in management considerations in frail older 
adults by these experienced caregivers might be applicable in skin cancer care. For example, 
the Dutch Association of Clinical Geriatrics and the The Dutch Society of Internal Medicine 
developed general recommendations to provide assistance in the development of “older 
adult-proof” CPGs, which can be very useful in the field of dermatology as well.49  
 
A final consideration which should be pointed out is the role of CPGs in current clinical 
medicine. CPGs are more and more considered as standard of care and CPGs are 
increasingly used as quality indicators and performance incentives by several parties. 
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Therefore, flexibility for tailoring management or deviation from clinical standards in the 
context of a CPG is considered of significant importance.48,50 
 
Final considerations regarding nonmelanoma skin cancer management in frail older 
adults 
In conclusion, management of NMSC in frail older adults remains challenging. Key elements 
expected to provide guidance to clinicians in daily practice and to improve tailoring of skin 
cancer care in this population are: more research, better CPG-integration, and improving 
education and interdisciplinary collaboration on this topic.  
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Summary 
 
Healthcare providers are expected to be increasingly confronted with the growing 
population of older adults. In the Netherlands, the frailest and most dependent older adults 
live in nursing homes. Skin problems are common in this patient population and they can 
result in a high level of morbidity, causing a significant impact on quality of life. Management 
decisions in frail older adults may be challenging since several factors should be taken in 
consideration, such as a limited life expectancy, immobility, and dementia. A major group of 
skin disorders resulting in these challenges in frail older adults is skin cancer. The most 
common subgroup of skin cancer is nonmelanoma skin cancer (NMSC), including basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC) and its precursors. NMSC has a 
relative low-malignant natural course compared to many other types of cancer, however the 
impact on quality of life in the longer term may be significant. Balancing the risk of under- 
and overtreatment in older adults with NMSC, together with patient- and tumor 
characteristics is therefore not easily performed. 
 
The aims of the studies presented in this thesis were to obtain insight in the current need 
for, provision of, and quality of general dermatologic care among nursing home patients 
(Part A of this thesis), and to study current skin cancer care among older adults and provide 
guidance in medical-decision making (Part B of this thesis).  
 
D E R M A T O L O G I C  C A R E  I N  I N S T I T U T I O N A L I Z E D  O L D E R  A D U L T S  
In Chapters 2 and 3 two nationwide surveys are described aimed to assess the need for 
and provision of dermatologic care in Dutch nursing homes from both the perspective of 
physicians working in nursing homes and dermatologists.  
 
Nursing home physicians (NHPs) are often confronted with skin problems among their 
patients (62.5% ≥10 times during the last 3 months), mostly (pressure) ulcers, eczema, and 
fungal infections. A lack of availability and experience of NHPs were noted to limit the 
possibility to diagnose and treat common skin problems in nursing home patients. 
Dermatology outpatient clinic visits or other forms of consultation of a dermatologist are 
frequently needed according to the responding NHPs, especially in case of (a suspicion of) a 
cutaneous (pre)malignancy. The vast majority of the NHPs indicated to collaborate with a 
dermatologist on a regular basis (79.3% ≥1 time(s)/year, 41.5% ≥4 times/year), mostly by 
phone. Moreover, 88.5% of the NHPs noted one or more of their patients visited a 
dermatology outpatient clinic during the last year. Almost all participating NHPs received 
some form of basic dermatology training (mostly during medical school). However, more 
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and better training was requested by a majority of the NHPs, especially regarding cutaneous 
(pre)malignancies. 
 
Dermatologists and dermatology residents noted that 79.2% ever had contact with a NHP 
concerning a nursing home resident, mostly by phone. In contrast, only a minority (30.0%) 
ever visited a patient within a nursing home. Of these respondents, nursing homes are 
mostly visited on a regular basis (48.7% ≥4 times/year). A majority of the dermatologists and 
dermatology residents (68.5%) is willing to visit (more) patients within a nursing home, but a 
lack of time and inadequate financial compensation are mentioned as important barriers. 
Cutaneous (pre)malignancies (51.4%), eczema/dermatitis (25.7%) and (pressure) ulcers 
(8.6%) were mentioned as the most common reasons for dermatologists to visit a nursing 
home patient. Most dermatologists visiting patients within nursing homes perform 
diagnostic and treatment procedures within the nursing home, ranging from punch biopsy 
(65.7%) and dermatoscopic examination (62.9%), to cryotherapie (68.6%) and surgical 
excision (22.9%). Nevertheless, diagnostic and treatment procedures are less frequently 
used by dermatologists in a nursing home compared to the dermatology outpatient clinic. 
This less frequent use of procedures may reflect a deliberate omission in the best interest of 
a patient, for instance to prevent an unnecessary patient burden in case of a limited life 
expectancy. However, unavailability of a diagnostic of treatment procedure and a lack of 
supporting staff are other frequently mentioned reasons which could possible lead to an 
unintended omission of a contemplated procedure. 
 
The respondents in the two nationwide surveys were additionally asked how they believe 
that dermatologic care among nursing home patients can be improved, as described in 
Chapters 2 and 4 (for NHPs and dermatologists, respectively). The most frequently made 
suggestion in both groups was better utilization of telemedicine applications (21.6% and 
26.5% of the suggestions made by NHPs and dermatologists, respectively). More nursing 
home visits by dermatologists was the second commonly made suggestion in both groups 
of physicians (21.4% and 22.1%, respectively). Other suggestions to improve dermatologic 
care among nursing home patients were: (1) better education of healthcare providers and 
(2) to improve the availability of diagnostic and/or treatment procedures needed to provide 
proper dermatologic care. 
 
S K I N  C A N C E R  C A R E  I N  F R A I L  O L D E R  A D U L T S   
As described before, skin cancer is common among nursing home patients. Therefore, the 
current and potential future role of NHPs in skin cancer management was studied in more 
detail (Chapter 5). It was found that NHPs consider their knowledge to diagnose the 
different skin cancer subtypes to be sufficient, with the exception of Bowen’s disease. 
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Though, only a minority of the NHPs considered their knowledge and experience to be 
sufficient to treat all different skin cancer subtypes. A minority of the respondents 
performed treatment of skin cancer or precursor lesion on their own initiative (37.8%) or 
after dermatologist consultation (57.6%). Actinic keratosis was the subtype treated the most 
by NHPs. Cryotherapy and topical 5-fluorouracil were the treatment options most often 
used by NHPs. Most of the NHPs (94.5%) expected to be able to perform treatment more 
frequently after more education. Most NHPs indicated that the role of dermatologists in the 
diagnosis and treatment of skin cancer remains essential, especially in SCC and melanoma. 
 
In Chapter 6, a study is described which aimed to assess the influence of high age and 
comorbidity on the management of NMSC. Since these factors are closely related to a 
limited life expectancy, it was hypothesized these factors would influence management 
decisions and guideline-adherence. However, the results of this study showed NMSC 
management is not or only minimally influenced by high age and comorbidity, which was in 
contradiction with our expectations. Future research on general prognostication, prediction 
of the patient burden caused by tumor and treatment, and time to benefit in NMSC 
management is strongly recommended. 
 
In Chapter 7 current literature was systematically reviewed on the epidemiology and 
clinicopathological features of BCC in persons aged ≥80 years. BCC is the type of skin cancer 
with the lowest malignant potential. This often creates management dilemma’s as 
mentioned before. It was found that the incidence rates of BCC among persons aged ≥80 
years are high and increasing over time. Furthermore, BCC in this population are more 
prevalent in men, most often of the nodular subtype, and located in the head and neck area. 
Little is known regarding the impact on health-related quality of life of BCC and data 
concerning prognostication is scarce. These topics should be further studied in the future, 
to provide better guidance for clinicians in daily practice dilemma’s. 
 
More guideline-integration of items related to NMSC management in frail older adults might 
assist clinicians to determine the most appropriate skin cancer care in their individual 
patients. In Chapter 8 a multidisciplinary working group was formed to collect and prioritize 
items related to frail older adults with NMSC for integration into clinical practice guidelines 
(CPGs). Additionally, a systematic review was performed to assess the current integration of 
these items in CPGs. It was found that CPG-integration of many items is broadly desired, but 
currently limited. Recommendations for future CPG-development were provided. 
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Conclusions 
 
To conclude, this thesis provides insight in the current status of dermatologic care among 
frail older adults, especially those inhabiting nursing homes and those suffering from skin 
cancer. Important challenges and limitations in dermatologic care among frail older adults 
were found and suggestions to optimize dermatologic care in these populations were 
provided. 
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Nederlandse samenvatting 
 
Naar verwachting zullen zorgverleners in de toekomst steeds vaker geconfronteerd worden 
met het groeiend aantal ouderen. In Nederland wonen de meest kwetsbare en afhankelijke 
ouderen in verpleeghuizen. Huidproblemen komen veel voor in deze patiëntpopulatie en 
kunnen veel klachten veroorzaken. Daardoor kunnen huidproblemen een aanzienlijke 
invloed hebben op de kwaliteit van leven. Behandelafwegingen bij kwetsbare ouderen 
kunnen een uitdaging zijn, aangezien verschillende factoren in overweging genomen dienen 
te worden. Voorbeelden van deze factoren zijn een beperkte resterende levensverwachting, 
immobiliteit en dementie. Huidkanker is een veelvoorkomend probleem bij kwetsbare 
ouderen, waarbij deze uitdagingen met betrekking tot behandelafwegingen duidelijk naar 
voren komen. De meest voorkomende subgroep van huidkanker wordt gevormd door niet-
melanoom huidkanker, welke het basaalcelcarcinoom (BCC) en het plaveiselcelcarcinoom 
(PCC) met diens voorstadia omvat. Niet-melanoom huidkanker heeft een relatief laag-
maligne natuurlijk beloop vergeleken met veel andere vormen van kanker. Desalniettemin 
kan de invloed van niet-melanoom huidkanker op de kwaliteit van leven op de langere 
termijn aanzienlijk zijn. Het afwegen van het risico op onder- en overbehandeling van niet-
melanoom huidkanker bij ouderen en het meewegen van patiënt- en tumorkenmerken 
daarbij is daarom niet eenvoudig. 
 
De doelstellingen van het onderzoek beschreven in dit proefschrift waren om meer inzicht 
te krijgen in de vraag naar, het aanbod van, en de kwaliteit van algemene dermatologische 
zorgverlening onder verpleeghuispatiënten (Deel A van dit proefschrift). Daarnaast werd de 
huidige huidkankerzorg voor ouderen bestudeerd en getracht ondersteuning te bieden bij 
behandelafwegingen (Deel B van dit proefschrift). 
 
D E R M A T O L O G I S C H E  Z O R G  V O O R  V E R P L E E G H U I S P A T I Ë N T E N   
In Hoofdstuk 2 en 3 worden twee landelijke vragenlijstonderzoeken beschreven over de 
vraag naar en het aanbod van algemene dermatologische zorg in Nederlandse 
verpleeghuizen, vanuit het perspectief van artsen werkzaam in verpleeghuizen en 
dermatologen. 
 
Artsen werkzaam in verpleeghuizen worden vaak geconfronteerd met huidproblemen bij 
hun patiënten (62.5% ≥10 keer gedurende de afgelopen 3 maanden), met name wonden 
(inclusief decubitus), eczeem en schimmelinfecties. Een beperkte beschikbaarheid van 
diagnostische en therapeutische hulpmiddelen, alsmede een beperkte ervaring hiermee, 
werd door deze artsen benoemd als belangrijke limitaties om zelf de optimale 
dermatologische zorg te kunnen leveren aan hun patiënten. De overgrote meerderheid van 
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de artsen werkzaam in verpleeghuizen consulteert regelmatig een dermatoloog op afstand 
(79.3% ≥1 keer/jaar, 41.5% ≥4 keer/jaar), meestal telefonisch. De belangrijkste reden voor 
deze consultaties is (de verdenking op) huidkanker of een voorstadium hiervan. Daarnaast 
geeft 88.5% van alle artsen werkzaam in verpleeghuizen aan dat één of meer van hun 
patiënten een polikliniek dermatologie bezocht gedurende het afgelopen jaar. Vrijwel alle 
participerende artsen werkzaam in verpleeghuizen volgden in het verleden basaal 
dermatologisch onderwijs (meestal gedurende de basisopleiding geneeskunde). 
Desalniettemin gaf het merendeel van de artsen aan meer en beter dermatologisch 
onderwijs te willen, met name op het gebied van huidkanker. 
 
Dermatologen (in opleiding) gaven aan dat 79.2% van hen ooit contact had met een arts uit 
een verpleeghuis over een verpleeghuispatiënt, meestal telefonisch. Slechts een minderheid 
van hen (30.0%) bezocht ooit een patiënt op locatie binnen een verpleeghuis. De 
respondenten die wel eens patiënten op locatie binnen het verpleeghuis bezoeken doen dit 
meestal op regelmatige basis (48.7% ≥4 keer/jaar). Een meerderheid van de dermatologen 
(in opleiding) is bereid om (meer) patiënten binnen een verpleeghuis te bezoeken voor 
beoordeling, maar een gebrek aan tijd en ontoereikende financiële compensatie worden 
genoemd als belangrijke drempels. Huidkanker en voorstadia (51.4%), eczeem (25.7%) en 
wonden (inclusief decubitus) worden aangegeven als de meest voorkomende redenen voor 
dermatologen om patiënten op locatie binnen een verpleeghuis te bezoeken. De meeste 
dermatologen die patiënten bezoeken binnen een verpleeghuis verrichten aldaar ook 
diagnostische en therapeutische verrichtingen, variërend van het nemen van een stansbiopt 
(65.7%) en dermatoscopische beoordeling (62.9%), tot cryotherapie (68.6%) en chirurgische 
excisie (22.9%). Desalniettemin worden er minder diagnostische en therapeutische 
verrichtingen uitgevoerd door dermatologen binnen het verpleeghuis in vergelijking met de 
polikliniek. Enerzijds zou dit kunnen wijzen op het weloverwogen en gewenst afzien van 
bepaalde diagnostiek of therapie in het algemeen belang van de patiënt, bijvoorbeeld om 
onnodige belasting voor de patiënt te voorkomen bij een beperkte levensverwachting. 
Echter, het onvoldoende beschikbaar zijn van benodigde materialen en ondersteunend 
personeel worden ook frequent genoemd als redenen voor het genoemde verschil tussen 
het verpleeghuis en de polikliniek. Dit kan leiden tot het ongewenst moeten afzien van een 
voorgenomen diagnostische en/of therapeutische verrichting. 
 
De respondenten in de twee landelijke vragenlijstonderzoeken werden vervolgens gevraagd 
hoe zij denken dat de dermatologische zorg voor verpleeghuispatiënten verbeterd zou 
kunnen worden, zoals beschreven in Hoofdstuk 2 en 4 (respectievelijk voor artsen 
werkzaam in verpleeghuizen en dermatologen). Het meest genoemde verbeterpunt door 
beide groepen artsen was het beter gebruik maken van teledermatologie (21.6% en 26.5% 
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van de genoemde verbeterpunten door artsen werkzaam in verpleeghuizen en 
dermatologen respectievelijk). Meer verpleeghuisbezoeken door dermatologen werd tevens 
vaak genoemd als verbeterpunt door beide groepen artsen (21.4% en 22.1%). Andere 
belangrijke suggesties die werden gedaan zijn: (1) betere scholing van zorgverleners en (2) 
verbetering van de beschikbaarheid van benodigdheden voor diagnostiek en therapie. 
 
H U I D K A N K E R Z O R G  V O O R  K W E T S B A R E  O U D E R E N  
Zoals eerder beschreven komt huidkanker veel voor bij verpleeghuispatiënten. Daarom 
werd de huidige en mogelijke toekomstige rol van artsen werkzaam in verpleeghuizen in de 
huidkankerzorg in meer detail bestudeerd (Hoofdstuk 5). Er werd gevonden dat artsen 
werkzaam in verpleeghuizen hun kennis over de verschillende subtypen huidkanker als 
voldoende beschouwen om ze te kunnen herkennen, met uitzondering van morbus Bowen 
(een voorstadium van het PCC). Desalniettemin beschouwt slechts een minderheid van de 
respondenten hun kennis en ervaring als voldoende om behandeling uit te voeren. Slechts 
een beperkt deel van de artsen werkzaam in verpleeghuizen behandelde eerder een vorm 
van huidkanker of voorstadium op eigen initiatief (37.8%) of na consultatie van een 
dermatoloog (57.6%). Het meest behandelde subtype door de respondenten was actinische 
keratose (een voorstadium van het PCC). Cryotherapie en 5-fluorouracil crème waren de 
meest toegepaste behandelmethoden door artsen werkzaam in verpleeghuizen. De meeste 
respondenten (94.5%) gaven de verwachting aan vaker behandeling te kunnen verrichten na 
meer scholing. Daarentegen gaf de meerderheid van de artsen ook aan dat zij de rol van de 
dermatoloog bij de diagnostiek en therapie van huidkanker essentieel vinden, met name in 
het geval van een PCC of melanoom. 
 
In Hoofdstuk 6 is de invloed van hoge leeftijd en comorbiditeiten op de beleidsbepaling bij 
niet-melanoom huidkanker onderzocht. Aangezien deze factoren een sterke samenhang 
hebben met resterende levensverwachting werd verwacht dat zij van invloed zouden zijn op 
beleidsbepaling en richtlijnadherentie (het wel of niet opvolgen van aanbevelingen uit 
richtlijnen). Echter, de resultaten van de studie tonen dat het beleid bij niet-melanoom 
huidkanker niet of nauwelijks wordt beïnvloedt door hoge leeftijd en comorbiditeiten. 
Toekomstig onderzoek naar het bepalen van de algehele prognose van een patiënt, het 
voorspellen van de belasting voor de patiënt door de tumor en eventuele behandeling, en 
de tijd nodig om de voordelen van behandeling op te laten wegen tegen de eventuele 
nadelen van behandeling (Engels: time to benefit) worden sterk aanbevolen. 
 
In Hoofdstuk 7 werd de huidige literatuur systematisch bestudeerd naar beschikbare 
informatie over de epidemiologie en de clinicopathologische karakteristieken van BCC bij 
personen van 80 jaar en ouder. BCC is de meest voorkomend vorm van huidkanker, met 
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tegelijkertijd het minst maligne karakter van alle huidkankervormen. Zoals eerder 
beschreven resulteert dit vaak in behandeldilemma’s. Vanuit de huidige beschikbare 
literatuur werd gevonden dat de incidentiecijfers van BCC bij personen van 80 jaar en ouder 
hoog zijn en toenemen door de tijd. Daarnaast komt BCC in deze leeftijdscategorie vaker 
voor bij mannen, betreft het meestal het nodulaire subtype en bevindt het BCC zich meestal 
in het hoofdhalsgebied. Er is weinig bekend over de impact van BCC op de 
gezondheidsgerelateerde kwaliteit van leven van een patiënt en gegevens over 
prognosticering zijn tevens schaars. In de toekomst zouden deze aspecten beter 
onderzocht moeten worden om zorgverleners beter te kunnen ondersteunen bij 
behandeldilemma’s in de dagelijkse praktijk. 
 
Meer richtlijnintegratie van aspecten gerelateerd aan beleidsbepaling bij niet-melanoom 
huidkanker bij kwetsbare ouderen zou zorgverleners mogelijk kunnen helpen bij 
behandeldilemma’s in de dagelijkse praktijk. In Hoofdstuk 8 werd door een 
multidisciplinaire werkgroep een lijst samengesteld met aspecten gerelateerd aan niet-
melanoom huidkanker bij kwetsbare ouderen. Vervolgens werden deze aspecten 
geprioriteerd op basis van de wens om hieraan meer aandacht te schenken in richtlijnen 
over niet-melanoom huidkanker. Tot slot werden de huidige richtlijnen systematisch 
beoordeeld op de integratie van deze aspecten. Er werd gevonden dat er verschillende 
aspecten zijn waarbij de wens tot meer richtlijnintegratie groot is, maar dat de huidige 
richtlijnintegratie slechts beperkt is. Aanbevelingen worden daarom gedaan voor 
richtlijnontwikkeling in de toekomst. 
 
 
Conclusies 
 
Concluderend biedt dit proefschrift inzichten in de huidige staat van dermatologische 
zorgverlening aan kwetsbare ouderen, in het bijzonder verpleeghuispatiënten en oudere 
patiënten met huidkanker. Een aantal belangrijke uitdagingen en limitaties in de 
dermatologische zorgverlening onder kwetsbare ouderen werden gevonden en aansluitend 
werden suggesties gedaan om de zorg in deze patiëntpopulatie te verbeteren. 
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dat dit mij bijzonder heeft gestimuleerd in mijn ontwikkeling.  
 
Dr. Rianne Gerritsen, beste Rianne, ik wil je bedanken voor jouw begeleiding als 
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List of abbreviations 
 
5FU topical 5-fluorouracil 
95%CI: 95% confidence interval 
ACN Australian Cancer Network 
AGREE II Appraisal of Guidelines for Research and Evaluation II instrument 
AJCC American Joint Committee on Cancer 
ANAES French National Agency for Accreditation and Evaluation in Healthcare (French: Agence Nationale 
d'Accréditation et d'Évaluation en Santé) 
APC annual percentage change 
AK actinic keratosis 
BAD British Association of Dermatologists  
BD Bowen’s disease 
BCC basal cell carcinoma 
CCA Cancer Council Australia  
CCI Charlson comorbidity index 
CME continuing medical education 
CPG clinical practice guideline 
CRYO cryotherapy 
DDG German Society of Dermatology (German: Deutschen Dermatologischen Gesellschaft) 
DKG German Cancer Society (German: Deutsche Krebsgesellschaft) 
DLQI Dermatology Life Quality Index 
DOC dermatology outpatient clinic 
EADO European Association of Dermato-Oncology  
EDF European Dermatology Forum 
EMBASE Excerpta Medica Database 
EORTC European Organization for Research and Treatment of Cancer 
FACT-G Functional Assessment of Cancer Therapy-General 
G8 Geriatric 8 
GA geriatric assessment 
GFI Groningen Frailty Index 
HRQoL health-related quality of life 
i/morfBCC infiltrative/morpheaform basal cell carcinoma 
IMI topical imiquimod 
IR incidence rate 
LE life expectancy 
mBCC metastatic basal cell carcinoma 
MeSH Medical Subject Headings 
MMS Mohs micrographic surgery 
MR mortality rate 
NA not applicable 
nBCC nodular basal cell carcinoma 
NCCN National Comprehensive Cancer Network 
NHP nursing home physician 
NMSC nonmelanoma skin cancer 
NR not reported 
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NVDV Dutch Dermatological and Venereological Society (Dutch: Nederlandse Vereniging voor Dermatologie 
en Venereologie) 
OR Odds ratio 
PALGA Dutch national pathology database (Dutch: Pathologisch Anatomisch Landelijk Geautomatiseerd 
Archief) 
PDT photodynamic therapy 
PHI permanent healthcare institution 
Pinkus fibroepithelioma of Pinkus 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
QoE quality of evidence 
QRS quality rating scheme 
RT radiotherapy 
SAMPL Statistical Analyses and Methods in the Published Literature 
sBCC superficial basal cell carcinoma 
SCC squamous cell carcinoma 
SD standard deviation 
SE surgical excision 
S&F store-and-forward 
SF-36 36-Item Short Form Health Survey 
SFD French Dermatology Society (French: Société Française de Dermatologie) 
SIGN Scottish Intercollegiate Guidelines Network 
SPSS Statistical Package for Social Sciences 
STROBE STrengthening the Reporting of OBservational studies in Epidemiology 
SUR surgery 
UVR ultraviolet radiation 
VES-13 Vulnerable Elders Survey-13 
YoE years of experience 
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